NZ717560B2 - Human antibodies and antibody-drug conjugates against cd74 - Google Patents
Human antibodies and antibody-drug conjugates against cd74 Download PDFInfo
- Publication number
- NZ717560B2 NZ717560B2 NZ717560A NZ71756012A NZ717560B2 NZ 717560 B2 NZ717560 B2 NZ 717560B2 NZ 717560 A NZ717560 A NZ 717560A NZ 71756012 A NZ71756012 A NZ 71756012A NZ 717560 B2 NZ717560 B2 NZ 717560B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- antibodies
- cells
- cell
- cancer
- Prior art date
Links
- 102000004965 antibodies Human genes 0.000 title abstract description 561
- 108090001123 antibodies Proteins 0.000 title abstract description 561
- 239000000611 antibody drug conjugate Substances 0.000 title description 69
- 108091008116 antibody drug conjugates Proteins 0.000 title description 69
- 201000011510 cancer Diseases 0.000 abstract description 80
- 230000001225 therapeutic Effects 0.000 abstract description 44
- 239000002246 antineoplastic agent Substances 0.000 abstract description 20
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract description 7
- 230000001472 cytotoxic Effects 0.000 abstract description 6
- 231100000433 cytotoxic Toxicity 0.000 abstract description 6
- 230000002101 lytic Effects 0.000 abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 6
- 102000004127 Cytokines Human genes 0.000 abstract description 5
- 108090000695 Cytokines Proteins 0.000 abstract description 5
- 229920001895 acrylonitrile-acrylic-styrene Polymers 0.000 abstract 1
- 101710007476 CD74 Proteins 0.000 description 332
- 102100004099 CD74 Human genes 0.000 description 332
- 210000004027 cells Anatomy 0.000 description 279
- 239000000203 mixture Substances 0.000 description 99
- 230000027455 binding Effects 0.000 description 96
- 238000009739 binding Methods 0.000 description 93
- 229920002574 CR-39 Polymers 0.000 description 79
- 206010028980 Neoplasm Diseases 0.000 description 73
- 239000003795 chemical substances by application Substances 0.000 description 72
- 239000000427 antigen Substances 0.000 description 70
- 239000003814 drug Substances 0.000 description 66
- 108091007172 antigens Proteins 0.000 description 65
- 102000038129 antigens Human genes 0.000 description 65
- 241000282326 Felis catus Species 0.000 description 55
- 230000014509 gene expression Effects 0.000 description 52
- 150000002500 ions Chemical class 0.000 description 46
- 201000010099 disease Diseases 0.000 description 43
- 108090001095 Immunoglobulin G Proteins 0.000 description 41
- 102000004851 Immunoglobulin G Human genes 0.000 description 41
- -1 FR3 Proteins 0.000 description 39
- 229940079593 drugs Drugs 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 34
- 238000004166 bioassay Methods 0.000 description 33
- 125000005647 linker group Chemical group 0.000 description 33
- 150000007523 nucleic acids Chemical class 0.000 description 32
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 31
- 108020004707 nucleic acids Proteins 0.000 description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 25
- 238000000034 method Methods 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 24
- 102000018358 Immunoglobulins Human genes 0.000 description 23
- 108060003951 Immunoglobulins Proteins 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 230000002401 inhibitory effect Effects 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 22
- 108010045030 monoclonal antibodies Proteins 0.000 description 21
- 102000005614 monoclonal antibodies Human genes 0.000 description 21
- 239000000651 prodrug Substances 0.000 description 21
- 210000001519 tissues Anatomy 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 229940002612 prodrugs Drugs 0.000 description 20
- 210000004881 tumor cells Anatomy 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- 239000000562 conjugate Substances 0.000 description 18
- 230000001939 inductive effect Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 17
- 210000004408 Hybridomas Anatomy 0.000 description 16
- 238000003384 imaging method Methods 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 14
- 102100002977 CDR1 Human genes 0.000 description 14
- 101700073818 CDR1 Proteins 0.000 description 14
- 230000001093 anti-cancer Effects 0.000 description 14
- 230000002147 killing Effects 0.000 description 14
- 239000002609 media Substances 0.000 description 14
- 206010066476 Haematological malignancy Diseases 0.000 description 13
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 12
- MFRNYXJJRJQHNW-NARUGQRUSA-N Monomethyl auristatin F Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)C([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-NARUGQRUSA-N 0.000 description 12
- 101710034060 RUNX1T1 Proteins 0.000 description 12
- 210000002966 Serum Anatomy 0.000 description 12
- 231100000765 Toxin Toxicity 0.000 description 12
- 230000000875 corresponding Effects 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 108010093470 monomethyl auristatin E Proteins 0.000 description 12
- 108010059074 monomethylauristatin F Proteins 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 108020003112 toxins Proteins 0.000 description 12
- 229910052720 vanadium Inorganic materials 0.000 description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 description 11
- 239000000969 carrier Substances 0.000 description 11
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 10
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 10
- 230000035693 Fab Effects 0.000 description 10
- 229920001850 Nucleic acid sequence Polymers 0.000 description 10
- DAEPDZWVDSPTHF-UHFFFAOYSA-M Sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 10
- 235000018417 cysteine Nutrition 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 229960000060 monoclonal antibodies Drugs 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 230000022534 cell killing Effects 0.000 description 9
- 230000001413 cellular Effects 0.000 description 9
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000004602 germ cell Anatomy 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 201000000050 myeloid neoplasm Diseases 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000001404 mediated Effects 0.000 description 8
- 230000002829 reduced Effects 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 229920002676 Complementary DNA Polymers 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 229960005322 Streptomycin Drugs 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000002708 enhancing Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000003834 intracellular Effects 0.000 description 7
- 230000000670 limiting Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000003442 weekly Effects 0.000 description 7
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 6
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 6
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N ABTS Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 229960002433 Cysteine Drugs 0.000 description 6
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 6
- 229940100601 Interleukin-6 Drugs 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 210000001165 Lymph Nodes Anatomy 0.000 description 6
- 206010025650 Malignant melanoma Diseases 0.000 description 6
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 6
- 206010025310 Other lymphomas Diseases 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 229950010131 PUROMYCIN Drugs 0.000 description 6
- 229940049954 Penicillin Drugs 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
- 108010044540 auristatin Proteins 0.000 description 6
- 229960000626 benzylpenicillin Drugs 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 230000000051 modifying Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000022983 regulation of cell cycle Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229960005486 vaccines Drugs 0.000 description 6
- 230000003612 virological Effects 0.000 description 6
- 206010003816 Autoimmune disease Diseases 0.000 description 5
- 210000003719 B-Lymphocytes Anatomy 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 description 5
- 102000004854 Immunoglobulin M Human genes 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 229940072417 Peroxidase Drugs 0.000 description 5
- 108090000437 Peroxidases Proteins 0.000 description 5
- 102000003992 Peroxidases Human genes 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 229940054269 Sodium Pyruvate Drugs 0.000 description 5
- 102100015249 VEGFA Human genes 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000240 adjuvant Effects 0.000 description 5
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 5
- 230000001580 bacterial Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 230000001721 combination Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 108010028930 invariant chain Proteins 0.000 description 5
- 238000011068 load Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000001105 regulatory Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 4
- 239000012099 Alexa Fluor family Substances 0.000 description 4
- 108010055216 Anti-Idiotypic Antibodies Proteins 0.000 description 4
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 4
- 102100013077 CD4 Human genes 0.000 description 4
- 101700022938 CD4 Proteins 0.000 description 4
- 102100011842 CEACAM5 Human genes 0.000 description 4
- 102100006400 CSF2 Human genes 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 4
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 229940117681 Interleukin-12 Drugs 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 102100000165 MS4A1 Human genes 0.000 description 4
- 101710010909 MS4A1 Proteins 0.000 description 4
- 210000002540 Macrophages Anatomy 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 4
- 102000035443 Peptidases Human genes 0.000 description 4
- 108091005771 Peptidases Proteins 0.000 description 4
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 4
- 101710040537 TNF Proteins 0.000 description 4
- 229940035295 Ting Drugs 0.000 description 4
- 210000003462 Veins Anatomy 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000011231 colorectal cancer Diseases 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- 230000001809 detectable Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037240 fusion proteins Human genes 0.000 description 4
- 201000009277 hairy cell leukemia Diseases 0.000 description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 4
- 230000002519 immonomodulatory Effects 0.000 description 4
- 230000001506 immunosuppresive Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229960004768 irinotecan Drugs 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000003211 malignant Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000003638 reducing agent Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- 206010059512 Apoptosis Diseases 0.000 description 3
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 3
- 108010005144 Bevacizumab Proteins 0.000 description 3
- 108010071919 Bispecific Antibodies Proteins 0.000 description 3
- 102100005826 CD19 Human genes 0.000 description 3
- 101700087100 CD19 Proteins 0.000 description 3
- 102100000189 CD22 Human genes 0.000 description 3
- 101700020617 CD22 Proteins 0.000 description 3
- 102100003279 CD38 Human genes 0.000 description 3
- 101700044948 CD38 Proteins 0.000 description 3
- 102100013137 CD40 Human genes 0.000 description 3
- 101710040446 CD40 Proteins 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100003729 CD40LG Human genes 0.000 description 3
- 101710027020 CD46 Proteins 0.000 description 3
- 102100019144 CD46 Human genes 0.000 description 3
- 101700080477 CD80 Proteins 0.000 description 3
- 102100019451 CD80 Human genes 0.000 description 3
- 102100009368 CR2 Human genes 0.000 description 3
- 101700020447 CR2 Proteins 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 3
- 102000019679 Cell-Penetrating Peptides Human genes 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010008943 Chronic leukaemia Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 229960004397 Cyclophosphamide Drugs 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 210000004443 Dendritic Cells Anatomy 0.000 description 3
- OFDNQWIFNXBECV-VFSYNPLYSA-N Dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 3
- 102100010912 EPCAM Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 3
- 101700053597 FCER2 Proteins 0.000 description 3
- 102100014608 FCER2 Human genes 0.000 description 3
- 229960002949 Fluorouracil Drugs 0.000 description 3
- 206010017758 Gastric cancer Diseases 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102100006815 IL2RA Human genes 0.000 description 3
- 101700082799 IL2RA Proteins 0.000 description 3
- 101700015336 ISG20 Proteins 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 241000764238 Isis Species 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 102100011339 KLK3 Human genes 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- 229940067606 Lecithin Drugs 0.000 description 3
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108060001084 Luciferase family Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 3
- 206010061289 Metastatic neoplasm Diseases 0.000 description 3
- 229960004857 Mitomycin Drugs 0.000 description 3
- 108010008707 Mucin-1 Proteins 0.000 description 3
- 102000007298 Mucin-1 Human genes 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 229960003171 Plicamycin Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- UOWVMDUEMSNCAV-WYENRQIDSA-N Rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 102100010587 SDC1 Human genes 0.000 description 3
- 101700070405 SDC1 Proteins 0.000 description 3
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N Seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 3
- 108010008478 TNF-Related Apoptosis-Inducing Ligand Proteins 0.000 description 3
- 102100002198 TNFSF10 Human genes 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000002491 angiogenic Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001772 anti-angiogenic Effects 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 230000000692 anti-sense Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 230000003115 biocidal Effects 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000006143 cell culture media Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 108091006028 chimera Proteins 0.000 description 3
- 230000002759 chromosomal Effects 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 229960003901 dacarbazine Drugs 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000002612 dispersion media Substances 0.000 description 3
- 108010045524 dolastatin 10 Proteins 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000003054 hormonal Effects 0.000 description 3
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 3
- 229960002411 imatinib Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001394 metastastic Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 201000005746 pituitary adenoma Diseases 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000002285 radioactive Effects 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 239000001187 sodium carbonate Substances 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229940001593 sodium carbonate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 230000002992 thymic Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-Hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229960003272 ASPARAGINASE Drugs 0.000 description 2
- 208000004064 Acoustic Neuroma Diseases 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N Anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 229940120638 Avastin Drugs 0.000 description 2
- 102100013894 BCL2 Human genes 0.000 description 2
- 108060000885 BCL2 Proteins 0.000 description 2
- 208000004860 Blast Crisis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 2
- 241000208199 Buxus sempervirens Species 0.000 description 2
- 102100003755 CCNO Human genes 0.000 description 2
- 101700047412 CCNO Proteins 0.000 description 2
- 101700033362 CD28 Proteins 0.000 description 2
- 102100019461 CD28 Human genes 0.000 description 2
- 102100008191 CD8A Human genes 0.000 description 2
- 101700054655 CD8A Proteins 0.000 description 2
- 102100005284 CTAG2 Human genes 0.000 description 2
- 101700050838 CTAG2 Proteins 0.000 description 2
- 229960004562 Carboplatin Drugs 0.000 description 2
- 108010022830 Cetuximab Proteins 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 229960004630 Chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 229940119017 Cyclosporine Drugs 0.000 description 2
- 229960000684 Cytarabine Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 102100000760 DNASE1 Human genes 0.000 description 2
- 229960000640 Dactinomycin Drugs 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 229960000975 Daunorubicin Drugs 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 229940082789 Erbitux Drugs 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- 102100004572 FLT3LG Human genes 0.000 description 2
- 101710022257 FLT3LG Proteins 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 229940022353 Herceptin Drugs 0.000 description 2
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 108010066979 Interleukin-27 Proteins 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 210000004698 Lymphocytes Anatomy 0.000 description 2
- 210000003712 Lysosomes Anatomy 0.000 description 2
- 102100009692 MAGEC2 Human genes 0.000 description 2
- 101710027725 MAGEC2 Proteins 0.000 description 2
- 102100008857 MLANA Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229960004961 Mechlorethamine Drugs 0.000 description 2
- FRQMUZJSZHZSGN-HBNHAYAOSA-N Medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 Mitoxantrone Drugs 0.000 description 2
- 210000001616 Monocytes Anatomy 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 229950005751 Ocrelizumab Drugs 0.000 description 2
- 229960002450 Ofatumumab Drugs 0.000 description 2
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- 210000002741 Palatine Tonsil Anatomy 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 108010077397 Pseudomonas aeruginosa toxA protein Proteins 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
- 210000003705 Ribosomes Anatomy 0.000 description 2
- 102100017680 SMAD4 Human genes 0.000 description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 2
- 108020004459 Small Interfering RNA Proteins 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N Staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- 229960001052 Streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001940 Sulfasalazine Drugs 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 102100009534 TNF Human genes 0.000 description 2
- 229960001278 Teniposide Drugs 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 229960005454 Thioguanine Drugs 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- YJDYDFNKCBANTM-QCWCSKBGSA-N Valspodar Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 2
- 229950000815 Veltuzumab Drugs 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 229950009002 Zanolimumab Drugs 0.000 description 2
- LQKSHSFQQRCAFW-CCVNJFHASA-N [(2S)-1-[(2S)-2-benzyl-3-methoxy-5-oxo-2H-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 229960002616 ancestim Drugs 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003080 antimitotic agent Substances 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000001086 cytosolic Effects 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 230000002074 deregulated Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 108010045552 dolastatin 15 Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000002710 external beam radiation therapy Methods 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 229940027318 hydroxyurea Drugs 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000003308 immunostimulating Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 108090000237 interleukin-24 Proteins 0.000 description 2
- 102000003898 interleukin-24 Human genes 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 230000001868 lysosomic Effects 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 229960005485 mitobronitol Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108010010621 modeccin Proteins 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 201000009251 multiple myeloma Diseases 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 2
- 108010030900 ocrelizumab Proteins 0.000 description 2
- 108010052070 ofatumumab Proteins 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000000174 oncolytic Effects 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000005298 paramagnetic Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 229920002033 ribozyme Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 239000002924 silencing RNA Substances 0.000 description 2
- 238000003530 single readout Methods 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001954 sterilising Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N trans-Retinyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 230000000989 vascularization Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 108010063727 veltuzumab Proteins 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 108010052251 zanolimumab Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2S)-2-amino-3-phenylpropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical group NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KNSSRCNQLVQGJW-UHFFFAOYSA-N 1-ethyl-9H-carbazol-2-amine Chemical compound N1C2=CC=CC=C2C2=C1C(CC)=C(N)C=C2 KNSSRCNQLVQGJW-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N 17-Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-Methoxyestradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- HDTIFOGXOGLRCB-VVGYGEMISA-N 2-[2-[(2R,3R)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCC(OCCO)[C@H]1OCC(OCCO)[C@H]1OCCO HDTIFOGXOGLRCB-VVGYGEMISA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PBSPQZHJEDTHTL-UHFFFAOYSA-N 2-benzoylpentanoic acid Chemical compound CCCC(C(O)=O)C(=O)C1=CC=CC=C1 PBSPQZHJEDTHTL-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101700027111 3SA0 Proteins 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N 5-Dimethylaminonaphthyl-5-sulfonyl chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2R)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- PHEZJEYUWHETKO-UHFFFAOYSA-N 6-Fluoro-2-(2'-Fluoro-1,1'-Biphenyl-4-Yl)-3-Methylquinoline-4-Carboxylic Acid Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
- WQHXQLSSMJYNOJ-UHFFFAOYSA-N 7-[[4-[[4-[[5-[[5-[(6,8-disulfonaphthalen-2-yl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]carbamoylamino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]naphthalene-1,3-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=CC(NC(=O)C3=CC(=CN3C)NC(=O)C3=CC(NC(=O)NC4=CN(C)C(C(=O)NC5=CN(C)C(C(=O)NC=6C=C7C(=CC(=CC7=CC=6)S(O)(=O)=O)S(O)(=O)=O)=C5)=C4)=CN3C)=CC=C21 WQHXQLSSMJYNOJ-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 102100018024 ANG Human genes 0.000 description 1
- 102100007742 ANGPT1 Human genes 0.000 description 1
- 229940033495 ANTIMALARIALS Drugs 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 229940022698 Acetylcholinesterase Drugs 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010007562 Adalimumab Proteins 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 229940003969 Adrenergic and dopaminergic agents combinations Drugs 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229940001019 Aluminium antacid compound combinations Drugs 0.000 description 1
- 229940010996 Amide local anesthetic combinations Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 Aminoglutethimide Drugs 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 206010002449 Angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 108090000644 Angiozyme Proteins 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
- 229940084438 Antiinfective irrigating solution combinations Drugs 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 210000000702 Aorta, Abdominal Anatomy 0.000 description 1
- 229940078010 Arimidex Drugs 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N Atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 102100011431 BAGE Human genes 0.000 description 1
- 108060000856 BAGE Proteins 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- 102000036638 BRCA1 Human genes 0.000 description 1
- 108010042977 BRCA1 Protein Proteins 0.000 description 1
- 102000002280 BRCA2 Protein Human genes 0.000 description 1
- 108010000750 BRCA2 Protein Proteins 0.000 description 1
- 210000003651 Basophils Anatomy 0.000 description 1
- 229940095835 Beta-lactamase sensitive penicillin combinations Drugs 0.000 description 1
- 230000037177 Biodistribution Effects 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 229950010231 Brequinar Drugs 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100016450 CCL7 Human genes 0.000 description 1
- 101700044004 CCL7 Proteins 0.000 description 1
- 101700027514 CD14 Proteins 0.000 description 1
- 102100003268 CD14 Human genes 0.000 description 1
- 101700017647 CD33 Proteins 0.000 description 1
- 102100016493 CD33 Human genes 0.000 description 1
- 102100016530 CD37 Human genes 0.000 description 1
- 101700044364 CD37 Proteins 0.000 description 1
- 101700078950 CD44 Proteins 0.000 description 1
- 102100003735 CD44 Human genes 0.000 description 1
- 102100005828 CD5 Human genes 0.000 description 1
- 101700066525 CD5 Proteins 0.000 description 1
- 102100019283 CD52 Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102100004444 CD58 Human genes 0.000 description 1
- 101710018147 CD58 Proteins 0.000 description 1
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 1
- 108091007476 CDKs Proteins 0.000 description 1
- 210000003229 CMP Anatomy 0.000 description 1
- 102100016705 COL18A1 Human genes 0.000 description 1
- 102100009789 COL4A2 Human genes 0.000 description 1
- 101710038502 COL4A2 Proteins 0.000 description 1
- 102100001891 CTAG1A Human genes 0.000 description 1
- 101710004449 CTAG1A Proteins 0.000 description 1
- 102100005310 CTLA4 Human genes 0.000 description 1
- 101700054183 CTLA4 Proteins 0.000 description 1
- 102100002212 CXCR4 Human genes 0.000 description 1
- 101710003734 CXCR4 Proteins 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- 229940046731 Calcineurin inhibitors Drugs 0.000 description 1
- 229940001469 Calcium antacid compound combinations Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229940073688 Caries prophylactic agent combinations Drugs 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 108050004290 Cecropins Proteins 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000256135 Chironomus thummi Species 0.000 description 1
- 210000003763 Chloroplasts Anatomy 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108009000280 Complement Activation Proteins 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- BKRDNYHYNZJMPG-UHFFFAOYSA-A Custirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].COCCOC1C(O)C(COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2COP([O-])(=S)OC2C(C(OC2CO)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C3=NC=NC(N)=C3N=C2)OCCOC)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C3=NC=NC(N)=C3N=C2)OCCOC)OC1N1C=C(C)C(=O)NC1=O BKRDNYHYNZJMPG-UHFFFAOYSA-A 0.000 description 1
- 102000003903 Cyclin-Dependent Kinases Human genes 0.000 description 1
- 108090000266 Cyclin-Dependent Kinases Proteins 0.000 description 1
- 108050006400 Cyclins Proteins 0.000 description 1
- 102000016736 Cyclins Human genes 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N Cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229960001305 Cysteine Hydrochloride Drugs 0.000 description 1
- 210000000172 Cytosol Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 101710034658 DNASE1 Proteins 0.000 description 1
- 101700000624 DUT Proteins 0.000 description 1
- 229960004969 Dalteparin Drugs 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 230000035687 Dissociation Rate Constant Effects 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 229950004203 Droloxifene Drugs 0.000 description 1
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 1
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 1
- 101710013128 EEF1E1 Proteins 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N Emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 1
- 210000001163 Endosomes Anatomy 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 229940060167 Enema combinations Drugs 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 231100000655 Enterotoxin Toxicity 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- 231100000776 Exotoxin Toxicity 0.000 description 1
- 102100014610 FCAR Human genes 0.000 description 1
- 101700041688 FCAR Proteins 0.000 description 1
- 102100015540 FCGR1A Human genes 0.000 description 1
- 101710003440 FCGR1A Proteins 0.000 description 1
- 101710044640 FCGR2A Proteins 0.000 description 1
- 102100015543 FCGR2B Human genes 0.000 description 1
- 101710044641 FCGR2B Proteins 0.000 description 1
- 101710044642 FCGR2C Proteins 0.000 description 1
- 102100015541 FCGR3A Human genes 0.000 description 1
- 101710044656 FCGR3A Proteins 0.000 description 1
- 101710044657 FCGR3B Proteins 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 102100017996 FGFR1 Human genes 0.000 description 1
- 102100018000 FGFR2 Human genes 0.000 description 1
- 102100020191 FGFR3 Human genes 0.000 description 1
- 102100020189 FGFR4 Human genes 0.000 description 1
- 101700075612 FGFR4 Proteins 0.000 description 1
- 101710009074 FLT3 Proteins 0.000 description 1
- 101710030894 FLT4 Proteins 0.000 description 1
- 102100019327 FUT4 Human genes 0.000 description 1
- 101700004786 FUT4 Proteins 0.000 description 1
- 230000036809 Fabs Effects 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 1
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N Fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000036328 Free drug Effects 0.000 description 1
- 229960002258 Fulvestrant Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100000899 GNRH1 Human genes 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 108010089239 Gelonium multiflorum GEL protein Proteins 0.000 description 1
- 210000001280 Germinal Center Anatomy 0.000 description 1
- 208000007465 Giant Cell Arteritis Diseases 0.000 description 1
- 229940080856 Gleevec Drugs 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- LLEUXCDZPQOJMY-AAEUAGOBSA-N Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 LLEUXCDZPQOJMY-AAEUAGOBSA-N 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 1
- IUAYMJGZBVDSGL-UHFFFAOYSA-N Gramicidin Chemical compound N1C(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 IUAYMJGZBVDSGL-UHFFFAOYSA-N 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 1
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical class CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 229960003366 Hepatitis vaccine combinations Drugs 0.000 description 1
- 206010066957 Hepatosplenic T-cell lymphoma Diseases 0.000 description 1
- 108091006038 His-tagged proteins Proteins 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 229940048921 Humira Drugs 0.000 description 1
- 210000004754 Hybrid Cells Anatomy 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 Hydroxychloroquine Drugs 0.000 description 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 101700033123 IAAT Proteins 0.000 description 1
- 102100004115 ICAM1 Human genes 0.000 description 1
- 101700051176 ICAM1 Proteins 0.000 description 1
- 101700070228 IFN Proteins 0.000 description 1
- 101700066403 IFNA1 Proteins 0.000 description 1
- 101700023446 IFNT Proteins 0.000 description 1
- 208000010159 IGA Glomerulonephritis Diseases 0.000 description 1
- 102100015835 IGHV3-33 Human genes 0.000 description 1
- 101710002419 IGHV3-33 Proteins 0.000 description 1
- 102100014202 IL24 Human genes 0.000 description 1
- 101700047997 IL24 Proteins 0.000 description 1
- 102100008185 IL6R Human genes 0.000 description 1
- 101710022769 IL6R Proteins 0.000 description 1
- 229960001438 IMMUNOSTIMULANTS Drugs 0.000 description 1
- OMEUGRCNAZNQLN-UHFFFAOYSA-N ISIS 5132 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(S)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(O)C1 OMEUGRCNAZNQLN-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 229950002248 Idoxifene Drugs 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 229940031471 Imidazole and triazole derivative topical antifungal combinations Drugs 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 108010053490 Infliximab Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108091022066 Insulin-Like Growth Factor Binding Proteins Proteins 0.000 description 1
- 102000020344 Insulin-Like Growth Factor Binding Proteins Human genes 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108050006617 Interleukin-1 receptor family Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor family Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 229940000248 Intermediate-acting sulfonamide combinations Drugs 0.000 description 1
- 108010089187 Ipilimumab Proteins 0.000 description 1
- 229940084651 Iressa Drugs 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 229960005280 Isotretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 102100006987 KCNH4 Human genes 0.000 description 1
- 101700077860 KCNH4 Proteins 0.000 description 1
- 102100013180 KDR Human genes 0.000 description 1
- 101700033678 KDR Proteins 0.000 description 1
- 101710030888 KDR Proteins 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 1
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 1
- 125000003290 L-leucino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 101710031883 LINS1 Proteins 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010024459 Light chain disease Diseases 0.000 description 1
- 229940107315 Local hemostatic combinations Drugs 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N Lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 229940007270 Long-acting sulfonamide combinations Drugs 0.000 description 1
- 229940076783 Lucentis Drugs 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N Luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000003002 Lymphoma, T-Cell, Peripheral Diseases 0.000 description 1
- 101700016008 MAFK Proteins 0.000 description 1
- 102100009702 MAGEB5 Human genes 0.000 description 1
- 101710027701 MAGEB5 Proteins 0.000 description 1
- 102100009700 MAGEB6 Human genes 0.000 description 1
- 101710027699 MAGEB6 Proteins 0.000 description 1
- 102100012876 MAGEC3 Human genes 0.000 description 1
- 101710027724 MAGEC3 Proteins 0.000 description 1
- 101700067074 MAPK Proteins 0.000 description 1
- 101710041325 MAPKAPK2 Proteins 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 101700004513 MCHR2 Proteins 0.000 description 1
- 102100012644 MIF Human genes 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- 101710027015 MIMI_R382 Proteins 0.000 description 1
- 101700013924 MITF Proteins 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N MIZORIBINE Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 101710012533 MLANA Proteins 0.000 description 1
- 102100014416 MLH1 Human genes 0.000 description 1
- 102100013820 MSH2 Human genes 0.000 description 1
- 101700083509 MSH2 Proteins 0.000 description 1
- 229910015837 MSH2 Inorganic materials 0.000 description 1
- 102100006044 MUC16 Human genes 0.000 description 1
- 229940000523 Magnesium antacid compound combinations Drugs 0.000 description 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 Marimastat Drugs 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 229940090004 Megace Drugs 0.000 description 1
- VDXZNPDIRNWWCW-UHFFFAOYSA-N Melitten Chemical compound NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-UHFFFAOYSA-N 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 229960002514 Melphalan hydrochloride Drugs 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229960003151 Mercaptamine Drugs 0.000 description 1
- 241001436793 Meru Species 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229950003063 Mitumomab Drugs 0.000 description 1
- 240000004175 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 108090000393 Muromonab-CD3 Proteins 0.000 description 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- XLXSAKCOAKORKW-KPKRHBJMSA-N N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl] Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-KPKRHBJMSA-N 0.000 description 1
- YDRYCKQMBHLPPU-UHFFFAOYSA-M N-[(4-aminophenyl)methyl]carbamate Chemical compound NC1=CC=C(CNC([O-])=O)C=C1 YDRYCKQMBHLPPU-UHFFFAOYSA-M 0.000 description 1
- JMUPMJGUKXYCMF-UHFFFAOYSA-N N-[2-[2-[[6-[5-acetamido-6-(5-acetamido-1,2,4-trihydroxy-6-oxohexan-3-yl)oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-[3-[3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymet Chemical compound OC1C(NC(C)=O)C(OC(C(O)C(C=O)NC(=O)C)C(O)CO)OC(CO)C1OC1C(O)C(OC2C(C(O)C(O)C(CO)O2)OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)NC(C)=O)C(O)C(COC2C(C(O)C(O)C(CO)O2)OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)NC(C)=O)O1 JMUPMJGUKXYCMF-UHFFFAOYSA-N 0.000 description 1
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 1
- 101710008030 NME2 Proteins 0.000 description 1
- 102100016102 NTRK1 Human genes 0.000 description 1
- 101700043017 NTRK1 Proteins 0.000 description 1
- 102100016105 NTRK3 Human genes 0.000 description 1
- 108060005034 NTRK3 Proteins 0.000 description 1
- 229920002957 Naked DNA Polymers 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 108010035649 Natalizumab Proteins 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 210000001178 Neural Stem Cells Anatomy 0.000 description 1
- 208000002040 Neurosyphilis Diseases 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 229950010203 Nimotuzumab Drugs 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 101710005363 ORF85 Proteins 0.000 description 1
- 229960002700 Octreotide Drugs 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- CKNAQFVBEHDJQV-UHFFFAOYSA-N Oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 1
- 229950008687 Oltipraz Drugs 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 229940111336 Other anti-dementia drug combinations in ATC Drugs 0.000 description 1
- 229940032419 Other antifungal combinations for topical use in ATC Drugs 0.000 description 1
- 229940106059 Other intestinal adsorbent combinations in ATC Drugs 0.000 description 1
- 229940076421 Other irrigating solution combinations in ATC Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 230000035982 PAB Effects 0.000 description 1
- 101700027293 PER18 Proteins 0.000 description 1
- 101710038828 PRKCA Proteins 0.000 description 1
- 102100004042 PTK7 Human genes 0.000 description 1
- 101700007351 PTK7 Proteins 0.000 description 1
- 101700059076 PTPRC Proteins 0.000 description 1
- 102100005499 PTPRC Human genes 0.000 description 1
- 102100009677 PWWP3A Human genes 0.000 description 1
- 108060006838 PWWP3A Proteins 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 108010061219 Panitumumab Proteins 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229960002566 Papillomavirus vaccines Drugs 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 229940097635 Penicillins with extended spectrum combinations Drugs 0.000 description 1
- 229960003330 Pentetic Acid Drugs 0.000 description 1
- FCCNSUIJIOOXEZ-SJYYZXOBSA-N Pentosan Polysulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@@H](OS(O)(=O)=O)[C@H](O)CO[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](O)OC1 FCCNSUIJIOOXEZ-SJYYZXOBSA-N 0.000 description 1
- 229940043138 Pentosan Polysulfate Drugs 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000001322 Periplasm Anatomy 0.000 description 1
- 206010034695 Pernicious anaemia Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N Phenylalanyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 241000186704 Pinales Species 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 229940012957 Plasmin Drugs 0.000 description 1
- 229940001079 Platelet aggregation inhibitor combinations excl. heparin Drugs 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 229940086052 Potassium supplement combinations Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 229940063222 Provera Drugs 0.000 description 1
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 1
- 102100016115 RAF1 Human genes 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 101710004305 RIP30A Proteins 0.000 description 1
- 101700000014 RIPS Proteins 0.000 description 1
- 229920000320 RNA (poly(A)) Polymers 0.000 description 1
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 1
- 101700044827 RNMT Proteins 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 229940116176 Remicade Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 230000036141 SERUM STABILITY Effects 0.000 description 1
- 101700062085 SMAD4 Proteins 0.000 description 1
- 229940100996 SODIUM BISULFATE Drugs 0.000 description 1
- 229940084925 Salt solution combinations Drugs 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 229940072272 Sandostatin Drugs 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 208000005511 Schoenlein-Henoch Purpura Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N Seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- 229950009921 Seocalcitol Drugs 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 108010091769 Shiga Toxin 1 Proteins 0.000 description 1
- 108010090763 Shiga Toxin 2 Proteins 0.000 description 1
- 229940000628 Short-acting sulfonamide combinations Drugs 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 229940115586 Simulect Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 206010040767 Sjogren's syndrome Diseases 0.000 description 1
- 108010050282 Smad4 Protein Proteins 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229960000553 Somatostatin Drugs 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229940036145 Specific immunoglobulin combinations Drugs 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- 229950001248 Squalamine Drugs 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J Strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 Suramin Drugs 0.000 description 1
- 206010042732 Sydenham's chorea Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 101710037124 TEK Proteins 0.000 description 1
- 101710040448 TNFRSF4 Proteins 0.000 description 1
- 102100013135 TNFRSF4 Human genes 0.000 description 1
- 101710040533 TNFRSF8 Proteins 0.000 description 1
- 102100009538 TNFRSF8 Human genes 0.000 description 1
- 102100012502 TRAPPC1 Human genes 0.000 description 1
- 101710032090 TRAPPC1 Proteins 0.000 description 1
- 101700019351 TRYM Proteins 0.000 description 1
- 208000002025 Tabes Dorsalis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229960001967 Tacrolimus Drugs 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 229940120982 Tarceva Drugs 0.000 description 1
- 102000004591 Telomerase Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010043207 Temporal arteritis Diseases 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N Threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 208000008732 Thymoma Diseases 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N Thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 208000005057 Thyrotoxicosis Diseases 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108010081291 Type 1 Fibroblast Growth Factor Receptor Proteins 0.000 description 1
- 108010081268 Type 2 Fibroblast Growth Factor Receptor Proteins 0.000 description 1
- 108010081267 Type 3 Fibroblast Growth Factor Receptor Proteins 0.000 description 1
- 229940079023 Tysabri Drugs 0.000 description 1
- 229960004854 VIRAL VACCINES Drugs 0.000 description 1
- 229950010938 Valspodar Drugs 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N Vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
- 101710033820 XVIII Proteins 0.000 description 1
- 229940099073 Xolair Drugs 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 101710002368 ZNF197 Proteins 0.000 description 1
- 229950008250 Zalutumumab Drugs 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N [(1R)-1-carboxy-2-sulfanylethyl]azanium;chloride;hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- OUUYBRCCFUEMLH-YDALLXLXSA-N [(1S)-2-[4-[bis(2-chloroethyl)amino]phenyl]-1-carboxyethyl]azanium;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 OUUYBRCCFUEMLH-YDALLXLXSA-N 0.000 description 1
- HHVGDFKKILAWTA-UHFFFAOYSA-L [4-amino-5-[[[[2-[[[[2-(hydroxymethyl)-5-$l^{1}-boranyloxolan-3-yl]amino]-oxidophosphinothioyl]oxymethyl]-5-$l^{1}-boranyloxolan-3-yl]amino]-sulfidophosphoryl]oxymethyl]oxolan-2-yl]boron Chemical compound O1C([B])CC(N)C1COP([S-])(=O)NC1C(COP([O-])(=S)NC2C(OC([B])C2)CO)OC([B])C1 HHVGDFKKILAWTA-UHFFFAOYSA-L 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- XQEJFZYLWPSJOV-XJQYZYIXSA-N acetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosa Chemical compound CC(O)=O.C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 XQEJFZYLWPSJOV-XJQYZYIXSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated Effects 0.000 description 1
- LXQXZNRPTYVCNG-YPZZEJLDSA-N americium-241 Chemical compound [241Am] LXQXZNRPTYVCNG-YPZZEJLDSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003692 aminobutyric acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agents Drugs 0.000 description 1
- 230000000078 anti-malarial Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 108010027090 biotin-streptavidin complex Proteins 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 101700018328 ccdB Proteins 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- GUTLYIVDDKVIGB-YPZZEJLDSA-N cobalt-57 Chemical compound [57Co] GUTLYIVDDKVIGB-YPZZEJLDSA-N 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940086715 combination drugs used in erectile dysfunction Drugs 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 101700067609 ctx Proteins 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 108010031324 daratumumab Proteins 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- AZVARJHZBXHUSO-UHFFFAOYSA-N duocarmycin a Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3CC4CC44C5=C(C(C=C43)=O)NC(C5=O)(C)C(=O)OC)=CC2=C1 AZVARJHZBXHUSO-UHFFFAOYSA-N 0.000 description 1
- 108010010371 efalizumab Proteins 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229940050438 excl. combinations with cough suppressants expectorant combinations Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 229940048784 expectorant combinations excluding combinations with cough suppressants Drugs 0.000 description 1
- 229940050564 fast-acting combinations Insulins and analogs for injection Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 201000010915 glioblastoma multiforme Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 229940090613 gonadotropin combinations Drugs 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 201000008064 heavy chain disease Diseases 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000003652 hormone inhibitor Substances 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 229940052038 intermediate-acting combinations Insulins and analogs for injection Drugs 0.000 description 1
- 229940052297 intermediate-acting combined with fast-acting- combinations Insulins and analogs for injection Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XMBWDFGMSWQBCA-AHCXROLUSA-M iodine-123(1-) Chemical compound [123I-] XMBWDFGMSWQBCA-AHCXROLUSA-M 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 101700026636 lin Proteins 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229940074591 local opthalmologic anesthetic combinations Drugs 0.000 description 1
- 229940051883 long-acting insulins and analogs for injection combinations Drugs 0.000 description 1
- 229940042835 lung surfactant combinations Drugs 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 230000002132 lysosomal Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- URXWVWVPMJSAJD-KOORYGTMSA-N megestrol acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 URXWVWVPMJSAJD-KOORYGTMSA-N 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 230000002438 mitochondrial Effects 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000005962 mycosis fungoide Diseases 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 108010043585 nimotuzumab Proteins 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940064925 opium alkaloids and derivative combination cough suppressants Drugs 0.000 description 1
- 229940064347 other cough suppressant combinations in ATC Drugs 0.000 description 1
- 229940021273 other nasal preparation combinations in ATC Drugs 0.000 description 1
- 229940067531 otologic analgesic and anesthetic combinations Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 201000007923 peripheral T-cell lymphoma Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 229960004723 phenylbutyrate Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 230000000896 plasminic Effects 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 108010078110 pokeweed antiviral protein Proteins 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical Effects 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 101710024887 rl Proteins 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000001296 salvia officinalis l. Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 description 1
- IGHGOYDCVRUTSU-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O IGHGOYDCVRUTSU-UHFFFAOYSA-M 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 101700045897 spk-1 Proteins 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000003582 thrombocytopenic Effects 0.000 description 1
- 108060008245 thrombospondin family Proteins 0.000 description 1
- 102000002938 thrombospondin family Human genes 0.000 description 1
- 201000009365 thymic carcinoma Diseases 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229940030476 topical antibiotic combinations Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108010082372 valspodar Proteins 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940022453 vitamin D and analog combinations Drugs 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 108010023055 zalutumumab Proteins 0.000 description 1
- LBDSXVIYZYSRII-IGMARMGPSA-N α-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
Classifications
-
- Y02A50/472—
Abstract
Disclosed is an antibody comprising LCDR sequences SEQ ID NO: 24, AAS and SEQ ID NO:25 and HCDRs selected from SEQ ID NOs: 20-22, 8-10, 12-14, or 16-18. Further discloses conjugates comprising the antibodies and a therapeutic moiety attached to sulphydryl residues in the antibody. The therapeutic moiety may be selected from cytotoxic moieties, radioisotopes, chemotherapeutic agents, lytic peptides and cytokines. Further disclosed is the suitability of the antibody for use in the treatment of cancer. iety may be selected from cytotoxic moieties, radioisotopes, chemotherapeutic agents, lytic peptides and cytokines. Further disclosed is the suitability of the antibody for use in the treatment of cancer.
Description
HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES T CD74
FIELD OF THE INVENTION
The present invention relates to CD74-specific antibodies and antibody-drug conjugates
(ADCs) thereof, pharmaceutical compositions of such antibodies or ADCs, and their use in
therapeutic applications.
BACKGROUND OF THE INVENTION
Human leukocyte antigen (HLA) class I I histocompatibility antigen gamma chain, also called
HLA-DR antigen-associated invariant chain, l a antigen-associated ant chain, I i and
CD74, is a transmembrane protein with a short cytoplasmic tail. The primary function of
CD74 is to regulate e loading onto the major histocompatibility complex (MHC) class
I I heterodimers in intracellular compartments.
Only a small portion of the total cell CD74 content is sed on the cell surface.
Cell surface CD74 is very rapidly alized both with and without CD74 antibodies bound
(Roche PA et al., PNAS 1993; 90: 8581-8585; Hansen H et al., Biochem J 1996; 320: 293-
300; Ong GL et al., Immunology 1999; 98:296-302). The steady-state level of cell surface
CD74 is therefore rather low, varying in monocytes from a few hundred t o a few thousand
molecules per cell.
The exact function of cell surface-expressed CD74 is not known, but studies have
documented CD74 as a membrane or for the pro-inflammatory cytokine macrophage
migration inhibitory factor (MIF). MIF binding t o CD74 activates downstream signaling
through the MAPK and Akt pathways and es cell proliferation and survival. This
interaction is likely regulated also by the presence of CD44, CXCR2 or CXCR4 as co-
receptors.
Upregulation of CD74 expression has been observed in many types of cancer, as well
as in certain ions and matory conditions. Various formats of a humanized
CD74-specific monoclonal dy, hLLl, have been proposed for treatment of CD74-
positive tumors (Chang CH et al., Blood 2005;106:4308-4314; Sapra P et al., Clin Can Res
2005;11:5257-5264; Stein R et al., Blood 04:3705-11; Govindan SV et al. J Nucl
Med 2000;41 :2089-2097; Hertlein E et al., Blood 2010; 116: 2554-2558; Stein R et al., Clin
Cancer Res 2009; 15: 2808-2817; Sharkey RM et al., J Nucl Med 2009; 50: 444-453;
Lundberg BB et al., Drug Deliv 2007; 14: 171-175; Griffiths GL et al., Int J Cancer 1999;
81: 985-992; Griffiths GL et al., Cancer Res 2003; 9 : 6567-6571; Ochakovskaya R et al.,
Clin Cancer Res 2001; 7 : 510; Shih L et al., Cancer Immunol Immunother; Burton
D et al., Clin Cancer Res 2004; 10: 6606-6611; Lundberg BB et al., J Control Release
2004; 94: 155-161).
????????????????????????????????????????????????????????????????????????
???????????????????????????????????????˘?˘????????????????????????????????????????
??????????????????????????? ?ˇˆ?˘ ?
???????????????????????? ?
??????????????????????? ?????????????˝???????????????????????????????????
ˆˇ˛˚ ˜?????????????????????????ˇˆ??????????ˆˇ˛˚ ˜???????????????????˘?˙??????????????
????ˇˆ???????????????????? ??????ˆˇ˛˚?????????????????????????? ???????????????????
ˆˇ˛˚ ˜? ???????????????????????????????????????????????????????????????˘?!??????????˝??
?????????????????????????????"????˝????????????????"??????????????????????ˆˇ˛˚?
???????????#???????????????????????????????????????????????????????????? ???ˇˆ??????
???????????????????????$????????????????????"?????????????????????˘?˙??????????ˇˆ??????
????"????˝?????????????????˝????#???????ˆˇ˛˚ ˜? ??????????????˘ ?
??????????????????????????????????????????????? ??????????˝?$??????????????
ˆˇ˛˚????? ????????$?????????????????& '???????????????????????ˆˇ(%????????)?
??*??????????+,-?.ˇ?/01?˚???????????????????*????????+?????+,-?.ˇ?/01?2?????? ?
3?4 ??& 5???????????????????????ˆˇ(%????????)???*??????????+,-?.ˇ?/01?
?6???%????????7 ?
3?4 ??& 5?????????????????????? ?ˆˇ(%????????)???*??????????+,-?.ˇ?/0+1?
8??9?????%6?7 ?
3?4 ??& 5???????????????????????ˆˇ(%????????)???*??????????+,-?.ˇ?/01?
%???%)?????%˚?7??? ?
3?4 ??& 5???????????????????????ˆˇ(%????????)???*??????????+,-?.ˇ?/01?
%:??%˛?????%8 ˘?
˙?????????????????????????????????ˇˆ?? ???????????????????????????˝????
???????????????????????????????????????????????˝????????????????????????????????˝?
???????˘?.?????????????????????????????????????????????????˘ ?
˙?? ??????????????????? ???? ???????? ???ˇˆ????????????????ˆˇ˛˚ ????
???????????? ?????????????????????????????????????????????????????$?˝?????????????????
????????????????????˘ ?
˙????????????????????????????????????????????????????????????????????????????$˘ ?
????????????????????????????????? ?
???˘ˇˆ?˙˝ ??????????????*?????????????????????? ˆˇ˛˚??????????????????????, ??????˘?
ˆˇ˛˚?%????? ˇ˛˚???? ˜):?%????? ;????????5??ˆˇ˛˚?%????? ;?????????????????
+,-?.ˇ?/0+1?% ˜:?????????????˝˘ ?
???˘ˇˆ?˛˝ ???????????????????????????˝?3&54????????????????????3&'4?????????*???????
??????????????????????????????????????????˘?˙???+,-?.ˇ?/0?????????&5<&'???*?????????
???????$????????????????????????????????????????*?????˘?ˆ?????????????˝ ˜????????????
????????3ˆˇ(? 4??????????????.=>˙??????????????????????????????????????$?1?
??*????????????????????????????ˆˇ(%???????????????*?????????????????ˆˇ(????????????
??*?????????????????ˆˇ()˘ ?
???˘ˇˆ?˚˝? ???????????ˆˇ˛˚ ???????????????????????????????????????????????????
???? ? ??????????????????????????????????%????????????????3ˆˇ˛˚?%?????ˆˇ˛˚??4??
????????????˝?,'.+?˘??????????????????????$??????????????˝???????????˝??? ˜
?????????????5,@ ˜?9)A???????$?????????????????˝?????????????????? ????????????????˘ ?
???˘ˇˆ?˜˝ ??????ˆˇ˛ ˚˜????????????????????????????????ˆˇ˛˚????(?B?????????
????????????˝?A?ˆ+˘??????????????????????$??????????????˝???????????˝??? ˜
?????????????5,@ ˜?9)A???????$?????????????????˝?????????????????? ????????????????˘ ?
Figure 5 : Cross-reactivity of pecific antibodies with cynomolgus CD74. Human tonsil
(upper panel) and cynomolgus lymph nodes (lower panel) were stained with CD74-specific
antibodies. * : germinal center; Mf: macrophages; # : Mantle zone B cells.
Figure 6 : Dose-dependent induction of cell killing by anti-kappa-ETA'-pre-incubated
pecific antibodies. A representative experiment is shown. Data shown are mean
percentages ity of duplicate wells of cells treated with anti-kappa-ETA'-pre-incubated
CD74 HuMab antibodies. Percentage viability was calculated as described in Example 14.
Figure 7 : Binding of CD74 HuMab antibodies 005 and 006 (A) and 011 (B) and the
corresponding ADCs t o recombinant protein of the CD74vl extracellular , as
determined by ELISA. One representative experiment is shown.
Figure 8 : Binding of CD74 HuMab antibodies 005 and 006 (A) and 011 (B) and the
corresponding ADCs t o surface-expressed CD74, determined by FACS analysis on Daudi
cells. Data shown are mean fluorescence intensities (MFI), calculated from three
independent experiments.
Figure 9 : Dose-dependent ion of cell killing by CD74-specific ADCs. One
representative experiment is shown for each of the following cell lines: Daudi (A), Raji (B),
M4A4 (C) and NCI-H747 (D) cells. Data shown are percentages survival of duplicate wells of
cells treated with pecific ADCs.
Figure 10: I n vivo efficacy of pecific ADCs in therapeutic treatment of Daudi-luc
xenografts in SCID mice. Mice with established Daudi-luc tumors were treated with
CD74-specific ADCs. Data shown are mean bioluminescence imaging (BLI) signals ± S.E.M.
per group (n = 7 mice per group).
Figure 11: I n vivo cy of CD74-specific ADCs in therapeutic treatment of uc
xenografts in SCID mice. Mice with established Raji-luc tumors were treated with
CD74-specific ADCs. Data shown are mean BLI signals ± S.E.M. per group (n = 7 mice per
group).
Figure 12: I n vivo cy of CD74-specific ADCs in therapeutic treatment of Raji
xenografts in SCID mice. Mice with established s.c. Raji tumors were treated with
CD74-specific ADCs. Data shown are mean tumor volumes ± S.E.M. per group (n = 6 mice
per group).
Figure 13: I n vivo efficacy of anti CD74 ADCs in therapeutic treatment of M4A4 xenografts
in SCID mice. Mice with established M4A4 tumors were treated with anti CD74 ADCs. Data
shown are mean tumor volumes ± S.E.M. per group (n = 7 mice per .
Figure 14: Determination of off-rates of CD74-specific HuMab antibodies. One
representative experiment is shown. Data shown are mean fluorescence intensities (MFI) of
triplicate wells of cells incubated with Alexa Fluor 488® Dye-labeled CD74 HuMab
antibodies, followed by incubation with unlabeled CD74 HuMab antibodies for the indicated
time intervals.
?????? ??? ???? ?????????? ??????????????? ??? ???????????? ?? ???? ????? ??˘?ˇ
????ˇ????ˆ ˙ ˝?? ?????ˆ??????˛? ?˚???????? ?ˆ ˆ˜? ? ??? ???˜ ???? ????˙ ???? ˆ˜? ? ??? ????
??????ˆ????? ?????ˆ????ˆ !˘"#$ ?? ????????? ???ˆ ?? ? ???ˆ ??? ??˜ %??˚? ??&& ???ˇ????
???? ????? ??˘?ˇ ????ˇ????ˆ ˙ ????? ????ˆ ??? ??? ??˜ %??˚? ??&& ???ˇ???? ???? ?????
??˘?ˇ ????ˇ????ˆ ?? ?'? !%$ ?? (?'? !)$˙ *?+? ????ˆ !?$ ??? ˘?%? ????ˆ !?$ ??? ????ˇ????
?? (?'?˙
?????? ??? ?? ???? ???????, ?? ???? ????? ??˘?ˇ ????ˇ????ˆ ?? ?????? ????????? ??
????? ??? ˚???-????ˆ ?? .?#? ????˙ ˘??? ??? ??????? ??˜ ???? ???? ??˘?ˇ ????ˇ????ˆ
??˜?? ??? ˜??? ????? ?????˛????ˆ ??????????? ?? ????? ??? ˙ ???? ˆ˜? ? ??? ???? )/#
ˆ?-???ˆ 0 .˙1˙˘˙ ??? -?? ?? !? 2 ? ???? ??? -????$˙
?? ??????????? ?? ?˘? ??ˇ??????
Definitions
?˜? ????ˆ 3 ???? 4 ??? 3???? ????-??4 ??? ?ˆ?? ??????˜??-??ˇ?, ˜????? ˙ 5???ˆˆ ˆ????????
??˜?? ?ˆ?6 ?˜? ????ˆ ??????? ??, ˛??????ˆ6 ?ˆ?????ˆ ??? ˆ?????ˆ ˜?????-ˆ ?? ˜???? ????
˜??˜ ??? ????????, ?˚???ˆˆ?? ˇ, ????ˆ ?? ??? ?˚???ˆˆ?? ?? ????ˆ ????ˆ?????? ??˜ ?˜? ????
-???˙ %? ???ˆ? ???? ˜???? ?ˆ?????ˆ ??? 7?? ? ?? ?˚?ˆ? 8 ??(6 ??96 ?(: ??? ??(( !)??-˜?ˆ?
" ?? ??˙6 1˚???? ˝??? ?˜?? ???-??ˆ ;<998 9:!($= ;(? ?;:9 $˙??˜?ˆ? ??ˆ??? ???? ? ????? ???˛?
????ˆ????? ˆ??????- ??? ? ? ????ˆ?????? ˆ???? ˆ???ˆ ˙ ??( !??ˆ? 7?? ? ?ˆ ???? ?ˆ????? 96
?ˆ????? ? 6 ?? 3???- 48 ˆ?? 5??>??? ????, ><?;(( ?9 ??? ??)# *???????? .?@????? ?>
((< $ ?? ?????ˆ ;AB ????? ????ˆ6 ??˜ ??ˆ????ˆ ?( ?;AB ??????- ?˜? ?˚?????????? ?
???????˙ >?????? ???ˆ ?? ???? ˜?˛??- ?˜? ?˚??????????? ???? ?? ?ˆ????? 9 ??? ˜?????
???????? ?? ?ˆ 3˛?????? 94 ?? 3????˛9˙4 ?(: !??ˆ? 7?? ? ?ˆ ???? ?ˆ????? ;6 ?ˆ????? ˇ ??
3ˆ˜??? 48 ˆ?? 5?????? ????, ><?;(( ?; ??? ??)# *???????? .?@????? ?> <<?(?B $ ? ??7ˆ
??ˆ????ˆ ;<A ?;?; ???? ?˜? ?˚??????????? ???? ??? ?? ?????????˛? ˆ??????- ˙ >?????? ???ˆ?????ˆ
?? ???? ˜?˛??- ?˜? ?˚??????????? ???? ?? ?ˆ????? ; ??? ˜????? ???????? ?? ?ˆ 3˛?????? ;4 ??
3????˛;˙4 ??9 ??? ?(( ???ˆ? ???? ?? ?????????˛? ????ˆ?????? ˆ???? ˆ??? !?& ˇ? ?? ?ˆ?????8
9B ????? ????ˆ ˆ˜????? ???????$ ??????- ?? ˛??????ˆ ???7??- ?˜? ???????ˆ??? ????????? !1*$
????????? ˆ?-??? ?˜?? ?ˆ ???ˆ??? ??˜?? ?˜?ˆ? 9B ????? ????ˆ6 ˇ?? ˜?˛??- ?? ?????????
?˚??????????? ???? ?ˆ ??( ??? ?(:6 ??ˆ?????˛??, ˙ ?˜? ˆ? @????? ?? ????˜?? ?ˆ????? !7?? ? ?ˆ
?ˆ????? ( ??? ?ˆ????? ?$6 ?? ˜??˜ ??ˆ????ˆ 9?& ?9B< ??? ???????? ??? ??ˆ????ˆ 9B9 ?;AB ???
???7??-6 ?ˆ ???˛???? ?? ?> (;A˙ ?˜? ˆ?@????? ˆ ?? ?,?????-?ˆ ???? ˜?????- ˆ ???
???˛???? ?? 6 ?˙-˙6 ??)# ??? .?@?????= C> A?A9˙; ??? ??)# *????????
.?@?????= &<?B;?˙9 ˙
?˜? ???? ?-??ˇ????4 ?????ˆ ?? ? ???ˆˆ ?? ˆ??????????, ??????? -?,?????????ˆ
???ˆ?ˆ???- ?? ? ? ????ˆ ?? ???,??????? ?˜???ˆ6 ??? ???? ?? ??-˜? !/$ ?? ????????? ??-˜?
?˜???ˆ ??? ??? ???? ?? ˜?? ˛, !?$ ?˜???ˆ6 ??? ???? ????? ?????????? ˇ, ??ˆ?????? ˇ???ˆ˙ ?˜?
structure of globulins has been well characterized. See for instance Fundamental
Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)). Briefly, each heavy
chain typically is comprised of a heavy chain variable region (abbreviated herein as V or
VH) and a heavy chain constant region (C or CH). The heavy chain constant region
typically is comprised of three domains, C 1, C 2, and C 3 . Each light chain typically is
H H H
comprised of a light chain variable region (abbreviated herein as V or VL) and a light chain
constant region. The light chain constant region typically is comprised of one domain, C or
CL. Typically, the numbering of amino acid residues in the constant region is performed
according to the EU-index as described in Kabat et al., Sequences of Proteins of
Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health,
Bethesda, MD. (1991). The VH and VL regions may be further subdivided into regions of
hypervariability (or hypervariable regions which may be hypervariable in sequence and/or
form of structurally d loops), also termed complementarity ining s
(CDRs), interspersed with regions that are more conserved, termed framework regions
(FRs). Each V and V is typically composed of three CDRs and four FRs, arranged from
H L
amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3,
CDR3, FR4 (see also Chothia and Lesk J. Mol. Biol. 196, 901 917 (1987)).
The term "antibody" or "Ab" in the context of the present invention refers t o an
immunoglobulin molecule, a fragment of an globulin molecule, or a derivative of
either thereof, which has the ability t o specifically bind to an antigen under typical
physiological conditions with a half life of significant periods of time, such as at least about
minutes, at least about 45 minutes, at least about one hour, at least about two hours, at
least about four hours, at least about eight hours, at least about 12 hours, about 24 hours
or more, about 48 hours or more, about three, four, five, six, seven or more days, etc., or
any other relevant functionally-defined period (such as a time sufficient t o induce, promote,
e, and/or te a physiological response associated with dy binding t o the
antigen and/or time sufficient for the antibody to recruit an effector activity). The le
regions of the heavy and light chains of the immunoglobulin molecule contain a binding
domain that cts with an antigen. The constant regions of the antibodies (Abs) may
mediate the binding of the immunoglobulin to host tissues or factors, including various cells
of the immune system (such as or cells) and components of the complement system
such as Clq, the first component in the classical y of complement activation. An
antibody may also be multispecific, having specificities for two or more different es,
typically non-overlapping. es of multispecific antibodies include bispecific dies,
diabodies, and similar antibody les. As indicated above, the term antibody herein,
unless otherwise stated or clearly contradicted by context, includes fragments of an
antibody that retain the ability t o specifically bind t o the antigen. I t has been shown that the
antigen-binding function of an antibody may be performed by nts of a full-length
antibody, e.g., Fab and F(ab')2 fragments. It also should be understood that the term
antibody, unless specified otherwise, also includes polyclonal dies, monoclonal
antibodies (mAbs), antibody-like polypeptides such as chimeric antibodies and humanized
antibodies. An antibody as generated can possess any isotype.
The terms "human antibody", "human Ab" or "HuMab", as used herein, is intended to
include antibodies having variable and constant regions derived from human germline
immunoglobulin sequences. The human dies of the invention may e amino acid
residues not encoded by human germline immunoglobulin sequences (e.g., mutations
introduced by random or site-specific nesis in vitro or by somatic mutation in vivo).
However, the term "human antibody", as used herein, is not ed to include antibodies
in which CDR sequences derived from the germline of another mammalian species, such as
a mouse, have been grafted onto human framework sequences.
As used herein, a human dy is "derived from" a particular germline sequence if
the antibody is obtained from a system using human immunoglobulin sequences, for
instance by immunizing a transgenic mouse carrying human immunoglobulin genes or by
screening a human globulin gene library, and wherein the selected human antibody
is at least 90%, such as at least 95%, for instance at least 96%, such as at least 97%, for
instance at least 98%, or such as at least 99% identical in amino acid sequence to the
amino acid ce d by the germline immunoglobulin gene. Typically, outside the
heavy chain CDR3, a human antibody derived from a particular human germline sequence
will display no more than 20 amino acid differences, e.g. no more than 10 amino acid
ences, such as no more than 9, 8, 7, 6 or 5, for instance no more than 4, 3, 2, or 1
amino acid ence from the amino acid ce encoded by the germline
immunoglobulin gene.
The terms "monoclonal antibody", "monoclonal Ab", "monoclonal antibody
composition", "mAb", or the like, as used herein refer to a ation of antibody
molecules of single molecular composition. A monoclonal antibody composition displays a
single binding specificity and affinity for a particular epitope. Accordingly, the term "human
monoclonal antibody" refers to antibodies displaying a single binding specificity which have
le and constant regions derived from human germline immunoglobulin sequences.
The human monoclonal dies may be produced by a oma which includes a B cell
obtained from a transgenic or transchromosomal non-human animal, such as a transgenic
mouse, having a genome comprising a human heavy chain transgene and a light chain
transgene, fused to an immortalized cell.
As used herein, "isotype" refers to the immunoglobulin class (for instance IgGl,
IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM) that is encoded by heavy chain constant region
genes.
??? ???? ????? ??????? ????????? ??? ? ?˘?? ??????ˇ ?????˘ ?? ?? ?? ???ˆ?
ˆ??????˘ ??? ???˙? ??? ????? ˆ???? ˆ??˘???? ??? ˙??????? ??????˘ ???? ??? ???????? ????? ??
?? ???????? ?? ???? ?˛
˚??? ?˘?? ??????ˇ ????˘˘ ˆ???????ˆ??? ?? ˆ????˜?ˇ ??? ???? ? ?? ????? ?? ?????
?????˘ ?? ??? ???˙? ˆ???? ?????? ˆ???? ˝???˛
˚??? ?˘?? ??????ˇ ????˘˘ ˆ???????ˆ??? ?? ˆ????˜?ˇ ??? ???? ? ˆ ??????? ?????˘ ?? ??
???????? ?????? ˆ??˝??˘??? ?? ???˘? ??? ????? ??????ˇ ? ! "# ??????ˇ ??? ? ! "$ ??????˛
%? ????????? ????ˆ???? ?? ????ˆ??? ???ˆ????? ?? ?? ???? ?ˆ??? ???ˆ???? ?????ˆ????
????????? ?????˘ ?? ?? ???????? ???ˆ? ??˘ ? ˘??????ˆ????? ????ˆ?? ?? ?? ??????? ?? ?ˆ??˙???
??? ?? ???? ????ˆ??? ??ˆ????˘?˘ˇ ˘?ˆ? ?˘ ˆ??˝?????? ?ˆ??˙????? ?? ˆ ??ˆ?˝??? ???????˛
???˘ˇ ????ˆ??? ????ˆ???? ????ˆ???? ?????????˘ ??˙? ˘? ?????ˆ????? ????ˆ?? ?? ?? ? ??
??????? ?? ???˝?????? ˆ??? ????????? ˆ?????˜?ˆ??? &%'!!( ???)?? ˆ??˝?????? ?
??˝?????? ˆ?????˜?ˆ??? &!'!(˛ %? ? ?? ˘?ˆ? ?? ???????? ?˘ ?? ???????? ?? *?+,
?˘???˝? ?? ? ????? ?˘??????-?? ???? ????? ?? ˛ %?????? ?˜?? ˝?? ?˘ ??? ???????ˆ???? ?? ????????˘
?? ˆ ?????? ???ˆ? ˆ?? ˘??????? ????ˆ? ??? ??????ˆ???? ???? ˆ??˝?????? ˝??????˘ ??? ˆ
??ˆ?˝???˘˛ .??ˇ ??? ?˜??˝??ˇ /??? . ?? ?? ˛ˇ 0?? 1 *?????? 233$ˇ #$4,5$ ?,226 7????˘???ˇ
%ˆ?? !??˘˛ #558ˇ '9,ˇ ?55 :?5,6 ??? ˘ ?? ?? ˛ˇ 1/! #552ˇ #?94 9;32 :995, ˛
%˘ ?˘?? ˇ ??? ???? <????ˆ??? ˆ???< ?????˘ ?? ?? ?????? ˆ??? ???ˆ? ?˘ ??˙??˙?? ??
??? ????ˆ??? ˝??˘? ?? ?? ?????? ??˘˝??˘?ˇ ?˘ ? ?? ??? ˆ??????˙? ??? ?ˆ??˙?????
˝??˘?˘ ?? ?? ?????? ??˘˝??˘?˛ 0˜??˝???? ?????? ˆ???˘ ??ˆ???? ? ˆ??? ?? ? ??????? ??
???˝???? ??????ˇ ??? ??˘???ˆ? ???˝??ˆ???˘ &˘?ˆ? ?˘ / ˆ???˘ ??? ? ˆ???˘ ??ˆ?????? ˆ???????ˆ ?
ˆ???˘ &!?=˘((ˇ >????? ˆ???˘ˇ ??????? >????? ˆ???˘ˇ ??ˆ??˝????˘ˇ ????ˆ???˘ ˇ ??˘? ˆ???˘ ???
?ˆ???˘ ˇ ˘?ˆ? ?˘ ??????˝???˘ˇ ??˘??? ˝???˘ ??? ??˘?˝???˘ ˛ .??? ????ˆ??? ˆ???˘ ?˜˝??˘˘
˘˝?ˆ???ˆ ˆ ??ˆ?˝???˘ & ˆ?˘( ??? ˆ???? ??? ˘˝?ˆ???ˆ ?????? ???ˆ????˘˛ *? ˘??? ??????????˘ˇ
?? ????ˆ??? ˆ??? ?˘ ˆ?˝???? ?? ????ˆ??? %'!!ˇ ˘?ˆ? ?˘ ? ? >????? ˆ???˛ ?? ?˜??˝??ˇ
????ˆ???˘ˇ ??ˆ??˝????˘ˇ ?? ?ˆ? ?˜˝??˘˘ ˆ?˘ˇ ??? ??˙??˙?? ?? ˘˝?ˆ???ˆ >?????? ?? ?????? ˆ???˘
??? ˝??˘?????? ???????˘ ?? ????? ???˘ ?? ??? ?????? ˘?˘???˛ *? ˘???
??????????˘ˇ ?? ????ˆ??? ˆ??? ??? ˝????ˆ???˘? ? ?????? ??????? ?? ?????? ˆ???˛ ???
?˜˝??˘˘??? ?? ? ˝????ˆ???? ˆ? ? ? ?? ????ˆ??? ˆ??? ??? ?? ????????? ?? ??????? ??ˆ???˘ ˘?ˆ?
?˘ ??˘˛ %? ????ˆ??? ˆ??? ˆ?? ???˘? ? ?????? ??????? ?? ˝????ˆ???˘? ?? ??˘? ?
?????? ˆ???˛
*? ??? ˆ??? ?˜? ?? ??? ˝??˘??? ??˙?????? ˇ ?? ?%'!? ?????˘ ?? ?? ???????? ?????
ˆ??@?????ˇ ?? ??? ˆ????˜? ?? ??? ˝??˘??? ??˙?????? ??˝?ˆ???? ????????? ?? ? !'?, ?˘˝?ˆ???ˆ
???????? ˇ ???ˆ? ?˘ ˆ??˝??? ?? ??????? ?????? ?˘ ??˘ˆ????? ?? ??? ? ?˝˝??ˆ?????˛
% ?!'?, ?????????ˇ ????? ?!'?, ?????????ˇ ?!'?, %? ?ˇ ?!'?, ?˘˝?ˆ???ˆ ????????? ??
????? ?!'?, %?? ?˘ ?? ???????? ?˘ ??˘ˆ????? ???˙?ˇ ???ˆ? ????˘ ˘˝?ˆ???ˆ???? ?? ??? ???????
!'?, ˛
I n a preferred embodiment, the antibody of the invention is isolated. An "isolated
Ab," as used herein, is intended to refer to an antibody which is substantially free of other
antibodies having different antigenic specificities (for instance an isolated antibody that
specifically binds to CD74 is substantially free of antibodies that specifically bind antigens
other than CD74). An isolated dy that specifically binds to an epitope, m or
variant of human CD74 may, however, have cross-reactivity to other related antigens, for
instance from other species (such as CD74 species homologs). er, an isolated
antibody may be substantially free of other ar material and/or chemicals. I n one
embodiment of the present invention, two or more "isolated" monoclonal antibodies having
different antigen-binding specificities are combined in a well-defined composition.
When used herein in the t of two or more antibodies, the term "competes
with" or "cross-competes with" indicates that the two or more antibodies compete for
binding t o CD74, e.g., to CD74 variants 1, 2 or both. For example, the constructs described
in Example 1 can be used in such an assay. I n one exemplary type of assay, CD74 is coated
on a plate and allowed to bind the first dy, after which the second, labeled antibody is
added. If the presence of the first antibody reduces binding of the second antibody, the
antibodies compete. The term "competes with" when used herein is also intended to cover
combinations of antibodies where one antibody reduces binding of another antibody, but
where no competition is observed when the antibodies are added in the reverse order.
The term "epitope" means a protein determinant capable of specific g t o an
dy. Epitopes usually consist of surface groupings of les such as amino acids or
sugar side chains and usually have specific three dimensional ural teristics, as
well as specific charge characteristics. Conformational and non-conformational es are
distinguished in that the binding to the former but not the latter is lost in the presence of
denaturing solvents. The epitope may comprise amino acid residues which are directly
involved in the g, and other amino acid residues, which are not ly ed in the
binding, such as amino acid residues which are effectively blocked or covered by the
specifically antigen binding peptide (in other words, the amino acid residue is within the
footprint of the specifically antigen binding peptide).
As used herein, the term "binding" in the context of the binding of an antibody t o a
predetermined antigen or epitope typically is a binding with an affinity corresponding t o a K
of about 10 7 M or less, such as about 10 8 M or less, such as about 10 9 M or less, about 10
M or less, or about 10 11 M or even less when ined by for instance surface plasmon
resonance (SPR) technology in a BIAcore 3000 instrument using a soluble form of the
antigen as the ligand and the antibody as the e. Typically, an antibody binds to the
predetermined antigen with an affinity ponding t o a K that is at least ten-fold lower,
such as at least 100-fold lower, for instance at least 1,000-fold lower, such as at least
,000-fold lower, for instance at least 100,000-fold lower than its K for binding to a non-
specific antigen (e.g., BSA, ), which is not cal or closely related to the
predetermined n. When the K of the antibody is very low (that is, the antibody has a
high affinity), then the K with which it binds the antigen is typically at least 10,000-fold
lower than its K for a non-specific antigen.
The term " k " (sec 1) , as used herein, refers to the dissociation rate constant of a
particular Ab-antigen interaction. Said value is also referred to as the k ff value.
The term "k " ( M 1 x sec 1) , as used herein, refers t o the association rate constant of
a particular Ab-antigen interaction.
The term "K " (M), as used herein, refers to the dissociation equilibrium constant of
a particular Ab-antigen interaction.
The term " K " ( 1) , as used herein, refers t o the association equilibrium constant of
a particular Ab-antigen interaction and is obtained by dividing the k by the k .
a d
As used herein, "internalization", when used in the context of a CD74 antibody
es any mechanism by which the antibody is internalized from the cell-surface into a
xpressing cell. The internalization of an antibody can be evaluated in an indirect
assay measuring the effect of an internalized in conjugate or a toxin specifically
bound to an antibody by pre-incubation (such as, e.g., the anti-kappa-ETA ' assay of
e 14).
As used herein, the term its growth" (e.g. referring to cells, such as tumor
cells) is intended t o include any able decrease in the cell growth when contacted
with a CD74 antibody or ADC as compared t o the growth of the same cells not in contact
with a CD74 antibody or ADC, e.g., the tion of growth of a cell culture by at least
about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. Such a
decrease in cell growth can occur by a variety of mechanisms, e.g. internalization,
antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cell-mediated
xicity (ADCC), complement-dependent cytotoxicity (CDC), drug-mediated cell-kill
and/or sis.
The present invention also provides antibodies comprising functional variants of the
V region, V region, or one or more CDRs of the antibodies of the examples. A functional
L H
variant of a V , V , or CDR used in the context of a CD74 antibody still allows the antibody
L H
to retain at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95%
or more) of the affinity/avidity and/or the specificity/selectivity of the parent antibody and
in some cases such a CD74 antibody may be associated with greater affinity, ivity
and/or specificity than the parent Ab.
Such functional ts typically retain significant sequence identity t o the parent
Ab. The percent identity between two sequences is a function of the number of identical
positions shared by the sequences (i.e., % homology = # of identical positions/total # of
positions x 100), taking into account the number of gaps, and the length of each gap, which
need to be introduced for optimal alignment of the two sequences. The comparison of
sequences and determination of percent identity between two sequences may be
accomplished using a mathematical algorithm, as described in the non-limiting examples
below.
The percent identity between two nucleotide sequences may be determined using the
GAP program in the GCG software package (available at http://www.gcg.com), using a
NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1,
2, 3, 4, 5, or 6 . The percent identity between two nucleotide or amino acid sequences may
also be determined using the algorithm described by E. Meyers and W. Miller (Comput.
Appl. Biosci 4, 11-17 ), which has been incorporated into the ALIGN program
(version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap
penalty of 4 . I n addition, the percent identity n two amino acid sequences may be
determined using the Needleman and Wunsch algorithm (Needleman and , J. Mol.
Biol. 48, 444-453 (1970)), which has been orated into the GAP program in the GCG
software e able at http://www.gcg.com), using either a Blossum 62 matrix or a
PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2,
3, 4, 5, or 6 .
The sequence of CDR variants may differ from the sequence of the CDR of the parent
antibody sequences through mostly conservative substitutions; for instance at least about
%, about 50% or more, about 60% or more, about 70% or more, about 75% or more,
about 80% or more, about 85% or more, about 90% or more, (e.g., about 65-95%, such as
about 92%, 93% or 94%) of the substitutions in the t are conservative amino acid
residue ements.
The ces of CDR variants may differ from the sequence of the CDRs of the
parent antibody sequences through mostly conservative substitutions; for instance at least
, such as at least 9, 8, 7, 6, 5, 4, 3, 2 or 1 of the substitutions in the variant are
conservative amino acid residue replacements.
The term "stabilized IgG4 antibody" refers to an IgG4 antibody which has been
modified to reduce olecule exchange (see, e.g., international patent application
publication WO2008145142 or van der Neut Kolfschoten M et al. (2007) Science
14;317(5844) and references therein.
I n the context of the present invention, vative substitutions may be defined by
substitutions within the s of amino acids reflected in one or more of the following
three tables:
Amino acid residue classes for conservative substitutions
Alternative conservative amino acid e tution classes
Alternative Physical and Functional Classifications of Amino Acid Residues
Alcohol group-containing residues S and T
Aliphatic residues I , L, V, and M
Cycloalkenyl-associated residues F, H, W, and Y
Hydrophobic residues A, C, F, G, H, I , L, M, R, T, V, W, and
vely charged residues D and E
Polar residues C, D, E, H, K, N, Q, R, S, and T
Positively charged residues H, K, and R
Small es A, C, D, G, N, P, S, T, and V
Very small residues A, G, and S
Residues involved in turn A, C, D, E, G, H, K, N, Q, R, S, P, and
formation T
Flexible residues Q, T, K, S, G, P, D, E, and R
More conservative substitutions groupings include: valine-leucine-isoleucine,
phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.
Additional groups of amino acids may also be formulated using the principles
described in e.g. ton (1984) Proteins: Structure and Molecular Properties (2d Ed.
1993), W.H. Freeman and Company.
Conservation in terms of hydropathic/hydrophilic properties and residue weight/size
also is substantially retained in a variant CDR as compared to a CDR of an antibody of the
examples (e.g., the weight class, athic score, or both, of the sequences are at least
about 50%, at least about 60%, at least about 70%, at least about 75%, at least about
80%, at least about 85%, at least about 90%, at least about 95%, or more (e.g., about 65-
99%) retained). For example, conservative residue tutions may also or alternatively
be based on the replacement of strong or weak weight-based conservation groups, which
are known in the art.
The retention of similar residues may also or alternatively be measured by a
similarity score, as determined by use of a BLAST program (e.g., BLAST 2.2.8 ble
through the NCBI using standard settings 62, Open Gap=ll and Extended Gap=l).
Suitable variants typically exhibit at least about 45%, such as at least about 55%, at least
about 65%, at least about 75%, at least about 85%, at least about 90%, at least about
95%, or more (e.g., about 70-99%) similarity t o the parent peptide.
The term "vector," as used herein, is intended to refer to a nucleic acid molecule
capable of transporting another nucleic acid to which it has been linked. One type of vector
is a "plasmid", which refers t o a circular double ed DNA loop into which additional
DNA segments may be ligated. Another type of vector is a viral vector, wherein onal
DNA segments may be ligated into the viral genome. Certain vectors are capable of
autonomous replication in a host cell into which they are introduced (for instance bacterial
vectors having a bacterial origin of replication and episomal mammalian vectors). Other
vectors (such as non-episomal mammalian vectors) may be integrated into the genome of a
host cell upon introduction into the host cell, and y are replicated along with the host
genome. Moreover, certain vectors are capable of directing the expression of genes to which
they are operatively linked. Such vectors are referred to herein as "recombinant expression
vectors" (or simply, "expression vectors"). I n general, expression s of utility in
recombinant DNA ques are often in the form of plasmids. I n the present specification,
"plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly
used form of vector. However, the present invention is intended t o include such other forms
of expression s, such as viral vectors (such as replication-defective retroviruses,
adenoviruses and adeno-associated s), which serve equivalent functions.
The term "recombinant host cell" (or simply "host cell"), as used herein, is intended
to refer to a cell into which an expression vector has been introduced. It should be
understood that such terms are intended to refer not only to the ular subject cell, but
also t o the progeny of such a cell. Because certain modifications may occur in ding
generations due to either mutation or environmental influences, such progeny may not, in
fact, be identical t o the parent cell, but are still included within the scope of the term "host
cell" as used herein. Recombinant host cells include, for example, transfectomas, such as
CHO cells, HEK-293 cells, PER.C6, NSO cells, and lymphocytic cells, and prokaryotic cells
such as E. coli.
The term "transfectoma", as used herein, includes recombinant eukaryotic host cells
expressing the Ab, such as CHO cells, PER.C6, NSO cells, HEK-293 cells, plant cells, or fungi,
including yeast cells.
The term "transgenic non-human animal" refers t o a non-human animal having a
genome sing one or more human heavy and/or light chain transgenes or
transchromosomes r integrated or non-integrated into the animal's natural genomic
DNA) and which is capable of expressing fully human Abs. For example, a transgenic mouse
can have a human light chain ene and either a human heavy chain transgene or
human heavy chain transchromosome, such that the mouse produces human CD74
antibodies when immunized with CD74 antigen and/or cells sing CD74. The human
heavy chain transgene may be integrated into the chromosomal DNA of the mouse, as is
the case for transgenic mice, for instance HuMAb® mice, such as HCo7 or HCol2 mice, or
the human heavy chain transgene may be maintained extrachromosomally, as is the case
for transchromosomal KM mice as described in 3478. Such enic and
transchromosomal mice (collectively ed to herein as "transgenic mice") are capable of
producing multiple isotypes of human monoclonal antibodies to a given antigen (such as
IgG, IgA, IgM, IgD and/or IgE) by undergoing V-D-J recombination and isotype switching.
Transgenic, non-human animal can also be used for production of dies against a
specific antigen by introducing genes encoding such specific Ab, for e by operatively
linking the genes to a gene which is sed in the milk of the .
"Treatment" refers t o the administration of an effective amount of a therapeutically
active compound of the present invention with the purpose of easing, ameliorating,
arresting or eradicating (curing) symptoms or e states.
An "effective amount" refers to an amount effective, at dosages and for s of
time necessary, to achieve a desired therapeutic result. A therapeutically effective amount
of a CD74 antibody may vary according to factors such as the disease state, age, sex, and
weight of the individual, and the ability of the CD74 antibody t o elicit a desired se in
the individual. A therapeutically effective amount is also one in which any toxic or
detrimental effects of the antibody or antibody portion are outweighed by the
therapeutically beneficial effects.
An "anti-idiotypic" (Id) antibody is an antibody which recognizes unique
determinants generally associated with the antigen-binding site of an Ab.
Further aspects and embodiments of the invention
The invention provides an isolated dy, such as a human monoclonal antibody, which
binds to human CD74 isoforms 1 and 2 . The antibody may additionally bind to other CD74
ms or species homologs, such as the cynomolgus homolog. I n particular, the antibody
of the invention efficiently alizes after binding t o CD74 expressed on the surface of a
cell, which is advantageous for therapeutic applications of an ADC approach. As shown in
es 19 to 22, ADCs of CD74 antibodies and linker-drug combinations vcMMAE or
mcMMAF effectively reduced the size of tumors in several in vivo tumor models. CD74 ADCs
were surprisingly effective despite the low surface expression of the CD74 target on the
tumor cells (Example 22). Further, CD74 antibodies were shown effective in preventing the
outgrowth of tumors in an in vivo model of tumor prophylaxis (Example 25).
The antibody can be further characterized by one or more functional properties such
that it binds t o one or more human CD74 variants with high affinity, inhibits MIF binding t o
CD74, or any combination of the foregoing properties.
I n one aspect, the antibody of the invention binds with high affinity to human CD74
variants 1 and/or 2 or to human cells naturally expressing CD74. For example, in one
embodiment, the dy (a) binds to the extracellular domain of CD74 variant 1 with an
EC (apparent affinity) of less than about 500 ng/mL, less than about 400 ng/mL, less than
about 350 ng/mL, or less than about 330 ng/mL; b) binds t o the extracellular domain of
CD74 variant 2 with an EC of less than about 400 ng/mL, less than about 300 ng/mL, less
than about 250 ng/mL, or less than about 220 ng/mL; or (c) both of (a) and (b), when
ined as bed in Example 11. Also, or alternatively, the antibody may bind to
CD74 on Raji cells with an EC of less than about 400 ng/mL, less than about 300 ng/mL,
less than about 250 ng/mL, or less than about 200 ng/mL, when determined as described in
Example 12. Also, or alternatively, the dy may bind t o CD74 variants 1, 2 or both with
a K of about 10 8 M or less, such as about 10 9 M or less, or even about 10 10 M or less.
I n one aspect, the antibody is internalized after binding t o CD74 expressed on the
surface of a cell. This can be determined according to the assay bed in Example 24
using fluorescently labeled antibodies, according t o the assay described in Example 14,
using an ADC approach reflecting antibody internalization, or using a method described in
Ong GL et al., Immunology 1999;98:296-302; Hansen H et al., m J 1996; 320: 293-
300; Koch NG et al., J Immunol 1991; 147: 2643-2651; Roche PA et al., PNAS 1993; 90:
8581-8585). The cell may be from a B cell line, such as Raji cells, or from another type of
tumor cell line induced t o express high levels of CD74 by treatment with IFNy (for example
HT-29 colon cancer cells or SK-MEL-37 melanoma . I n one embodiment, the cell is a
Raji cell. I n another embodiment, the antibody has an EC of less than about 60 ng/mL,
less than about 40 ng/mL, less than about 30 ng/mL, or about 25 ng/mL or less in inducing
killing of Raji cells in an anti-kappa ETA' assay, when determined as described in Example
14. Alternatively, the antibody has an EC between about 25 to about 60 ng/L about 25 to
40 ng/mL, or about 25 to about 30 ng/mL in such an assay.
?? ??? ??????? ?? ???????? ?? ??? ????????? ??? ?? ?? ?? ?? ˘??? ???? ˇ? ?ˆ˙ ˝˛ ? ?˚ ??
?? ?? ?? ???˜? ? ?ˆ˙ ˝˛ ?˚ ˘???? !??? ????˚˝???? ?? ????˚???? ?? ?"?˝?˘? ?# $
?? ??? ? ??? ??? ????? ?? ???˚????˚?%?? ?? ??? ??? &˚??? ?˚?˝ ?'(# ????ˆ???
???? ???˘˘? ?"?˚????? ?? ??? ?˜˚???? ?? ? ??˘˘ $ )?? ??? &˚??? ??? ?? ????˚˝???? ? ??˚ ?"?˝?˘??
˜???ˆ ? ?˚ ????? ?˜?? ?? ??? ??? ?? ?"?˝?˘? ˇ ? ??????˘˘? ˜???ˆ ?˘˜?˚??????˘? *?˚
????˚!???+ ? ?????????? ??? ????˚˝????ˆ ??? ??? &˚??? ?? ?,? $ )?? ??˘˘ ˝?? ?? ?˚?˝ ? -
??˘˘ ˘???? ?˜?? ??? ?$ˆ$? '?˜?? ?˚ .?/? ??˘˘?? ?˚ ?˚?˝ ??????˚ ?˜????˘? ???? ?? ?˜˝?˚ ??˘˘ ˘???
*?$ˆ$? 0#1# ??˘˘? ?˚ 2?? &3(#( ??˘˘?+$ ?? ??? ?˝????˝??? ? ??? ??˘˘ ?? ? '?˜?? ??˘˘ $ ?? ???
?˝????˝???? ??? ???????? ??? ?? ??? &˚??? ?? ??? ˚??ˆ? ?? ? $? ?? ?$? ˝?? &?? ?˜?? ?? ???˜?
?$? ˇ ?? ???˜? ?$ˇ? ˝?? &?? ?˜?? ?? ?$?# ?? ?$?? ?˚ ?$ ?? ?? ?$ˇ? ˝?? &?$ ?? ??? ?˝????˝????
??? ???????? ??? ?? ??? &˚??? ?? ???˜? ?$?( ˝?? &?$ ?? ??? ?˝????˝???? ??? ???????? ??? ??
??? &˚??? ?? ???˜? ?$ ? ?˚ ?$ # ˝?? &?$
)?? ??? ????? ?? ??? ????????? ˝?? ?˘?? ? ?˚ ?˘??˚??????˘? ? ?? ???˚????˚?%?? ?? ?˚??? &
??˝?????ˆ !??? ? ?˚ ??????ˆ ?? ??? ??˝? ??????? ??? ? ˚???˚???? ???????? ?? ?˜˝?? ?'(#
??˚???? ?? ??˚???? ? ?˚ ???? ?? ??˚????? ? ??? $
1? ????? ???? ??ˆ ??˚ ??˝???????? ˆ ?? ??? ???????? !??? ? ˚???˚???? ????????
??? ˜??˘?%? ? ?$ˆ$? ??? ?"?˚???˘˘˜˘?˚ ??˝??? ?? ? ?'(# ??˚???? *?$ˆ$? ??? ?????˚˜??? ????˚????
?? ?"?˝?˘? ?+? ?'(# &?"?˚?????ˆ ??˘˘? ???˙?˚ ??˘˘ &˝?˝?˚???? ?˚???˚?? ?˚?˝ ?'(# &
?"?˚?????ˆ ??˘˘?$ ?? ?? ?˚? ????? ? ? '(# ????ˆ ??˘˘? ?˚? ?˚? &???˜????? !??? ???
???? ???????? ?? ?????˚??? ????? ??˚??????? ˚??ˆ??ˆ ?˚?˝ ? ?? ??? 4ˆ˙˝ ˛? ?˜???5˜???˘?
??? !??? ? ?˘˜?˚????˚? &˘???˘?? ˚???˚???? ???????? ?? ? ???????˚????? ?? ?? 4ˆ˙˝ ˛$
-?????ˆ ?? ?? ??? ˚???˚???? ??????? ? ?? ????˚˝???? ˜???ˆ 61?7 ???˘????$
?? ??? ? ??? ???????? ??˝????? ??˚ ??????ˆ ?? ??˚????? ? ??? ?? ?˜˝?? ?'(#
!??? ?? ˘???? ??? ??? ???????? ??˘????? ?˚?˝
*?+ ?? ???????? ?? ˝?˚????ˆ ? 83 ˚?ˆ??? ??˝?˚????ˆ ??? ??5˜???? ?? 7?9 ?' 2:; (
??? ? 8 ˛ ˚?ˆ??? ??˝?˚????ˆ ? ?? ??5˜???? ?? 7?9 ?' 2:; ˇ ????? <
*?+ ?? ???????? ??˝?˚????ˆ ? 83 ˚?ˆ??? ??˝?˚? ???ˆ ??? ??5˜???? ?? 7?9 ?' 2:;??
??? ? 8˛ ˚?ˆ??? ??˝?˚????ˆ ? ?? ??5˜???? ?? 7?9 ?' 2:; = ???? ?<
*?+ ?? ???????? ??˝?˚????ˆ ? 83 ˚?ˆ??? ??˝?˚? ???ˆ ??? ??5 ˜???? ?? 7?9 ?' 2:;??
??? ? 8˛ ˚?ˆ??? ??˝?˚????ˆ ? ?? ??5˜???? ?? 7?9 ?' 2:; = ???? ?< ???
*?+ ?? ???????? ??˝?˚????ˆ ? 83 ˚?ˆ??? ??˝?˚? ???ˆ ??? ??5˜???? ?? 7?9 ?' 2:;?>
??? ? 8˛ ˚?ˆ??? ??˝?˚????ˆ ? ?? ??5˜???? ?? 7?9 ?' 2:; = ???? ?$
?? ????˚??? ??? ???????? ?˝????˝??? ?? ??? ???????? ?? !??? ??? ???????? ??
*?+ ??? *?+? *?+ ??? *?+? *?+ ??? *?+? *?+ ??? *?+? *?+ ??? *?+? *?+ ??? *?+? ?? ˘???? ??˚?? ??
*?+ ?? *?+? ?˚ ?˘˘ ?? *?+? *?+? *?+ ??? *?+ $
?? ??? ?˝????˝???? ??? ???????? ????? ?? ??? ??˝? ??????? ? ? ?˜˝?? ?'(# ?? ??
˘???? ??? ?? ??? ˚???˚???? ?? ???????? ??????? ?? *?+? *?+? *?+ ? ??? *?+ $ )??? ??? ??
????˚˝???? ˜???ˆ ???!? ??????5˜?? ??˚ ??????? ????˚˝???????? ?˜?? ??? ?$ˆ$? ??????ˆ ??˚
???????? ??????ˆ ?? ?'(# ??˚????? !??? ?????˚??ˆ ????? &˝˜?????? ?? ?˚ ???ˆ? ????˘??
??????5˜?? *???? ?$ˆ$? -????˚ ?? ?˘$? ?????˚ .?? ??(<=(; ˇ??@ &ˇ? ˇ < ??˚??˚ A0 ?? ?˘$? ?˜˚˚
B˚?????˘? ?˝˝˜??˘ ??#< ?? >; C??? >$#< 3/?˘˝ - ?? ?˘$? 2 -????????˘ ???< (; ? > &?ˇ(<
.?????˚ˆ A ?? ?˘$? ?˜˚˚ B˚?????˘? ?˝˝˜??˘ ???< ?? >; C??? >$>< -??/?˝?? '? ?? ?˘$?
0?????? ?>>=< >; ??@ &??? +$
1? ???????? ?˚ ?˝˝˜??ˆ˘??˜˘?? ?? ??? ????????? ˝?? ?˘?? ?˚ ?˘??˚??????˘? ??
???˚????˚?%?? ?? ??˝?˚????ˆ ???????? 8 3? 8 ˛? ?˚ ?'. ??5˜????? ? ?˚ ???????? ??˝?????????
?? ??? ??????? ??? ???????? ?˚ ?˝˝˜??ˆ˘??˜˘?? ??? ??? 8 3 ?'. ˇ ˚?ˆ??? ?? ???
??? ?? 3˜0?? &?'(# &???? &??=? &??@? ??? &???$ )?? ????????? ??˜? ?? ??˚ ?? ????????
?˚ ?˝˝˜??ˆ˘??˜˘?? ??˝?˚????ˆ ? 8 3 ?'.ˇ ??˝?˚????ˆ ?˚ ?????????ˆ ?? ? ??5˜???? ??˘?????
?˚?˝ 7?9 ?' 2:7;??? ?#? ?@ ? ??? $ ?? ??? ?˝????˝???? ??? ???????? ?˚ ?˝˝˜??ˆ˘??˜˘??
??˝?˚???? 7?9 ?' 2:; $
?? ??? ? ??? ???????? ?˚ ?˝˝˜??ˆ˘??˜˘?? ??˝?˚???? ? 8 ˛ ˚?ˆ??? ??˝?˚????ˆ ???
?'.?? ??? ˇ ??5˜????? ?? 7?9 ?' 2:; #? 117 ??? 7?9 ?' 2:; = ???
?+ ? 8 3 ˚?ˆ??? ??˝?˚????ˆ ??? ?'.?? ??? ˇ ??? ?? 7?9 ?' 2: 7;@? > ??? ??
*??? +<
?+ ? 8 3 ˚?ˆ??? ??˝?˚????ˆ ??? ?'.?? ??? ˇ ??5˜????? ?? 7?9 ?' 2:; ? ? ?ˇ ??? ?#
*??? +<
?+ ? 8 3 ˚?ˆ??? ??˝?˚????ˆ ??? ?'.?? ??? ˇ ??5˜????? ?? 7?9 ?' 2:;?=? ?( ??? ?@
*?? ?+<
?+ ? 8 3 ˚?ˆ??? ??˝?˚????ˆ ? ?? ?'.?? ??? ˇ ??5˜????? ?? 7?9 ?' 2:; ?? ? ???
*??? +? ?˚
?+ ? ??˚???? ?? ??? ?? ???? ?????????? ?˚ ?˝˝˜??ˆ˘??˜˘??? ? !??˚??? ???? ??˚????
?˚???˚??˘? ??? ?? ˝??? ?? ?˚ ˇ ?˝??? ???? ˝????????????? ˝?˚? ?˚???˚??˘? ?˝???
???? ?˜?????˜?????? ?˜?? ?? ?????˚ ?????? ?˝??? ???? ?˜?????˜????? ?? ??? ?? ????
??5˜????? $
?? ??? ?????? ? ??? ?? ??˝?˚???? ? 8 3 ˚?ˆ??? ??˝?˚????ˆ ??? ?'.?? ??? ˇ ??5˜?????
?? 7?9 ?' 2:; ?? ? ??? ??? ? 8 ˛ ˚?ˆ??? ??˝?˚????ˆ ??? ?'.?? ??? ˇ ??5˜????? ??
7?9 ?' 2:; #? 117 ??? ?? !??? ?? ˝??? ˇ ?˝??? ???? ??????? ?? ??˝??˚?? ?? ???
?˚?ˆ???˘ ??5˜?????$ ?? ??? ?˝????˝???? ??? ?? ??˝?˚???? ? 8 3 ˚?ˆ??? ??˝?˚????ˆ ???
?'.?? ??? ˇ ??5˜????? ?? 7?9 ?' 2:; ?? ? ??? ??? ? 8 ˛ ˚?ˆ??? ??˝?˚????ˆ ???
?'.?? ??? ˇ ?? ? ?? 7?9 ?' 2:; #? 117 ??? 7?9 ?' 2:; ? ? !??? ?? ˝??? ? ?˝???
???? ˝???????????$ ?? ? ??˚???˜˘?˚ ?˝????˝??? ?? *?+? ??? ? ??˝?˚???? ?? ?˝??? ???? &
?˜?????˜???? ?? ˚????˜? ( ?? ??? 8 3 ?'. ?? *?+? ?˜?? ?? ? ?????˚?????? ?˝??? ????
?˜?????˜????$
I n one aspect, the antibody or immu nog lobu lin comprises a VH havi ng
a) at least 80% identity, such as at least 90%, at least 95%, or at least 98% or 100%
identity to a VH reg ion seq uence selected from the group consisting of SEQ I D NO :7,
11, 15 and 19, or
b) at most 20, such as 15, or 10, or 5, 4, 3, 2 or 1 amino acid mod ifications, more
prefera bly amino acid tutions, such as conservative amino acid substitutions as
compa red to a V H reg ion seq uence selected from the grou p consisting of SEQ I D
NO :7, 11, 15 and 19.
I n one aspect, the antibody or immu nog lobu lin comprises a VL having
a) at least 80% identity, such as at least 90%, at least 95%, or at least 98% or 100%
identity to a V L reg ion seq uence selected from the grou p consisting of: SEQ I D
NO :23 and 26 or
b) at most 20, such as 15, or 10, or 5, 4, 3, 2 or 1 amino acid mod ifications, more
prefera bly amino acid substitutions, such as vative amino acid substitutions as
compa red to a V L reg ion seq uence selected from the grou p consisting of: SEQ I D
NO :23 and 26.
I n one embod iment of (b), the V L reg ion comprises an amino acid substitution in the
on correspond ing to resid ue 36 in SEQ ID NO :23 and 26. I n SEQ ID NOS : 23 and 26,
the amino acid at t his on is F and Y, respectively.
I n sepa rate and specific aspects, the anti body or immu noglobul in comprises a VH and
a V L reg ion selected from any one of the following combi nations :
a) a V H reg ion sing the seq uence of SEQ I D NO :7 and a VL reg ion comprising the
seq uence of SEQ I D NO :23 (005);
b) a V H reg ion comprising the seq uence of SEQ I D NO :11 and a VL reg ion comprisi ng
the seq uence of SEQ I D NO :26 (006);
c) a V H reg ion comprising the seq uence of SEQ I D NO :15 and a VL reg ion comprisi ng
the seq uence of SEQ I D NO :26 (008),
d) a VH reg ion comprising the seq uence of SEQ I D NO : 19 and a VL reg ion comprisi ng
the seq uence of SEQ I D NO :26 (Oil), and
e) a VH reg ion comprising the seq uence of SEQ I D NO :7 and a VL reg ion comprising the
seq uence of SEQ I D NO :26 (005/011); and
f ) a varia nt of any of sa id antibod ies or immu nog lobu lins, wherei n sa id varia nt
prefera bly has at most 1, 2 or 3 amino acid mod ifications, more prefera bly amino
acid tutions, such as conservative amino acid substitutions in any of sa id V H
and/or V L reg ion seq uences.
I n one aspect, the invention provides an antibody or immunog lobul in comprisi ng a V L
reg ion comprising the seq uence of SEQ ID NO : 26. I n one embod iment, the antibody or
g lobuli n comprises the VH CDR3 of SEQ I D NO : 22. I n another embod iment, the
antibody comprises the V CDR1, 2 and 3 sequences of SEQ I D NOS: 20, 2 1 and 22,
respectively.
The antibody of the invention can be characterized by one or more of the onal or
structural features of the aspects described above, or by any combination of selected
onal and structural es. For example, in one embodiment, the antibody or
globulin of the invention is characterized by any one of the following characteristics:
a) an EC of less than 30 ng/mL, or an EC of about 25 ng/mL or less in an
0 0
anti-kappa-ETA' assay, when determined as described in Example 14;
b) competing with, or binding the same epitope as, an antibody having the V and V
H L
sequences of SEQ I D NOS: 19 and 26, respectively;
c) an off-rate in the range of 0.03 t o 0.30 min 1, when determined according to
Example 23;
d) a V CDR3 comprising SEQ ID NO:22;
e) a combination of (a) and (b);
f ) a combination of (a) and (c);
g) a combination of (a) and (d)
h) a ation of (b) and (c);
i) a combination of (b) and (d);
j ) a combination of (c) and (d); or
k) a combination of (a), (b), (c) and (d).
The antibodies of the invention are preferably onal. Monoclonal antibodies of the
t invention may e.g. be ed by the hybridoma method first described by Kohler
et al. (Nature 256 , 495 (1975)), or may be produced by recombinant DNA s.
Monoclonal antibodies may also be isolated from phage antibody libraries using the
techniques described in, for example, Clackson et al., Nature 352 , 624-628 (1991) and
Marks et al., J. Mol. Biol. 222 , 581-597 (1991). Monoclonal dies may be obtained
from any suitable source. Thus, for example, monoclonal antibodies may be obtained from
hybridomas prepared from murine splenic and lymph node B cells obtained from mice
immunized with an antigen of interest, for ce in the form of cells expressing an
antigen of interest on the surface, or a nucleic acid encoding an antigen of interest.
Monoclonal antibodies may also be obtained from hybridomas derived from antibodyexpressing
cells of immunized humans or non-human mammals such as rats, dogs,
primates, etc.
I n one embodiment, the antibody of the invention is a human antibody. Human
monoclonal antibodies directed against CD74 may be generated using enic or
transchromosomal mice carrying parts of the human immune system rather than the mouse
system. Such enic and transchromosomic mice include mice referred to herein as
HuMAb mice and KM mice, respectively, and are collectively referred to herein as
"transgenic mice".
The HuMAb mouse contains a human immunoglobulin gene minilocus that encodes
unrearranged human heavy (m and g ) and k light chain immunoglobulin ces, together
with targeted mutations that inactivate the endogenous m and k chain loci (Lonberg, N. et
al., Nature 368, 856-859 ). Accordingly, the mice exhibit reduced expression of
mouse IgM or k and, in response to immunization, the introduced human heavy and light
chain transgenes undergo class switching and somatic mutation to generate high affinity
human IgG,K monoclonal dies (Lonberg, N. et al. (1994), supra; reviewed in Lonberg,
N. Handbook of Experimental Pharmacology 113, 49-101 (1994) , Lonberg, N. and Huszar,
D., Intern. Rev. Immunol. Vol. 13 65-93 (1995) and Harding, F. and Lonberg, N. Ann. N.Y.
Acad. Sci 764 536-546 (1995)). The preparation of HuMAb mice is described in detail in
, L. et al., Nucleic Acids ch 20, 6287-6295 (1992), Chen, J. et al., International
Immunology 5, 647-656 (1993), Tuaillon et al., J. Immunol. 152, 2912-2920 (1994),
Taylor, L. et al., International Immunology 6, 579-591 (1994), ld, D. et al., Nature
Biotechnology 14, 845-851 . See also US 5,545,806, US 5,569,825, US 5,625,126,
US 5,633,425, US 5,789,650, US 5,877,397, US 5,661,016, US 5,814,318, US 5,874,299,
US 5,770,429, US 5,545,807, WO 84, WO 94/25585, WO 93/1227, WO 92/22645,
WO 92/03918 and WO 01/09187.
The HCo7, HCol2, HCol7 and HCo20 mice have a JKD tion in their
endogenous light chain (kappa; k) genes (as described in Chen et al., EMBO 1 12, 821-830
(1993)), a CMD disruption in their endogenous heavy chain genes (as described in Example
1 of WO 01/14424), and a KCo5 human kappa light chain transgene (as bed in
Fishwild e a/., Nature Biotechnology 14, 845-851 ). Additionally, the Hco7 mice have
a HCo7 human heavy chain transgene (as described in US 5,770,429), the HCol2 mice
have a HCol2 human heavy chain transgene (as described in e 2 of WO 01/14424),
the HCol7 mice have a HCol7 human heavy chain transgene (as described in Example 2 of
WO 01/09187) and the HCo20 mice have a HCo20 human heavy chain transgene. The
resulting mice express human immunoglobulin heavy and kappa light chain transgenes in a
background gous for disruption of the endogenous mouse heavy and kappa light
chain loci.
I n the KM mouse strain, the endogenous mouse kappa light chain gene has been
homozygously disrupted as described in Chen et al., EMBO J. 12, 811-820 (1993) and the
nous mouse heavy chain gene has been homozygously disrupted as described in
Example 1 of WO 01/09187. This mouse strain carries a human kappa light chain
transgene, KCo5, as described in Fishwild et al., Nature Biotechnology 14, 845-851 (1996).
This mouse strain also carries a human heavy chain transchromosome composed of
chromosome 14 fragment hCF (SC20) as described in WO 02/43478. HCol2-BALB/C mice
can be generated by crossing HCol2 to KCo5[J/K]-Balb/C as described in WO 097006.
Splenocytes and lymph node cells from these transgenic mice may be used to
generate hybridomas that secrete human monoclonal dies according t o well known
techniques.
Human monoclonal or polyclonal antibodies of the present invention, or antibodies of
the present invention originating from other species may also be generated transgenically
h the tion of another non-human mammal or plant that is transgenic for the
immunoglobulin heavy and light chain sequences of interest and production of the dy
in a rable form therefrom. I n connection with the transgenic production in mammals,
antibodies may be produced in, and recovered from, the milk of goats, cows, or other
s. See for instance US 5,827,690, US 5,756,687, US 5,750,172 and US 5,741,957.
Further, human antibodies of the present invention or antibodies of the present
invention from other species may be ted through display-type technologies,
including, without limitation, phage display, iral display, ribosomal display, and other
techniques, using techniques well known in the art and the resulting molecules may be
ted to additional maturation, such as affinity maturation, as such techniques are well
known in the art (see for instance Hoogenboom et al., J. Mol. Biol. 227, 381 (1991) (phage
display), Vaughan et al., Nature Biotech 14, 309 (1996) (phage display), Hanes and
au, PNAS USA 94, 4937-4942 (1997) (ribosomal display), Parmley and Smith, Gene
73, 305-318 (1988) (phage display), Scott TIBS 17, 241-245 (1992), Cwirla et al., PNAS
USA 87, 6378-6382 (1990), Russel et al., Nucl. Acids Research 21, 1081-1085 (1993),
Hogenboom et al., Immunol. Reviews 130, 43-68 , Chiswell and McCafferty H
, 80-84 (1992), and US 5,733,743). I f y technologies are ed to produce
antibodies that are not human, such dies may be humanized.
The antibody of the invention may be of any isotype. The choice of isotype typically
will be guided by the desired effector functions, such as ADCC induction. ary isotypes
are IgGl, IgG2, IgG3, and IgG4. Either of the human light chain constant regions, kappa or
lambda, may be used. If desired, the class of a CD74-specific antibody of the present
invention may be switched by known methods. For example, an antibody of the present
invention that was ally IgM may be class switched to an IgG antibody of the present
invention. Further, class switching techniques may be used to convert one IgG subclass to
another, for instance from IgGl t o IgG2. Thus, the effector function of the antibodies of the
present invention may be changed by isotype switching to, e.g., an IgGl, IgG2, IgG3, IgG4,
IgD, IgA, IgE, or IgM antibody for various therapeutic uses. I n one embodiment an antibody
of the present invention is an IgGl antibody, for instance an .
I n one embodiment, the antibody of the invention is a full-length antibody.
I n one embodiment, the full-length antibody is an IgGl antibody, such as an IgGl , K
antibody.
I n another embodiment, the full-length antibody is an IgG4 antibody.
I n a ular embodiment, the CD74-specific IgG4 antibody is a stabilized IgG4
antibody. Examples of suitable stabilized IgG4 dies are antibodies wherein arginine at
position 409 in a heavy chain constant region of human IgG4, which is indicated in the EU
index as in Kabat et al. supra, is substituted with lysine, ine, methionine, or leucine,
preferably lysine (described in WO2006033386) and/or wherein the hinge region comprises
a Cys-Pro-Pro-Cys sequence. Other suitable stabilized IgG4 antbodies are disclosed in
WO2008145142, which is hereby incorporated by nce in its entirety.
I n one embodiment, the stabilized IgG4 CD74-specific dy is an IgG4 dy
comprising a heavy chain and a light chain, wherein said heavy chain comprises a human
IgG4 constant region having a residue selected from the group consisting of: Lys, Ala, Thr,
Met and Leu at the position corresponding to 409 and/or a residue selected from the group
consisting of: Ala, Val, Gly, e and Leu at the position corresponding to 405, and wherein
said antibody optionally comprises one or more further substitutions, deletions and/or
insertions, but does not comprise a Cys-Pro-Pro-Cys sequence in the hinge region.
ably, said antibody comprises a Lys or Ala residue at the position corresponding to
409 or the CH3 region of the antibody has been replaced by the CH3 region of human IgGl,
of human IgG2 or of human IgG3.
I n another embodiment, the stabilized IgG4 CD74-specific antibody is an IgG4
antibody comprising a heavy chain and a light chain, n said heavy chain comprises a
human IgG4 constant region having a residue selected from the group consisting of: Lys,
Ala, Thr, Met and Leu at the position corresponding to 409 and/or a residue selected from
the group consisting of: Ala, Val, Gly, He and Leu at the position corresponding to 405, and
wherein said antibody optionally comprises one or more r substitutions, deletions
and/or insertions and wherein said antibody comprises a Cys-Pro-Pro-Cys sequence in the
hinge region. Preferably, said dy comprises a Lys or Ala residue at the position
corresponding to 409 or the CH3 region of the antibody has been replaced by the CH3 region
of human IgGl, of human IgG2 or of human IgG3.
I n r ment, the CD74-specific antibody is an antibody of a non-IgG4
type, e.g. IgGl, IgG2 or IgG3 which has been mutated such that the ability to mediate
effector functions, such as ADCC, has been reduced or even ated. Such mutations
have e.g. been described in cqua WF et al., J Immunol. 177(2): 138 (2006) and
Hezareh M, J Virol. 75(24): 12161-12168 (2001).
I n one embodiment, the respective isotypes and/or sequences of the two heavy
chain constant (Fc) regions are the same. I n another embodiment, the respective isotypes
and/or sequences of the two heavy-chain constant (Fc) regions of a single CD74-specific
antibody are different. This is ularly applicable to multispecific, such as bispecific,
CD74-specific antibodies, which are described in further detail below.
I n another aspect, the antibody is an antigen-binding nt. Antibody fragments
can be obtained by conventional techniques, such as by fragmentation of full-length
antibodies or by expression of c acids ng antibody fragments in recombinant
cells (see, for instance Evans et al., J. l. Meth. 184, 123-38 (1995)). The fragments
can then be tested or screened for their properties in the same manner as described herein
for full-length antibodies. The following describe exemplary formats for CD74-specific
antigen-binding fragments of the invention:
F(ab') fragments, which are bivalent fragments comprising two Fab fragments
linked by a disulfide bridge at the hinge region. These can be ted by, e.g., treating a
full-length antibody with pepsin.
Fab' or Fab fragments, which are monovalent fragments consisting of the V , V , C
L H L
and C 1 s. Fab fragments can be obtained, e.g., by treating an IgG antibody with
papain. Fab' fragments can be obtained, e.g., by reducing the disulfide bridges of a F(ab')
fragment using a reducing agent such as threitol.
Monovalent antibodies or "antibody half-molecules", which exist in aqueous solutions
as a heterodimer of a single light and single heavy chain, described in
WO2007059782 (Genmab A/S).
Fd fragments, which consist essentially of the V and C 1 domains.
H H
Fv fragments, which t essentially of the V and V domains of a single arm of
L H
an dy and -chain antibodies thereof. Single-chain antibodies (also known as
single chain Fv (scFv) dies) are constructs where the V and V domains of an Fv
L H
fragment are joined, using recombinant methods, by a synthetic linker that enables them to
be expressed as a single protein chain in which the V and V regions pair t o form
L H
monovalent les (see for instance Bird e a/., Science 242 , 423-426 (1988) and
Huston et al., PNAS USA 85, 5879-5883 ).
Domain antibodies (also called dAb fragments), which consists essentially of a V
domain (see, e.g., Ward et al., Nature 341 , 544-546 (1989); Holt et al; Trends Biotechnol.
2003 Nov;21(ll):484-90).
Other exemplary formats include camelids or nanobodies (see, e.g., Revets e a/;
Expert Opin Biol Ther. 2005 Jan;5(l): 111-24).
Multispecific antibody formats
I n another embodiment, the invention provides a multispecific antibody comprising a
first n binding site from a CD74-specific antibody molecule described herein above
and at least one second antigen binding site.
I n a particular embodiment, the second n-binding site is used for recruiting a
g mechanism such as, for example, by binding an antigen on a human effector cell or
by g a cytotoxic agent or a second therapeutic agent. Exemplary or cells include
a T cell such as, for example, a cytolytic T cell (CTL)), a natural killer (NK) cell, a
macrophage, a monocyte, a mast cell, and a granulocyte, such as, for example, a
neutrophil, an eosinophil and a basophil. Exemplary effector cell-antigens include, but are
not limited to, CD1, CD3, CD4, CD8, CD16, CD25, CD28, CD32, CD40, CD64, CD89, FcsRI
and HLA-DR. Suitable cytotoxic agents and second eutic agents are exemplified
below, and include toxins (such as radiolabeled peptides), chemotherapeutic agents and
prodrugs.
I n another particular embodiment, the second antigen-binding site binds t o an
antigen on a human B cell, such as, e.g., CD19, CD20, CD21, CD22, CD23, CD46, CD80,
CD138 and HLA-DR.
I n another particular embodiment, the second antigen-binding site binds a tissuespecific
antigen, promoting localization of the bispecific antibody to a specific tissue.
I n another particular embodiment, the second antigen-binding site binds t o an
antigen located on the same type of cell as the CD74-expressing cell, typically a tumorassociated
antigen (TAA), but has a binding specificity ent from that of the first
antigen-binding site. Such multi- or bispecific dies can enhance the specificity of the
tumor cell g and/or engage multiple effector pathways. Exemplary TAAs e
carcinoembryonic antigen (CEA), prostate specific antigen (PSA), RAGE (renal antigen),
a-fetoprotein, CAMEL (CTL-recognized antigen on melanoma), CT antigens (such as
MAGE-B5, -B6, -C2, -C3, and D; Mage-12; CT10; NY-ESO-1, SSX-2, GAGE, BAGE, MAGE,
and SAGE), mucin ns (e.g., MUC1, mucin-CA125, etc.), ganglioside antigens,
tyrosinase, gp75, c-Met, C-myc, Marti, , MUM-1, MUM-2, MUM-3, HLA-B7, Ep-CAM
or a cancer-associated in, such as a5b3 integrin. atively, the second antigenbinding
site binds t o a different e of CD74. The second antigen-binding site may
atively bind an angiogenic factor or other cancer-associated growth factor, such as a
ar endothelial growth factor, a fibroblast growth factor, epidermal growth factor,
angiogenin or a receptor of any of these, particularly receptors associated with cancer
progression.
I n another particular embodiment, the second antigen-binding site is from a second
CD74-specific antibody, such as a CD74-specific antibody of the invention.
Exemplary formats for the multispecific antibody molecules of the invention include,
but are not limited t o (i) two antibodies cross-linked by chemical heteroconjugation, one
with a specificity to CD74 and another with a specificity t o a second antigen; (ii) a single
antibody that comprises two different antigen-binding regions; (iii) a single-chain antibody
that comprises two different antigen-binding regions, e.g., two scFvs linked in tandem by an
extra peptide linker; (iv) a dual-variable-domain antibody (DVD-Ig), where each light chain
and heavy chain contains two variable domains in tandem through a short peptide linkage
(Wu et al., Generation and Characterization of a Dual Variable Domain Immunoglobulin
(DVD-Ig™) Molecule, In: dy Engineering, Springer Berlin berg (2010)); (v) a
chemically-linked bispecific (Fab')2 fragment; (vi) a Tandab, which is a fusion of two single
chain diabodies resulting in a tetravalent bispecific antibody that has two binding sites for
each of the target antigens; (vii) a flexibody, which is a combination of scFvs with a diabody
ing in a multivalent molecule; (viii) a so called "dock and lock" molecule, based on the
"dimerization and g domain" in Protein Kinase A, which, when applied to Fabs, can
yield a trivaient bispecific binding n consisting of two identical Fab fragments linked to
a different Fab fragment; (ix) a so-called on molecule, comprising, e.g., two scFvs
fused to both termini of a human Fab-arm; and (x) a diabody.
Another exemplary format for bispecific antibodies is IgG-like molecules with
complementary CH3 domains to force heterodimerization. Such molecules can be ed
using known technologies, such as, e.g., those known as Triomab/Quadroma (Trion
/Fresenius Biotech), Knob-into-Hole (Genentech), CrossMAb (Roche) and
electrostatically-matched (Amgen), LUZ-Y (Genentech), Strand Exchange ered
Domain body (SEEDbody)(EMD Serono), Biclonic (Merus) and DuoBody (Genmab A/S)
technologies.
I n one embodiment, the bispecific dy is obtained or obtainable via a controlled
Fab-arm exchange, typically using DuoBody technology. In vitro methods for producing
bispecific antibodies by controlled Fab-arm exchange have been described in WO
2008119353 and WO 2011131746 (both by Genmab A/S). I n one exemplary method,
described in WO 2008119353, a bispecific antibody is formed by "Fab-arm" or "halfmolecule"
ge (swapping of a heavy chain and attached light chain) between two
monospecific dies, both comprising IgG4-like CH3 s, upon incubation under
reducing conditions. The resulting product is a bispecific antibody having two Fab arms
which may comprise different sequences. I n another exemplary method, described in WO
2011131746, bispecific antibodies of the present invention are prepared by a method
sing the following steps, wherein at least one of the first and second antibodies is a
CD74 antibody of the present ion:
a) ing a first dy comprising an Fc region of an immunoglobulin, said Fc
region comprising a first CH3 region;
b) providing a second antibody comprising an Fc region of an immunoglobulin, said Fc
region comprising a second CH3 region;
wherein the sequences of said first and second CH3 regions are different and are such that
the heterodimeric interaction between said first and second CH3 regions is stronger than
each of the homodimeric ctions of said first and second CH3 regions;
c) incubating said first antibody together with said second antibody under reducing
ions; and
d) obtaining said bispecific antibody,
wherein the first antibody is a CD74 dy of the present invention and the second
dy has a different binding specificity, or vice versa.
The reducing conditions may, for example, be provided by adding a reducing agent,
e.g. selected from 2-mercaptoethylamine, dithiothreitol and tris(2-carboxyethyl)phosphine.
Step d) may further comprise restoring the conditions to become ducing or less
reducing, for example by removal of a reducing agent, e.g. by desalting.
Preferably, the sequences of the first and second CH3 regions are different,
comprising only a few, fairly vative, asymmetrical mutations, such that the
heterodimeric interaction between said first and second CH3 regions is stronger than each
of the homodimeric interactions of said first and second CH3 regions. More details on these
interactions and how they can be achieved are ed in WO 2011131746, which is
hereby incorporated by nce in its entirety. The following are exemplary embodiments
of ations of such assymetrical mutations, optionally wherein one or both Fc-regions
are of the IgGl isotype.
I n one embodiment, the first Fc region has an amino acid substitution at a position
selected from the group consisting of: 366, 368, 370, 399, 405, 407 and 409, and the
second Fc region has an amino acid substitution at a position selected from the group
consisting of: 366, 368, 370, 399, 405, 407 and 409, and wherein the first and second Fc
regions are not substituted in the same positions.
I n one ment, the first Fc region has an amino acid substitution at position
405, and said second Fc region has an amino acid substitution at a position selected from
the group consisting of: 366, 368, 370, 399, 407 and 409, optionally 409.
I n one embodiment, the first Fc region has an amino acid substitution at position
409, and said second Fc region has an amino acid substitution at a on selected from
the group consisting of: 366, 368, 370, 399, 405, and 407, optionally 405 or 368.
I n a particular embodiment, both the first and second Fc regions are of the IgGl
isotype, with the first Fc region having a Leu at position 405, and the second Fc region
having an Arg at position 409.
Conjugates
The t invention es a CD74-specific antibody conjugated to a therapeutic
moiety, i.e. a drug. The therapeutic moiety can be, e.g., a cytotoxin, a chemotherapeutic
agent, a cytokine, an immunosuppressant, an immune ator, a lytic peptide, or a
radioisotope. Such conjugates are referred to herein as an "antibody-drug conjugates" or
"ADCs".
Accordingly, in one , the antibody according to any above-described aspect or
embodiment is conjugated to a therapeutic moiety. Exemplary therapeutic moieties include
a cytotoxic moiety, a radioisotope, a cytokine, and a lytic peptide.
I n one embodiment, the antibody is capable of inducing cytotoxicity in a Raji cell by
internalization of the antibody conjugated to or associated with a therapeutic moiety in the
Raji cell, e.g., as described in Example 14 or a similar type of assay. In one embodiment,
the antibody induces cytotoxicity by internalization as described in Example 14, with an EC
value between about 25 ng/mL and about 60 ng/ml, such as n 25 ng/mL and 30
ng/mL, or an EC value less than 60 ng/mL, such as less than 40 ng/mL, or less than 30
ng/mL for inducing killing of Raji cells in an anti-kappa ETA' assay. I n another embodiment,
an ADC according to the present invention induces cytotoxicity with an EC value less than
ng/mL, such as less than 5 ng/mL, less than 1 ng/mL, less than 0.5 ng/mL or less than
0.1 ng/mL in inducing killing of Raji cells or other CD74-expressing cells.
I n one embodiment, the antibody is conjugated to a xic moiety. The cytotoxic
moiety may, for e, be selected from the group consisting of taxol; cytochalasin B;
gramicidin D; ethidium bromide; emetine; mitomycin; etoposide; tenoposide; vincristine;
vinblastine; colchicin; bicin; daunorubicin; oxy anthracin dione; a ninhibitor
such as maytansine or an analog or tive thereof; an antimitotic agent such
as monomethyl auristatin E or F or an analog or derivative thereof; dolastatin 10 or 15 or
an analogue thereof; irinotecan or an analogue thereof; mitoxantrone; mithramycin;
actinomycin D; drotestosterone; a glucocorticoid; procaine; aine; lidocaine;
propranolol; puromycin; calicheamicin or an analog or derivative thereof; an antimetabolite
such as rexate, 6 topurine, 6 thioguanine, cytarabine, fludarabin, 5
fluorouracil, decarbazine, hydroxyurea, asparaginase, abine, or cladribine; an
alkylating agent such as mechlorethamine, thioepa, chlorambucil, melphalan, tine
(BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin,
dacarbazine (DTIC), procarbazine, mitomycin C; a platinum derivative such as cisplatin or
carboplatin; duocarmycin A, duocarmycin SA, rachelmycin (CC-1065), or an analog or
derivative thereof; an antibiotic such as dactinomycin, bleomycin, daunorubicin,
doxorubicin, idarubicin, mithramycin, mitomycin, mitoxantrone, plicamycin, anthramycin
(AMC)); pyrrolo[2,l-c][l,4]-benzodiazepines (PDB); diphtheria toxin and related molecules
such as diphtheria A chain and active nts thereof and hybrid molecules, ricin toxin
such as ricin A or a osylated ricin A chain toxin, cholera toxin, a Shiga-like toxin such
as SLT I, SLT II, SLT IIV, LT toxin, C3 toxin, Shiga toxin, pertussis toxin, s toxin,
soybean Bowman-Birk protease inhibitor, Pseudomonas exotoxin, alorin, saporin, modeccin,
gelanin, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin
proteins, Phytolacca americana proteins such as PAPI, PAPII, and PAP-S, momordica
charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin,
restrictocin, phenomycin, and enomycin toxins; ribonuclease (RNase); DNase I ,
Staphylococcal enterotoxin A; pokeweed antiviral n; diphtherin toxin; and
Pseudomonas endotoxin.
I n one ment, the antibody is conjugated to an atin or a peptide analog,
derivative or prodrug thereof. Auristatins have been shown to interfere with microtubule
dynamics, GTP ysis and nuclear and cellular division (Woyke et al (2001) Antimicrob.
Agents and Chemother. 45(12): 3580-3584) and have anti-cancer (US5663149) and ant i
fungal activity t et al., (1998) Antimicrob. Agents and her. 42:2961-2965. For
example, auristatin E can be reacted with para-acetyl c acid or benzoylvaleric acid to
produce AEB and AEVB, respectively. Other typical auristatin derivatives include AFP, MMAF
(monomethyl auristatin F), and MMAE (monomethyl auristatin E). Suitable auristatins and
auristatin analogs, derivatives and prodrugs, as well as suitable linkers for conjugation of
auristatins to Abs, are bed in, e.g., U.S. Patent Nos. 483, 5,780,588 and
6,214,345 and in International patent application publications WO02088172,
WO2004010957, WO2005081711, WO2005084390, WO2006132670, WO03026577,
WO200700860, WO207011968 and WO205082023.
I n one embodiment, the antibody is conjugated to pyrrolo[2,l-c][l,4]-
benzodiazepine (PDB) or an analog, derivative or prodrug thereof. Suitable PDBs and PDB
derivatives, and related technologies are described in, e.g., Hartley J.A . et al., Cancer Res
2010; 70(17): 6849-6858; Antonow D. et al., Cancer J 2008; 14(3): 154-169; Howard P.W.
et al., Bioorg Med Chem Lett 2009; 19: 6463-6466 and Sagnou et al., Bioorg Med Chem
Lett 2000; 10(18): 2083-2086.
I n one embodiment, the antibody is conjugated t o a cytotoxic moiety selected from
the group consisting of an cycline, maytansine, calicheamicin, duocarmycin,
rachelmycin (CC-1065), dolastatin 10, atin 15, irinotecan, monomethyl auristatin E,
monomethyl auristatin F, a PDB, or an , derivative, or prodrug of any thereof.
I n a ular embodiment, the antibody is conjugated to an anthracycline or an
analog, derivative or g thereof. I n another ular embodiment, the antibody is
conjugated t o maytansine or an analog, derivative or prodrug thereof. I n another particular
embodiment, the antibody is conjugated to calicheamicin or an analog, derivative or
prodrug f. I n r particular embodiment, the antibody is conjugated to
duocarmycin or an analog, derivative or prodrug thereof. I n another particular embodiment,
the antibody is conjugated to rachelmycin (CC-1065) or an analog, derivative or prodrug
f. I n another particular embodiment, the antibody is conjugated t o dolastatin 10 or an
analog, derivative or prodrug thereof. I n another particular embodiment, the dy is
ated t o dolastatin 15 or an analog, derivative or g f. I n another
particular embodiment, the antibody is conjugated to monomethyl auristatin E or an analog,
derivative or prodrug thereof. I n another particular embodiment, the antibody is conjugated
to monomethyl auristatin F or an , derivative or prodrug thereof. I n another
particular embodiment, the antibody is conjugated t o o[2,l-c][l,4]-benzodiazepine or
an analog, derivative or prodrug thereof. I n another particular embodiment, the antibody is
conjugated t o ecan or an analog, derivative or prodrug thereof.
I n one embodiment, a CD74-specific antibody of the invention is conjugated to a
nucleic acid or nucleic acid-associated molecule. I n one such embodiment, the conjugated
nucleic acid is a cytotoxic ribonuclease ) or deoxy-ribonuclease (e.g., DNase I), an
antisense c acid, an inhibitory RNA le (e.g., a siRNA molecule) or an
immunostimulatory nucleic acid (e.g., an immunostimulatory CpG motif-containing DNA
le). I n another embodiment, a CD74-specific antibody of the invention is conjugated
to an r or a ribozyme.
I n one embodiment, a CD74-specific antibody of the invention is conjugated, e.g., as
a fusion protein, t o a lytic peptide such as CLIP, in 2, mellitin, Cecropin and P18.
I n one embodiment, the antibody is conjugated to a cytokine, such as, e.g., IL-2,
IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, IL-24, IL-27, IL-28a, IL-28b,
IL-29, KGF, IFNa, IFN3, IFNy, GM-CSF, CD40L, Flt3 ligand, stem cell factor, ancestim, and
TNFa.
I n one embodiment, the antibody is conjugated t o a radioisotope or to a
radioisotope-containing chelate. For example, the antibody can be conjugated t o a chelator
, e.g. DOTA, DTPA or tiuxetan, which allows for the antibody to be xed with a
radioisotope. The antibody may also or alternatively comprise or be ated to one or
more radiolabeled amino acids or other radiolabeled molecules. A radiolabeled CD74-specific
antibody may be used for both diagnostic and therapeutic purposes. Non-limiting examples
of radioisotopes include H, 14C, 1 N, S, 0Y, "Tc, 12 I , i In, 1 1I , 1 Re, 213Bi, 22 Ac and
22 Th. For therapeutic purposes, a sotope emitting beta- or alpha-particle radiation can
be used, e.g., 1 11, 0Y, 211At, 212Bi, Cu, 1 Re, 1 Re, and 212Pb.
A therapeutic agent that may be administered in combination with a CD74-specific
antibody of the present invention as described elsewhere herein, such as, e.g., a
chemotherapeutic agent, anti-cancer cytokine or chemokine, is also a ate for a
therapeutic moiety useful for conjugation to an antibody of the present invention.
A CD74-specific antibody of the present invention may also be chemically modified
by covalent conjugation t o a polymer to, for instance, increase its circulating half-life.
Exemplary polymers, and methods to attach them t o polypeptides, are illustrated in for
ce US 4,766,106, US 4,179,337, US 4,495,285 and US 4,609,546. onal
polymers include polyoxyethylated polyols and polyethylene glycol (PEG) (e.g., a PEG with a
molecular weight of between about 1,000 and about 40,000, such as between about 2,000
and about 20,000).
A therapeutic or other agent may be conjugated either directly or indirectly to a
CD74-specific antibody of the present invention, according to methods known in the art.
One example of indirect conjugation of a second agent is via a spacer moiety t o cysteine or
lysine residues in the antibody. The therapeutic or other moiety may also or alternatively be
conjugated t o an N- (amino-) terminal or C- (carboxy-) terminal residue of a CD74-specific
antibody polypeptide or fragment thereof (e.g., a CD74-specific antibody H or L chain) (see,
e.g., Antibody Engineering ok, edited by Osamu Kanemitsu, published by Chijin
Shokan (1994)). Conjugated antibody derivatives may also be generated by conjugation at
al residues or sugars, where appropriate. Exemplary methods are also bed in,
e.g., Hunter e a/., Nature 144, 945 (1962), David et al., Biochemistry 13, 1014 ,
Pain et al., . Immunol. Meth. 40, 219 (1981) and Nygren, J. Histochem. and Cytochem. 30,
407 (1982).
I n one embodiment, a pecific antibody is conjugated t o a prodrug molecule
via a spacer or linker that can be activated in vivo to a therapeutic drug. For example, the
prodrug moiety may be attached to the antibody via a , through the N- or inus
of the peptidic or non-peptidic drug moiety. After administration, the spacers or linkers are
cleaved by tumor cell-associated enzymes or other tumor-specific conditions, by which the
active drug is formed. Examples of such prodrug techologies and linkers are described in
3180, WO2004043493, WO2007018431, WO2007089149, WO2009017394 and
62171 by Syntarga BV, e ai. (all incorporated herein by reference) Suitable
antibody-prodrug logy and duocarmycin analogs can also be found in U.S. Patent No.
6,989,452 (Medarex) (incorporated herein by nce). Suitable prodrug technology for
auristatins is described in WO03026577 (Seatte Genetics) and other auristatin references
mentioned above.
I n one embodiment, a CD74-specific antibody is ated t o a therapeutic moiety
or prodrug via a linker sensitive t o changes in pH or reducing conditions. Suitable linker
technologies are known in the art, and include those described in, e.g., Ducry, L and Stump,
Bioconjugate Chem. 2010; 2 1:5-13; Senter P. D., Current Opinion in Chemical Biology
2009; 13:235-244; and , P. J. and Senter, P. D., The Cancer Journal 2010; 14: 154-
169.
I n some ments, the linker is cleavable under intracellular conditions, such
that the cleavage of the linker releases the drug unit from the antibody in the ellular
environment. I n some embodiments, the linker is cleavable by a cleavable agent that is
present in the intracellular environment (e. g . within a lysosome or endosome or caveolus).
The linker can be, e. g . a peptidyl linker that is cleaved by an intracellular peptidase or
protease enzyme, including but not limited to, a lysosomal or endosomal protease. I n some
embodiments, the yl linker is at least two amino acids long or at least three amino
acids long. Cleaving agents can include cathepsins B and D and plasmin, all of which are
known to hydrolyze dipeptide drug derivatives resulting in the release of active drug inside
the target cells (see e. g . Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123).
I n a specific embodiment, the peptidyl linker cleavable by an intracellular protease is a Val-
Cit (valine-citrulline) linker or a Phe-Lys (phenylalanine-lysine) linker (see e.g. US6214345,
which describes the synthesis of doxorubicin with the Val-Cit linker and different examples
of s linkers). Examples of the structures of a Val-Cit and a Phe-Lys linker include but
are not limited t o MC-vc-PAB bed below, MC-vc-GABA, MC-Phe-Lys-PAB or MC-Phe-
Lys-GABA, n MC or mc is an abbreviation for ido caproyi, vc is an abbreviation
for Val-Cit, PAB is an abbreviation for p-aminobenzylcarbamate and GABA is an abbreviation
for g -aminobutyric acid. An advantage of using ellular lytic release of the
therapeutic agent is that the agent is typically attenuated when conjugated and the serum
stabilities of the conjugates are typically high.
I n yet another embodiment, the linker unit is not cleavable and the drug is released
by antibody degradation (see, e.g., US 2005/0238649). Typically, such a linker is not
substantially sensitive to the extracellular nment. As used herein, "not substantially
sensitive to the extracellular environment" in the context of a linker means that no more
than 20%, typically no more than about 15%, more typically no more than about 10%, and
even more typically no more than about 5%, no more than about 3%, or no more than
about 1% of the s, in a sample of antibody-drug ate compound, are cleaved
when the antibody-drug conjugate compound presents in an extracellular environment (e.g.
plasma). Whether a linker is not ntially sensitive to the extracellular environment can
be determined for example by incubating with plasma the antibody-drug conjugate for a
predetermined time period (e.g. 2, 4, 8, 16 or 24 hours) and then quantitating the amount
of free drug present in the plasma.
I n a specific embodiment, the CD74-specific antibody is conjugated to MMAE la I):
n the wavy line indicates the covalent attachment site for the linker.
I n another specific embodiment, the CD74-specific antibody is ated t o MMAF
(formula II):
wherein the wavy line indicates the covalent attachment site for the linker.
I n a particular embodiment, the linker to MMAE or MMAF is ed t o sulfhydryl
groups (free cysteine residues) of the pecific antibody, obtained by (partial)
reduction of the CD74-specific antibody.
I n another particular embodiment, the linker-auristatin is MC-vc-PAB-MMAF (also
designated as vcMMAF) or MC-vc-PAB-MMAE (also designated as vcMMAE (formula III and
IV, respectively):
Ab-MC-vc-PAB-MMAF (vcMMAF)
Ab-MC-vc-PAB-MMAE (vcMMAE)
wherein p denotes a number of from 1 to 8, S ents a free cysteine thiol residue of the
pecific antibody, and Ab designates the CD74-specific antibody. I n one embodiment
thereof, the linker-auristatin is vcMMAE. The vcMMAE drug linker moiety and conjugation
methods are disclosed in WO2004010957, US7659241, US7829531, US7851437 and US
11/833,028 le Genetics, Inc.), (which are incorporated herein by reference), and the
vcMMAE drug linker moiety can be bound to the CD74-specific antibodies at the cysteines
using a method r t o those disclosed in therein.
I n another particular embodiment, the linker-conjugate is mcMMAF (formula V):
Ab-MC-MMAF (mcMMAF)
wherein p denotes a number of from 1 to 8, S represents a free cysteine thiol
residue of the CD74-specific antibody, and Ab designates the CD74-specific antibody. The
mcMMAF drug linker moiety and conjugation methods are sed in US7498298, US
11/833,954, and WO2005081711 (Seattle cs, Inc.) (which are incorporated herein by
reference), and the mcMMAF drug linker moiety can be bound to the CD74-specific
antibodies at the cysteines using a method similar t o those disclosed in therein.
I n one aspect, the invention provides a CD74-specific ADC comprising an antibody
binding t o the same epitope as an dy selected from 005, 006, 008 and 011, and a
drug which is auristatin or an analog, derivative or prodrug thereof. I n one embodiment, the
EC of the ADC in binding to the extracellular domain of CD47vl is lower than about 0.2
mg/mL, such as lower than 0.1 mg/mL, or lower than about 0.05 mg/mL, optionally higher
than 0.01 mg/mL, such as higher than 0.02 mg/mL, when determined in an assay as
described in Example 16. I n one embodiment, the CD74-specific ADC induces a cell kill
higher than 70%, 80% or 90% when measured for Raji, Daudi or M4A4 cells in an assay as
described in Example 18. I n one embodiment, the pecific ADC has an IC of less
than about 0.5 mg/mL, less than about 0.3 mg/mL, less than about 0.2 mg/mL, or less than
about 0 . 1 mg/mL, and optionally higher than 0.005 mg/mL or about 0.01 mg/mL, in inducing
killing of Raji, Daudi or M4A4 cells, when determined in an assay as described in Example
18. I n one embodiment, the antibody comprises at least the VH CDR3, such as the VH
CDRl, 2 and 3, optionally the VH CDRl, 2 and 3 and VL CDRl, 2 and 3 of 005, described in
Table 3 . I n one ment, the antibody comprises at least the VH CDR3, such as the VH
CDRl, 2 and 3, optionally the VH CDRl, 2 and 3 and VL CDRl, 2 and 3 of 006, described in
Table 3 . I n one ment, the antibody comprises at least the VH CDR3, such as the VH
CDRl, 2 and 3, optionally the VH CDRl, 2 and 3 and VL CDRl, 2 and 3 of 011, described in
Table 3 . I n one embodiment, the drug is a monomethyl auristatin derivative, optionally
selected from MMAE and MMAF.
I n one aspect, the invention provides a CD74-specific ADC sing an antibody
comprising the CDR, VH and/or VL ces of an antibody selected from the group
consisting of 005, 006 and 011, and a drug ed from MMAE and MMAF. I n one
embodiment, the antibody is 005. I n one embodiment, the antibody is 006. I n one
embodiment, the dy is 011. I n one particular embodiment, the antibody is 005 and
the drug is MMAE, optionally vcMMAE. I n one particular embodiment, the antibody is 005
and the drug is MMAF, optionally mcMMAF. In one particular embodiment, the antibody is
006 and the drug is MMAE, optionally vcMMAE. I n one particular embodiment, the antibody
is 006 and the drug is MMAF, optionally mcMMAF. In one particular embodiment, the
antibody is 011 and the drug is MMAE, optionally vcMMAE. I n one particular embodiment,
the dy is 011 and the drug is MMAF, optionally mcMMAF.
I n specific and separate embodiments, the invention provides the following
CD74-specific ADCs: 011-vcMMAE, 006-vcMMAE, 005-vcMMAE, 011-mcMMAF, 006-mcMMAF
and 005-mcMMAF.
The cytostatic drug loading is represented by p and is the average number of
atic drug moieties per antibody in a molecule (also designated as the drug to antibody
ratio, DAR). The cytostatic drug loading may range from 1 to 20 drug moieties per antibody
and may occur on amino acids with useful functional groups such as, but not d to,
amino or sulfhydryl groups, as in lysine or cysteine.
Depending on the way of conjugation, p may be limited by the number of
attachment sites on the antibody, for example where the attachment is a cysteine thiol, i.e.,
a sulphydryl group. Generally, antibodies do not contain many free and reactive cysteine
thiol groups, i.e., sulphydryl , which may be linked to a drug moiety, as most
cysteine thiol residues in antibodies exist as disulfide bridges. Therefore, in certain
embodiments, an antibody may be reduced with a reducing agent such as dithiothreitol
(DTT) or tricarbonylethylphosphine (TCEP), under partially or fully reducing conditions, t o
generate reactive dryl groups. I n certain embodiments, the drug loading for an ADC
of the invention ranges from 1 to about 8, such as about 2 to 5, such as about 3 to 5, such
as about 4 . A maximum of 8 free sulphydryl groups can become ble after (partial)
reduction of the antibody (there are 8 cysteines involved in inter-chain ide bonding).
Expression constructs
I n further and separate aspects, the invention relates t o nucleic acids encoding a ce
of an antibody of the invention, to expression vectors encoding the sequences of an
antibody of the invention, to host cells comprising such expression s, to omas
which produce antibodies of the ion, and to methods of producing an antibody of the
invention by culturing such host cells or hybridomas under appropriate ions whereby
the antibody is ed and, optionally, retrieved.
I n one embodiment, the invention provides an expression vector comprising a
nucleotide sequence encoding one or more amino acid sequences selected from SEQ I D
NOS: 7-26. I n one embodiment, the expression vector ses one or more nucleotide
sequences encoding one or more of the amino acid sequences selected from the group
consisting of SEQ ID NOS: 7, 11, 15, 19, 23 and 26, or any combination thereof. I n another
embodiment, the expression vector ses a nucleotide sequence encoding any one or
more of the V CDR3 amino acid sequences of SEQ ID NOS: 10, 14, 18 or 22. I n another
embodiment, the sion vector comprises a nucleotide ce encoding a V amino
acid sequence selected from SEQ I D NOS: 7, 11, 15 and 19. I n another embodiment, the
expression vector comprises a nucleotide sequence encoding a V amino acid sequence
ed from SEQ I D NOS: 23 and 26. I n another embodiment, the expression vector
further comprises a nucleotide sequence ng the constant region of a human antibody
light chain, of a human antibody heavy chain, or both.
I n a particular embodiment, the expression vector of the invention comprises a
nucleotide sequence encoding variants of one or more of the above amino acid ces,
said variants having at most 25 amino acid modifications, such as at most 20, such as at
most 15, 14, 13, 12 or 11 amino acid modifications, such as 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1
amino acid modifications, such as deletions or insertions, preferably tutions, such as
conservative substitutions or at least 80% identity t o any of said sequences, such as at
least 85% identity or 90% identity or 95% identity, such as 96% identity or 97% identity or
98% identity or 99% identity t o any of the afore-mentioned amino acid sequences.
An expression vector in the context of the present invention may be any suitable
vector, ing chromosomal, non-chromosomal, and synthetic nucleic acid vectors (a
nucleic acid ce comprising a le set of expression control elements). Examples
of such vectors include derivatives of SV40, bacterial ds, phage DNA, baculovirus,
yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and viral
nucleic acid (RNA or DNA) vectors. I n one embodiment, a CD74-specific antibody-encoding
nucleic acid is comprised in a naked DNA or RNA vector, including, for example, a linear
expression element (as described in for instance Sykes and Johnston, Nat Biotech 17,
355-59 ), a compacted nucleic acid vector (as described in for instance US 6,077,
835 and/or WO 00/70087), a d vector such as pBR322, pUC 19/18, or pUC 118/119,
a "midge" minimally-sized nucleic acid vector (as described in for instance Schakowski et
al., Mol Ther 3, 793-800 (2001)), or as a precipitated nucleic acid vector construct, such as
a CaP0 -precipitated construct (as described in for instance WO 00/46147, Benvenisty and
Reshef, PNAS USA 83, 9551-55 (1986), Wigler et al., Cell 14, 725 (1978), and Coraro and
Pearson, Somatic Cell Genetics 7, 603 (1981)). Such nucleic acid vectors and the usage
thereof are well known in the art (see for instance US 5,589,466 and US 5,973,972).
I n one embodiment, the vector is le for expression of the CD74-specific
antibody in a bacterial cell. Examples of such vectors include sion vectors such as
BlueScript (Stratagene), pIN s (Van Heeke & Schuster, J Biol Chem 264, 5503-5509
(1989)), pET vectors (Novagen, Madison WI) and the like.
An expression vector may also, or alternatively, be a vector suitable for sion in
a yeast system. Any vector suitable for expression in a yeast system may be employed.
le vectors include, for e, vectors comprising constitutive or inducible
promoters such as alpha factor, alcohol e and PGH (reviewed in: F. Ausubel et al., ed.
Current Protocols in Molecular Biology, Greene Publishing and Wiley InterScience New York
(1987), and Grant et al., Methods in Enzymol 153, 516-544 (1987)).
A nucleic acid and/or vector may also comprise a nucleic acid sequence encoding a
ion/localization sequence, which can target a polypeptide, such as a nascent
polypeptide chain, to the periplasmic space or into cell culture media. Such sequences are
known in the art, and include ion leader or signal peptides, organelle-targeting
sequences (e. g., nuclear zation sequences, ER retention signals, mitochondrial transit
sequences, chloroplast transit sequences), membrane localization/anchor sequences (e. g.,
stop transfer sequences, GPI anchor sequences), and the like.
I n an expression vector of the ion, CD74-specific antibody-encoding nucleic
acids may se or be associated with any suitable promoter, enhancer, and other
expression-facilitating elements. Examples of such elements include strong expression
promoters (e. g., human CMV I E promoter/enhancer as well as RSV, SV40, SL3-3, MMTV,
and HIV LTR ers), effective poly (A) termination sequences, an origin of replication
for plasmid product in E. coli, an antibiotic resistance gene as selectable marker, and/or a
convenient cloning site (e.g., a polylinker). Nucleic acids may also comprise an inducible
promoter as opposed to a constitutive er such as CMV I E (the skilled artisan will
ize that such terms are actually ptors of a degree of gene expression under
n conditions).
I n one embodiment, the CD74-specific antibody-encoding expression vector is
positioned in and/or delivered to the host cell or host animal via a viral vector.
Such expression vectors may be used for recombinant production of antibodies of
the invention.
I n one aspect, the invention provides a recombinant eukaryotic or prokaryotic host
cell which produces the antibody of any aspect or embodiment described .
Accordingly, the ion provides a recombinant eukaryotic or prokaryotic host cell, such
as a transfectoma, which produces an antibody or immunoglobulin of the invention as
defined herein. Examples of host cells include yeast, bacterial and mammalian cells, such as
CHO or 3 cells. For example, in one embodiment, the present invention provides a
cell comprising a nucleic acid stably integrated into the ar genome that comprises a
sequence coding for expression of a CD74-specific antibody of the present invention. I n
r embodiment, the present invention provides a cell comprising a non-integrated
nucleic acid, such as a plasmid, cosmid, phagemid, or linear expression element, which
comprises a sequence coding for expression of a CD74-specific antibody of the invention.
I n a further aspect, the invention relates to a oma which produces an antibody
of the invention as defined herein. In an even further aspect, the invention relates to a
transgenic non-human animal or plant comprising nucleic acids encoding a human heavy
chain and a human light chain, wherein the animal or plant produces an antibody of the
invention. Generation of such hybridomas and transgenic animals or plants has been
described above, and is further described in the Examples.
I n a further aspect, the invention relates to a method for producing a CD74-specific
antibody of the invention, said method comprising the steps of
a) culturing a hybridoma or a host cell of the invention as described herein above, and
b) retrieving and/or purifying the antibody of the invention from the e media and,
optionally,
c) preparing an ADC from the pecific antibody.
I n a further aspect, the nucleotide sequence encoding a sequence of an antibody of
the invention further encodes a second moiety, such as a therapeutic polypeptide.
Exemplary therapeutic polypeptides are dercribed elsewhere herein. In one embodiment,
the invention relates to a method for producing a CD74-specific antibody fusion protein,
said method comprising the steps of
a) culturing a host cell comprising an expression vector comprising such a nucleotide
sequence, and
b) retrieving and/or purifying the CD74-specific antibody fusion protein from the culture
media.
ceutical compositions
I n one , the ion provides a pharmaceutical composition comprising an antibody
or ADC as defined in any of the above aspects and embodiments, and a pharmaceutically
acceptable carrier.
The pharmaceutical compositions may be formulated with pharmaceutically
acceptable rs or diluents as well as any other known adjuvants and ents in
accordance with conventional techniques such as those sed in Remington: The Science
and Practice of Pharmacy, 19th Edition, o, Ed., Mack Publishing Co., Easton, PA,
1995.
The pharmaceutically acceptable rs or ts as well as any other known
adjuvants and excipients should be suitable for the dy or antibody conjugate of the
present invention and the chosen mode of administration. Suitability for carriers and other
components of pharmaceutical compositions is determined based on the lack of significant
negative impact on the desired biological properties of the chosen compound or
pharmaceutical composition of the present invention (e.g., less than a substantial impact
(10% or less relative inhibition, 5% or less relative inhibition, etc.) on antigen binding).
A pharmaceutical composition of the present invention may also include ts,
fillers, salts, buffers, detergents (e. g., a nonionic detergent, such as Tween-20 or Tween-
80), stabilizers (e.g., sugars or protein-free amino acids), preservatives, tissue fixatives,
solubilizers, and/or other materials suitable for inclusion in a pharmaceutical ition.
The actual dosage levels of the active ingredients in the pharmaceutical compositions
of the present invention may be varied so as to obtain an amount of the active ingredient
which is effective to achieve the desired therapeutic se for a particular patient,
ition, and mode of administration, without being toxic to the patient. The selected
dosage level will depend upon a variety of pharmacokinetic factors including the activity of
the particular compositions of the present invention employed, or the amide thereof, the
route of administration, the time of administration, the rate of ion of the particular
compound being employed, the duration of the treatment, other drugs, compounds and/or
materials used in combination with the particular compositions employed, the age, sex,
weight, condition, general health and prior l history of the patient being treated, and
like factors well known in the medical arts.
The pharmaceutical composition may be administered by any suitable route and
mode. le routes of administering a compound of the present ion in vivo and in
vitro are well known in the art and may be ed by those of ordinary skill in the art.
I n one ment, a ceutical ition of the present invention is
administered parenterally.
The phrases "parenteral administration" and "administered parenterally" as used
herein means modes of administration other than enteral and topical administration, usually
by injection, and include epidermal, intravenous, intramuscular, intra-arterial, intrathecal,
intracapsular, intra-orbital, intracardiac, intradermal, intraperitoneal, intratendinous,
transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid,
pinal, intracranial, intrathoracic, epidural and intrasternal injection and infusion.
I n one embodiment that pharmaceutical composition is administered by intravenous
or subcutaneous injection or infusion.
Pharmaceutically able carriers include any and all suitable solvents, dispersion
media, coatings, antibacterial and antifungal agents, isotonicity agents, antioxidants and
tion-delaying agents, and the like that are physiologically compatible with a
compound of the present invention.
Examples of suitable aqueous and nonaqueous carriers which may be ed in
the pharmaceutical compositions of the present invention include water, saline,
phosphate-buffered saline, ethanol, dextrose, polyols (such as glycerol, propylene glycol,
polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as
olive oil, corn oil, peanut oil, cottonseed oil, and sesame oil, carboxymethyl ose
dal solutions, tragacanth gum and injectable organic esters, such as ethyl oleate,
and/or various buffers. Other carriers are well known in the pharmaceutical arts.
Pharmaceutically able carriers include sterile s solutions or dispersions
and sterile powders for the oraneous preparation of sterile injectable solutions or
dispersion. The use of such media and agents for ceutically active substances is
known in the art. Except insofar as any conventional media or agent is incompatible with
the active compound, use thereof in the pharmaceutical compositions of the present
invention is contemplated.
Proper fluidity may be maintained, for example, by the use of coating als, such
as lecithin, by the maintenance of the required particle size in the case of dispersions, and
by the use of surfactants.
Pharmaceutical itions of the present invention may also se
pharmaceutically acceptable idants for ce (1) water-soluble antioxidants, such
as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium
sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated
hydroxyanisole (BHA), ted hydroxytoluene (BHT), lecithin, propyl gallate, ocopherol
, and the like; and (3) metal-chelating agents, such as citric acid,
ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the
like.
Pharmaceutical compositions of the present invention may also comprise isotonicity
agents, such as sugars, polyalcohols, such as mannitol, sorbitol, glycerol or sodium chloride
in the compositions.
The pharmaceutical compositions of the present invention may also contain one or
more adjuvants appropriate for the chosen route of administration such as preservatives,
wetting agents, emulsifying agents, dispersing agents, preservatives or buffers, which may
enhance the shelf life or effectiveness of the pharmaceutical composition. The compounds of
the present invention may be prepared with carriers that will protect the compound against
rapid release, such as a controlled release formulation, including ts, transdermal
patches, and micro-encapsulated delivery s. Such carriers may include gelatin,
glyceryl monostearate, glyceryl distearate, biodegradable, biocompatible polymers such as
ethylene vinyl acetate, hydrides, polyglycolic acid, collagen, poly-ortho-esters, and
polylactic acid alone or with a wax, or other materials well known in the art. Methods for the
preparation of such ations are generally known to those skilled in the art. See e.g.,
Sustained and Controlled Release Drug Delivery s, J.R. Robinson, ed., Marcel
Dekker, Inc., New York, 1978.
I n one embodiment, the compounds of the present invention may be formulated to
ensure proper bution in vivo. Pharmaceutically acceptable carriers for parenteral
administration include sterile aqueous solutions or dispersions and sterile powders for the
extemporaneous preparation of sterile injectable solutions or sion. The use of such
media and agents for pharmaceutically active substances is known in the art. Except insofar
as any conventional media or agent is incompatible with the active compound, use f
in the pharmaceutical compositions of the present invention is contemplated. Other active
or therapeutic compounds may also be incorporated into the compositions.
Pharmaceutical compositions for injection must typically be e and stable under
the conditions of manufacture and storage. The composition may be formulated as a
solution, micro-emulsion, liposome, or other ordered structure suitable to high drug
concentration. The carrier may be an aqueous or a non-aqueous solvent or sion
medium containing for instance water, ethanol, polyols (such as glycerol, propylene glycol,
polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as
olive oil, and injectable organic esters, such as ethyl oleate. The proper fluidity may be
maintained, for example, by the use of a coating such as lecithin, by the maintenance of the
required particle size in the case of dispersion and by the use of surfactants. I n many cases,
it will be preferable to include isotonic agents, for e, sugars, polyalcohols such as
glycerol, mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of
the injectable compositions may be brought about by including in the composition an agent
that delays absorption, for example, monostearate salts and gelatin. Sterile injectable
solutions may be prepared by incorporating the active compound in the required amount in
an appropriate solvent with one or a combination of ingredients e.g. as enumerated above,
as required, followed by sterilization microfiltration. lly, sions are prepared by
incorporating the active compound into a sterile vehicle that contains a basic dispersion
medium and the required other ingredients e.g. from those enumerated above. I n the case
of sterile powders for the preparation of sterile injectable ons, examples of methods of
preparation are vacuum-drying and freeze-drying (lyophilization) that yield a powder of the
active ingredient plus any additional desired ingredient from a previously e-filtered
solution thereof.
Sterile able ons may be prepared by incorporating the active compound in
the required amount in an appropriate solvent with one or a combination of ingredients
enumerated above, as required, followed by sterilization microfiltration. Generally,
sions are prepared by orating the active compound into a sterile e that
contains a basic dispersion medium and the ed other ients from those
enumerated above. In the case of sterile powders for the preparation of sterile injectable
solutions, examples of methods of preparation are vacuum-drying and freeze-drying
(lyophilization) that yield a powder of the active ingredient plus any additional desired
ient from a previously sterile-filtered solution thereof.
The ceutical composition of the present invention may contain one antibody
or ADC of the present invention, a combination of an antibody or ADC according to the
invention with another therapeutic compound, or a combination of nds of the
present invention.
Therapeutic applications
I n another aspect, the invention relates t o the antibody or ADC of the invention, as defined
in any aspect or embodiment herein, for use as a medicament.
The CD74-specific dies of the t invention can be used in the treatment
or prevention of disorders involving cells expressing CD74. For example, the antibodies may
be administered t o cells in culture, e.g., in vitro or ex vivo, or to human subjects, e.g., in
vivo, to treat or prevent disorders involving CD74-expressing cells. As used herein, the term
"subject" is typically a human who responds t o the CD74-specific antibody or ADC. Subjects
may for instance include human patients having disorders that may be corrected or
ameliorated by modulating CD74 function or by killing of the cell, directly or indirectly.
I n one embodiment, the invention provides a method for modulating CD74-
associated signaling in a CD74-expressing cell by contacting the cell with a CD74-specific
dy. A CD74-specific antibody of the invention may, for e, interfere with MIF-
binding t o CD74, which is a non-limiting example of how an antibody of the invention can
modulate CD74-associated signaling.
I n one embodiment, the invention provides a method for killing a CD74-expressing
cell by contacting the cell with a CD74-specific antibody of the invention. t being
limited to theory, antibody-mediated crosslinking or clustering (e.g., due t o the Fc-region of
CD74-bound antibodies binding t o FcR-expressing cells) of CD74 molecules on the surface
of a cell can lead t o apoptosis of the cell.
I n one embodiment, the invention provides a method for killing a CD74-expressing
cell by contacting the cell with a CD74-specific antibody of the invention in the presence of
effector cells capable of inducing an iated effector cell response such as a CDC,
ADCC or ADCP response. I n this embodiment, the dy is typically full-length and of an
isotype leading to a CDC or ADCC response, such as, e.g., an IgGl , K isotype.
The CD74-specific antibodies of the invention are characterized by efficient
internalization upon binding to CD74, making them suitable for an ADC approach using an
ADC as described in any aspect or ment bed herein.
Accordingly, in one embodiment, the invention es a method for g a CD74-
sing cell by contacting the cell with an ADC of the invention which requires
alization and trafficking to lysosomes for ic (i.e. cleavable linker) or non-specific
(non-cleavable linker) proteolytic cleavage of the antibody-linker-drug complex. I n another
embodiment, the invention provides for a method of g a CD74-expressing cell by
ting the cell with an ADC of the invention wherein the CD74-specific antibody is linked
to a therapeutic moiety via a linker allowing for release of the drug once the ADC is
internalized, e.g., by a change in pH or reducing conditions. Suitable linker technology is
known in the art, as described above.
I n another aspect, the present invention provides methods for treating or ting
a disorder involving cells expressing CD74 in a subject, which method comprises
administration of a therapeutically effective amount of a CD74-specific antibody or ADC of
the present invention t o a subject in need thereof. The method typically involves
administering t o a subject a CD74-specific dy or ADC in an amount effective to treat
or t the disorder.
I n a particular , a pecific antibody or ADC is administered
prophylactically in order to reduce the risk of developing cancer, delay the onset of an event
in cancer progression or reduce the risk of recurrence when a cancer is in remission and/or
a primary tumor has been surgically removed. I n the latter case, the CD74-specific antibody
could, for example, be administered in association with (i.e., before, during, or after) the
surgery. Prophylactic stration may also be useful in patients wherein it is ult to
locate a tumor that is believed t o be present due to other biological factors.
Cells over-expressing CD74, such as cancer cells, are particularly good targets for
the CD74-specific antibodies or ADCs of the invention, since more antibodies or ADCs may
be bound per cell. Thus, in one aspect, the disorder involving cells expressing CD74 is
cancer, i.e., a tumorigenic disorder, such as a disorder characterized by the presence of
tumor cells expressing CD74 including, for example, disorders where the cells are from a
solid tumor or hematological tumor. CD74 expression has been described in, e.g., breast
cancer (Koretz K et al., Int J Cancer 1989; 44: 816-822), colorectal cancer (Cuthbert F et
al., Eur J Cancer 2009; 45: 1654-1663), endometrial/cervical cancer (Glew SS et al., Cancer
Res 1992; 9-4016), gastric cancer (Tamori Y et al, Oncol Rep 2005; 14:873-877),
squamous cell carcinoma of the head and neck (SCCHN) (Han J et al., Head Neck Oncol
2009; 1:27), lung cancer (McClelland M et al., Am J Pathol 2009; 174:638-646),
glioblastoma (Kitange G et al., J Neurooncol 2010; 100: 6), malignant lymphoma
(Momburg F et al., Int J Cancer 1987; 40:598-603), B cell c lymhocytic leukemia
(B-CLL) (Narni F et al., Blood 1986; 68:372-377), non-Hodgkin's lymphoma (NHL),
monocytoid B cell lymphoma (MBCL) (Stroup R et al, Hum Pathol 1992; 23: 172-177), hairy-
cell leukemia (HCL) (Spiro RC et al., Leuk Res 1984; 8 : 55-62), malignant melanoma
(Weeraratna AT et al., Oncogene 2004; 23:2264-2274), n cancer (Rangel LB et al.,
Cancer Biol Ther 2004; 3 : 1021-1027), prostate cancer (Meyer-Siegler KL et al., BMC Cancer
2005; 5:73), pancreatic cancer (Koide N et al., Clin Cancer Res 2006; 12:2419-2426), renal
cancer (Saito T et al., Cancer Lett 1997; 115: 7), thymic epithelial neoplasms (Datta
MW et al., Appl Immunohistochem Mol Morphol 2000; 8:210-215), malignant fibrous
histiosarcomas (Lazova R et al., Cancer 1997; 79:2115-2124), and pituitary adenomas
(Rossi ML et al., Tumori 1990; 76:543-547). CD74 has also been found t o be ulated
in e.g., gastric epithelium during H. pylori infection and ulcerative s (Beswick, World J
Gastroenterol. 2009; 15(23):2855-61).
Exemplary cells expressing CD74 thus include cancer cells such as, e.g., cells from
NHL, multiple myeloma (MM), ovarian cancer, breast cancer, pancreatic , te
cancer, gastric cancer, colorectal oma and liver cancer.
I n one aspect, the present invention provides methods for treating or preventing a
hematological malignancy, which method comprises administration of a therapeutically
effective amount of a CD74-specific antibody or ADC of the present invention t o a subject in
need thereof, and wherein the hematological malignancy is selected from a lymphoma,
myeloma and/or a leukemia. I n one embodiment, the logical malignancy is selected
from the group consisting of malignant ma, B cell chronic lymphocytic leukemia
(B-CLL), c myeloid leukemia (CML) in blast phase, NHL, MM, MBCL, HCL and T cell
lymphoma.
I n one embodiment, the hematological malignancy is NHL. The CD74-specific
antibodies and ADCs of the present invention can, for example, be used in the treatment of
both indolent and aggressive forms of NHL. Examples of B cell NHLs include matoid
granulomatosis, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma,
primary effusion ma, intravascular large B cell lymphoma, mediastinal large B cell
lymphoma, heavy chain diseases (including g , m, and a e), lymphomas induced by
therapy with immunosuppressive agents, such as cyclosporine-induced lymphoma, and
methotrexate-induced lymphoma. I n one embodiment, the hematological malignancy is
multiple myeloma, such as, e.g., myeloma light chain disease and monoclonal gammapathy
of undetermined significance (MGUS). I n other separate and specific ments, the
hematological malignancy is malignant lymphoma, B-CLL (such as, e.g., small lymphocytic
lymphoma; SLL), CML in blast phase, MBCL, or HCL. I n one embodiment, the hematological
ancy is a T cell lymphoma, such as, e.g., mycosis fungoides, peripheral T cell
lymphomas unspecified, angioimmunoblastic T cell lymphoma, anaplastic large cell
ma (ALCL), enteropathy-associated T cell lymphoma, or hepatosplenic T cell
lymphoma. I n another embodiment, the hematological malignancy is Hodgkin's lymphoma.
I n r embodiment, the hematological malignancy is Waldenstrom's
macroglobulinemia. I n one embodiment, the hematological malignancy is CLL, such as B-
CLL (e.g., small lymphocytic lymphoma; SLL).
I n one aspect, the present invention provides methods for treating or preventing a
solid tumor, which method comprises administration of a therapeutically effective amount of
a CD74-specific antibody or ADC of the t ion to a subject in need thereof, and
wherein the solid tumor is a melanoma, carcinoma, a, adenoma and/or a glioma. I n
one embodiment, the cancer is ed from the group consisting of breast cancer (such
as, e.g., primary or metastatic breast ), colorectal cancer, trial/cervical
cancer, gastric cancer, head and neck cancer (such as, e.g., SCCHN), hepatocellular
carcinoma, lung cancer (such as, e.g., small cell lung cancer or non-small cell lung cancer),
malignant glioma (such as, e.g., anaplastic ytoma and glioblastoma multiforme),
malignant melanoma (such as, e.g., primary or metastatic melanoma), ovarian cancer (such
as, e.g., , endometrioid or clear cell arcinoma), pancreatic cancer, prostate
cancer, renal cancer, bladder cancer, thymic cancer (such as, e.g., thymic carcinoma and
invasive thymoma), malignant fibrous histiosarcoma, acoustic schwannoma, pituitary
adenoma, and a soft tissue tumor.
I n one embodiment, the cancer is ovarian cancer. In another embodiment, the
cancer is selected from primary or metastatic breast cancer. I n another embodiment, the
cancer is pancreatic , such as unresectable ed or metastatic pancreatic cancer.
I n another embodiment, the cancer is te cancer. In another embodiment, the cancer
is c cancer. I n another embodiment, the cancer is colorectal carcinoma, such as
metastatic colorectal carcinoma. I n another embodiment, the cancer is hepatocellular
carcinoma. In other te and specific embodiments, the cancer is endometrial/cervical
cancer, head and neck cancer, lung cancer, malignant glioma, malignant melanoma, ovarian
cancer, renal cancer, thymic cancer, malignant fibrous histiosarcoma, acoustic
schwannoma, pituitary adenoma, or a soft tissue tumor.
I n one aspect, the present invention es methods for treating or preventing an
autoimmune disease, which method comprises administration of a therapeutically effective
amount of a CD74-specific antibody or ADC of the t ion to a subject in need
thereof. In one embodiment, the autoimmune disease is ed from an immune-mediated
thrombocytopenia (such as acute idiopathic thrombocytopenic a and chronic
idiopathic thrombocytopenic purpura), dermatomyositis, Sjogren's syndrome, multiple
sclerosis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus
nephritis, rheumatic fever, polyglandular mes, bullous pemphigoid, diabetes mellitus,
Henoch-Schonlein purpura, post-streptococcal nephritis, erythema nodosum, Takayasu's
arteritis, Addison's disease, rheumatoid arthritis, dosis, ulcerative colitis, erythema
multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's
syndrome, thromboangitis ubiterans, primary biliary cinhosis, Hashimoto's thyroiditis,
thyrotoxicosis, scleroderma, c active hepatitis, polymyositis/dermatomyositis,
polychondritis, gus vulgaris, Wegener's granulomatosis, membranous nephropathy,
amyofrophic lateral sclerosis, tabes dorsalis, giant cell arteritis/polymyalgia, pernicious
anemia, rapidly ssive glomerulonephritis and fibrosing alveolitis.
I n one embodiment, the autoimmune disease is rheumatoid arthritis. I n another
embodiment, the autoimmune disease is systemic sclerosis. In r embodiment, the
autoimmune disease is le sclerosis. I n another embodiment, the autoimmune e
is an inflammatory bowel disease, such as, e.g, s disease or ulcerative colitis.
I n one embodiment, the invention provides a method of treatment of any one of the
disorders of the above aspects and embodiments by administration to an individual in need
thereof, of a CD74-specific antibody or ADC of any of the above aspects or embodiments.
The invention also s to CD74-specific antibodies or ADCs of the invention for use as a
therapeutic, e.g., in the treatment of cancer or other disorder mentioned herein.
I n an ment selection of patients to be treated with CD74-specific antibodies is
based on the level of CD74 expression in a , such as a sample containing tumor cells,
or by detecting CD74-expressing tumors using labeled pecific antibodies or antibody
fragments, e.g., those of the invention. Exemplary diagnostic assays for determining CD74-
expression using CD74 antibodies or antibody fragment of the invention are described
herein.
The efficient dosages and dosage ns for the CD74-specific antibody or ADC depend
on the disease or condition to be treated and may be determined by the persons skilled in
the art.
A physician having ordinary skill in the art may readily determine and prescribe the
effective amount of the pharmaceutical composition required. For example, the physician
could start doses of the CD74-specific antibody employed in the pharmaceutical composition
at levels lower than that ed in order to achieve the desired therapeutic effect and
gradually increase the dosage until the desired effect is achieved. I n general, a suitable
dose of a composition of the present invention will be that amount of the compound which is
the lowest dose effective to produce a eutic effect according to a particular dosage
regimen. Such an effective dose will generally depend upon the factors described above.
For example, an "effective amount" for therapeutic use may be measured by its
ability to stabilize the progression of disease. The ability of a compound to inhibit cancer
may, for example, be ted in an animal model system predictive of efficacy in human
tumors. Alternatively, this property of a composition may be evaluated by examining the
ability of the compound to t cell growth or to induce cytotoxicity by in vitro assays
known to the d tioner. A therapeutically effective amount of a therapeutic
compound may decrease tumor size, or otherwise ameliorate symptoms in a subject. One of
ordinary skill in the art would be able to determine such amounts based on such factors as
the t's size, the ty of the subject's symptoms, and the ular composition or
route of administration selected.
An exemplary, non-limiting range for a eutically effective amount of a
CD74-specific antibody of the present invention is about 0 mg/kg, such as about
0.1-50 mg/kg, for example about 0.1-20 mg/kg, such as about 0.1-10 mg/kg, for instance
about 0.5, about such as 0.3, about 1, about 3 mg/kg, about 5 mg/kg or about 8 mg/kg.
An exemplary, non-limiting range for a therapeutically effective amount of a
CD74-specific ADC of the invention is 0.02-100 mg/kg, such as about 0.02-30 mg/kg, such
as about 0.05-10 mg/kg or 0.1-3 mg/kg, for example about 0.5-2 mg/kg.
stration may e.g. be intravenous, intramuscular, intraperitoneal, or
subcutaneous, and for instance administered proximal to the site of the target.
Dosage ns in the above methods of treatment and uses are adjusted to
provide the optimum desired response (e.g., a therapeutic response). For example, a single
bolus may be stered, l d doses may be administered over time or the
dose may be proportionally reduced or increased as indicated by the exigencies of the
therapeutic situation.
I n one embodiment, the efficacy-safety window is optimized by lowering specific
toxicity such as for example by lowering the drug-antibody ratio (DAR) and/or mixing of
CD74-specific ADC with unlabeled CD74-specific dy.
I n one embodiment, the efficacy of the treatment is monitored during the therapy,
e.g. at predefined points in time. In one embodiment, the efficacy may be monitored by
measuring the level of CD74 in a sample containing tumor cells, by ization of the
disease area, or by other diagnostic methods described further herein, e.g. by performing
one or more PET-CT scans, for example using a labeled CD74-specific antibody, fragment or
ntibody derived from the CD74-specific antibody of the t invention.
If desired, an effective daily dose of a pharmaceutical composition may be
administered as two, three, four, five, six or more sub-doses administered separately at
appropriate intervals throughout the day, optionally, in unit dosage forms. In another
embodiment, the CD74-specific antibodies are administered by slow continuous infusion
over a long period, such as more than 24 hours, in order to minimize any unwanted side
effects.
While it is possible for a compound of the present invention to be administered
alone, it is able to administer the compound as a ceutical composition as
described above.
An effective dose of a CD74-specific antibody or ADC of the invention may also be
administered using a weekly, biweekly or triweekly dosing period. The dosing period may be
restricted to, e.g., 8 weeks, 12 weeks or until clinical progression has been established.
For example, in one ment, the pecific antibody or ADC is administered
by infusion in a weekly dosage of between 10 and 500 mg/m 2, such as between 200 and
400 mg/m 2. Such administration may be ed, e.g., 1 to 8 times, such as 3 to 5 times.
The administration may be performed by continuous infusion over a period of from 1 to 24
hours, such as of from 1 to 12 hours.
I n another embodiment, the CD74-specific antibody or ADC is administered by
infusion every three weeks in a dosage of between 10 and 500 mg/m 2, such as between 50-
200 mg/m 2. Such administration may be repeated, e.g., 1 to 8 times, such as 3 to 5 times.
The administration may be performed by continuous infusion over a period of from 1 to 24
hours, such as of from 1 to 12 hours.
I n one embodiment, a CD74-specific ADC is administered as a single dose of about
0.1-10 mg/kg, such as about 1-3 mg/kg, every week or every third week for up to twelve
times, up to eight times, or until clinical progression. The administration may be performed
by continuous infusion over a period of from 1 to 24 hours, such as of from 1 to 12 hours.
Such regimens may be repeated one or more times as necessary, for example, after 6
months or 12 . The dosage may be determined or adjusted by ing the
amount of compound of the present ion in the blood upon administration by for
instance taking out a biological sample and using anti-idiotypic dies which target the
antigen binding region of the CD74-specific dies of the t invention.
I n one embodiment, the CD74-specific antibodies are stered as maintenance
therapy, such as, e.g., once a week for a period of six months or more.
As non-limiting examples, treatment according to the present invention may be
provided as a daily dosage of a compound of the present invention in an amount of about
0.1-100 mg/kg, such as 0.2, 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80,
90 or 100 mg/kg, per day, on at least one of days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36,
37, 38, 39, or 40, or alternatively, at least one of weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19 or 20 after initiation of treatment, or any combination thereof,
using single or divided doses every 24, 12, 8, 6, 4, or 2 hours, or any combination thereof.
Parenteral compositions may be formulated in dosage unit form for ease of
administration and uniformity of dosage. Dosage unit form as used herein refers to
physically te units suited as unitary dosages for the subjects to be treated; each unit
contains a predetermined quantity of active compound calculated to produce the desired
therapeutic effect in ation with the required pharmaceutical carrier. The specification
for the dosage unit forms of the present invention are dictated by and directly dependent on
(a) the unique characteristics of the active compound and the particular therapeutic effect
to be achieved, and (b) the limitations inherent in the art of compounding such an active
compound for the treatment of sensitivity in individuals.
Combinations
The invention also provides for eutic applications where an antibody or ADC of the
invention is used in combination with at least one further therapeutic agent relevant for the
disease or er to be treated, as described above. Such administration may be
simultaneous, te or sequential. For simultaneous administration the agents may be
administered as one composition or as separate compositions, as appropriate.
Accordingly, the present invention provides methods for treating a disorder involving
cells expressing CD74 as described above, which methods comprise administration of a
CD74-specific antibody or ADC of the t invention combined with one or more
additional therapeutic agents. The present invention also es for the use of a
CD74-specific antibody or ADC of the t invention for the preparation of a
ceutical composition to be administered with at least one herapeutic agent
for treating such a disorder.
The further therapeutic agent is typically relevant for the disorder to be treated.
Exemplary therapeutic agents include other anti-cancer antibodies or ADCs, xic
agents, chemotherapeutic agents, anti-angiogenic agents, anti-cancer immunogens, cell
cycle control/apoptosis ting agents, hormonal regulating agents, and other agents
described below.
I n one aspect, the further therapeutic agent is at least one second antibody or ADC
which binds another target such as, e.g., CD4, CD5, CD8, CD14, CD15, CD19, CD21, CD22,
CD23, CD25, CD30, CD33, CD37, CD38, CD40, CD40L, CD46, CD52, CD54, CD80, CD126,
B7, MUCl, tenascin, HM1.24, or HLA-DR. For example, the second antibody may bind to a B
cell antigen, including, but not limited to CD20, CD19, CD21, CD23, CD38, CD46, CD80,
CD138, HLA-DR, CD22, or to another epitope on CD74. In another embodiment, the second
antibody binds vascular endothelial growth factor A (VEGF-A). I n separate and specific
ments, the further eutic agent is a CD20- or a specific antibody.
I n one embodiment, the CD74-specific antibody or ADC of the invention is for use in
combination with a specific therapeutic antibody, such as veltuzumab, bevacizumab
(Avastin®), zalutumumab, cetuximab (Erbitux®), panitumumab bix™), ofatumumab
ra™), ocrelizumab, zanolimumab, daratumumab, zumab (Lucentis®), Zenapax,
Simulect, Remicade, Humira, Tysabri, Xolair, raptiva, nimotuzumab, rituximab and/or
trastuzumab (Herceptin®). I n one embodiment, the CD74-specific antibody or ADC of the
present invention is administered in combination with a CD20-specific antibody such as,
e.g., veltuzumab, ocrelizumab or ofatumumab (Arzerra™). In r embodiment, the
CD74-specific antibody or ADC of the present ion is administered in combination with
bevacizumab (Avastin®).
I n one aspect, the invention provides an antibody or ADC of any of the above
aspects or embodiments for the treatment of a disorder involving CD74-expressing cells,
such as cancer, in combination with at least one chemotherapeutic agent.
I n one ment, the chemotherapeutic agent is selected from an antimetabolite,
such as methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, floxuridine (FudR),
3',5'dioleoyl-FudR, fludarabine, 5-fluorouracil, dacarbazine, hydroxyurea, asparaginase,
gemcitabine, cladribine and r agents.
I n one embodiment, the chemotherapeutic agent is selected from an alkylating
agent, such as mechlorethamine, thioepa, chlorambucil, melphalan, carmustine (BSNU),
lomustine (CCNU), cyclophosphamide, an, dibromomannitol, streptozotocin,
dacarbazine (DTIC), procarbazine, cin C, and a platinum derivative such as cisplatin,
carboplatin, and similar agents.
I n one ment, the chemotherapeutic agent is selected from an anti-mitotic
agent, such as s, for instance docetaxel, and paclitaxel, and vinca alkaloids, for
instance vindesine, vincristine, vinblastine, and vinorelbine.
I n one embodiment, the chemotherapeutic agent is selected from a topoisomerase
inhibitor, such as topotecan or irinotecan.
I n one embodiment, the chemotherapeutic agent is selected from a cytostatic drug,
such as etoposide and teniposide.
I n one embodiment, the chemotherapeutic agent is selected from a growth factor
receptor inhibitor, such as an inhibitor of ErbBl (EGFR) (such as Iressa, erbitux
(cetuximab), tarceva and similar agents), an inhibitor of ErbB2 (Her2/neu) (such as
herceptin and similar agents) and similar agents.
I n one ment, the chemotherapeutic agent is selected from a tyrosine kinase
inhibitor, such as imatinib (Glivec, Gleevec STI571), lapatinib, PTK787/ZK222584 and
similar agents.
I n one aspect, the present invention provides a method for ng a er
involving cells expressing CD74 in a subject, such as a cancer patient, which method
comprises administration of a therapeutically effective amount of a CD74-specific antibody
or ADC of the present invention and at least one tor of angiogenesis,
neovascularization, and/or other vascularization t o a subject in need thereof.
Examples of such angiogenesis inhibitors are urokinase inhibitors, matrix
metalloprotease inhibitors (such as marimastat, neovastat, BAY 6, AG 3340,
BMS-275291 and similar agents), tors of endothelial cell migration and proliferation
(such as TNP-470, squalamine, 2-methoxyestradiol, combretastatins, endostatin,
angiostatin, penicillamine, SCH66336 (Schering-Plough Corp, Madison, NJ), R115777
(Janssen Pharmaceutica, Inc, Titusville, NJ) and similar agents), antagonists of angiogenic
growth factors (such as such as ZD6474, SU6668, antibodies against angiogenic agents
and/or their ors (such as VEGF, bFGF, and angiopoietin-1), thalidomide, thalidomide
analogs (such as CC-5013), Sugen 5416, , antiangiogenic ribozyme (such as
angiozyme), interferon a (such as interferon a2a), suramin and similar ), VEGF-R
kinase inhibitors and other inhibitors of angiogenic tyrosine kinases (such as SU011248),
tors of endothelial-specific integrin/survival signaling (such as vitaxin and r
agents), copper antagonists/chelators (such as tetrathiomolybdate, captopril and r
agents), yamido-triazole (CAI), ABT-627, CM 101, interleukin-12 (IL-12), IM862,
PNU145156E as well as nucleotide molecules inhibiting angiogenesis (such as antisense-
VEGF cDNA, cDNA coding for angiostatin, cDNA coding for p53 and cDNA coding for
deficient VEGF receptor-2) and similar agents.
Other examples of such inhibitors of angiogenesis, neovascularization, and/or other
vascularization are anti-angiogenic heparin derivatives and related molecules (e.g.,
nase III), lomide, NK4, xygenase-2 tors, inhibitors of hypoxiainducible
factor 1, anti-angiogenic soy isoflavones, oltipraz, llin and analogs thereof,
somatostatin ues, pentosan polysulfate, tecogalan sodium, dalteparin, tin,
thrombospondin, NM-3, combretastatin, canstatin, avastatin, antibodies against other
relevant targets (such as anti-alpha-v/beta-3 integrin and anti-kininostatin mAbs) and
similar agents.
I n one ment, the therapeutic agent for use in combination with a
CD74-specific antibody or ADC for treating the disorders as bed above is an ant i
cancer immunogen, such as a cancer antigen/tumor-associated n (e.g., epithelial cell
adhesion molecule (EpCAM/TACSTDl), mucin 1 (MUC1), carcinoembryonic antigen (CEA),
associated glycoprotein 72 (TAG-72), gplOO, Melan-A, MART-1, KDR, RCASl, MDA7,
cancer-associated viral vaccines (e.g., human papillomavirus vaccines), tumor-derived heat
shock proteins, and similar agents. A number of other suitable cancer antigens/tumorassociated
antigens known in the art may also or atively be used in such embodiment.
Anti-cancer immunogenic peptides also include anti-idiotypic "vaccines" such as BEC2 antiidiotypic
antibodies (Mitumomab), CeaVac and related anti-idiotypic antibodies, antiidiotypic
antibody to MG7 antibody, and other anti-cancer diotypic antibodies (see for
instance Birebent et al., Vaccine. 21(15), 1601-12 (2003), Li et al., Chin Med J (Engl).
114(9), 962-6 (2001), Schmitt et al., Hybridoma. 13(5), 389-96 (1994), Maloney et al.,
Hybridoma. 4(3), 191-209 (1985), Raychardhuri et al., J Immunol. 13Z (5), 1743-9 (1986),
Pohl et al., Int J Cancer. 50(6), 958-67 (1992), Bohlen et al., Cytokines Mol Ther. 2(4),
231-8 (1996) and Maruyama, J Immunol Methods. 264(1-2), 121-33 (2002)). Such antiidiotypic
antibodies may optionally be conjugated to a carrier, which may be a synthetic
(typically inert) molecule carrier, a protein (for instance keyhole limpet hemocyanin (KLH)
(see for ce Ochi et al., Eur J Immunol. i Z( l l), 1645-8 (1987)), or a cell (for instance
a red blood cell - see for instance Wi et al., J l Methods. 122(2), 227-34 (1989)).
I n one embodiment, the therapeutic agent for use in combination with a
pecific antibody or ADC for treating the disorders as described above is a cytokine,
chemokine or cytokine/chemokine combination with cancer growth inhibitory properties.
Examples of suitable cytokines and growth factors include IFNy, IL-2, IL-4, IL-6, IL-7,
IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, IL-24, IL-27, IL-28a, IL-28b, IL-29, KGF, IFNa
(e.g., INFa2b), IFNP, GM-CSF, CD40L, Flt3 ligand, stem cell factor, ancestim, and TNFa.
Suitable chemokines may include Glu-Leu-Arg (ELR)-negative chemokines such as IP-10,
MCP-3, MIG, and SDF- I a from the human CXC and C-C chemokine families. Suitable
cytokines e cytokine derivatives, cytokine variants, cytokine fragments, and cytokine
fusion proteins. These and other methods or uses involving naturally occurring peptide-
encoding nucleic acids herein may alternatively, or onally, be med by "gene
activation" and homologous recombination gene upregulation techniques, such as those
described in US 5,968,502, US 6,063,630 and US 6,187,305 and EP 0505500.
I n one embodiment, the therapeutic agent for use in combination with a
CD74-specific antibody or ADC for treating the disorders as described above may be a cell
cycle control/apoptosis regulator (or "regulating agent"). A cell cycle control/apoptosis
regulator may include molecules that target and modulate cell cycle control/apoptosis
tors such as (i) cdc-25 (such as NSC 663284), (ii) cyclin-dependent kinases that
overstimulate the cell cycle (such as flavopiridol (L868275, HMR1275), 7-hydroxystaurosporine
(UCN-01, KW-2401), and roscovitine (R-roscovitine, CYC202)), and (iii)
telomerase modulators (such as 32, SOT-095, GRN163 and compositions described
in for instance US 6,440,735 and US 6,713,055). Non-limiting es of molecules that
interfere with apoptotic pathways include TNF-related apoptosis-inducing ligand
(TRAIL)/apoptosis-2 ligand L), antibodies that activate TRAIL ors, IFNs, and
anti-sense Bcl-2.
I n one embodiment, the therapeutic agent for use in ation with a
CD74-specific dy or ADC for treating the disorders as described above is a hormonal
regulating agent, such as agents useful for anti-androgen and anti-estrogen therapy.
Examples of such hormonal regulating agents are fen, idoxifene, fulvestrant,
droloxifene, toremifene, raloxifene, diethylstilbestrol, ethinyl estradiol/estinyl, an
ndrogene (such as inde/eulexin), a progestin (such as such as hydroxyprogesterone
caproate, medroxyprogesterone/provera, megestrol acepate/megace), an
adrenocorticosteroid (such as hydrocortisone, prednisone), luteinizing hormone-releasing
hormone (and analogs thereof and other LHRH agonists such as buserelin and lin), an
aromatase inhibitor (such as anastrazole/arimidex, aminoglutethimide/cytraden,
exemestane), a hormone inhibitor (such as tide/sandostatin) and similar agents.
I n one embodiment, the therapeutic agent for use in combination with a
CD74-specific antibody or ADC for treating the disorders as described above is an ant i
anemic agent (for instance small molecule compounds, proteins, glycoproteins, or
antibodies that break tolerance to tumor and cancer antigens). Examples of such
compounds are molecules that block the ty of , such as MDX-010 (ipilimumab,
Yervoy™) (Phan et al., PNAS USA 100, 8372 (2003)).
I n one embodiment, the therapeutic agent for use in combination with a
CD74-specific antibody or ADC for treating the ers as described above is a tumor
suppressor gene-containing nucleic acid or vector such as a replication-deficient adenovirus
encoding human recombinant wild-type p53/SCH58500, etc.; antisense nucleic acids
targeted to oncogenes, mutated, or deregulated genes; or siRNA targeted t o mutated or
deregulated genes. Examples of tumor suppressor targets include, for example, BRCA1,
RBI, BRCA2, DPC4 (Smad4), MSH2, MLH1, and DCC.
I n one embodiment, a therapeutic agent for use in ation with a CD74-specific
antibody or ADC for treating the ers as described above is an anti-cancer nucleic acid.
Exemplary anti-cancer nucleic acids include nse (augmerosen/G3139), 03
(ISIS 3521), ISIS 2503, OGX-011 (ISIS 112989), LE-AON/LEraf-AON (liposome
encapsulated c-raf antisense oligonucleotide/ISIS-5132), MG98, and other nse nucleic
acids that target PKCa, clusterin, IGFBPs, protein kinase A, cyclin Dl, or Bcl-2.
I n one embodiment, the therapeutic agent for use in combination with a
CD74-specific antibody or ADC for treating the disorders as described above is an ant i
cancer inhibitory RNA molecule (see for instance Lin et al., Curr Cancer Drug Targets. (3) ,
241-7 (2001), Erratum in: Curr Cancer Drug Targets. 3(3), 237 (2003), Lima et al., Cancer
Gene Ther. 11(5), 309-16 (2004), Grzmil et al., Int J Oncol. 4(1), 97-105 (2004), Collis et
al., Int J Radiat Oncol Biol Phys. 5_7(2 Suppl), S144 (2003), Yang et al., Oncogene. 22(36),
5694-701 (2003) and Zhang et al., Biochem Biophys Res Commun. 303(4), 1169-78
(2003)).
Compositions and combination administration methods of the present invention also
include the administration of nucleic acid vaccines, such as naked DNA vaccines encoding
such cancer antigens/tumor-associated antigens (see for instance US 466, US
,593,972, US 5,703,057, US 5,879,687, US 6,235,523, and US 6,387,888). I n one
embodiment, the combination administration method and/or ation composition
ses an autologous vaccine composition. I n one embodiment, the combination
composition and/or combination administration method comprises a whole cell vaccine or
cytokine-expressing cell (for instance a recombinant IL-2 expressing fibroblast, recombinant
cytokine-expressing dendritic cell, and the like) (see for instance Kowalczyk et al., Acta
Biochim Pol. 50(3), 613-24 (2003), Reilly et al., Methods Mol Med. 69, 233-57 (2002) and
Tirapu et al., Curr Gene Ther. 2(1), 79-89 (2002). r example of such an autologous
cell approach that may be useful in combination methods of the present invention is the
MyVax® Personalized Immunotherapy method (previously referred t o as GTOP-99)
(Genitope Corporation - d City, CA, USA).
I n one ment, a pecific antibody or ADC according to the invention is
combined or co-administered with a virus, viral proteins, or the like. ation-deficient
viruses, that generally are capable of one or only a few rounds of replication in vivo, and
that are targeted to tumor cells, may for instance be useful components of such
compositions and methods. Such viral agents may se or be associated with nucleic
acids encoding immunostimulants, such as GM-CSF and/or IL-2. Both naturally tic
and such recombinant oncolytic viruses (for instance HSV-1 viruses, reoviruses, replicationdeficient
and replication-sensitive adenovirus, etc.) may be useful components of such
methods and compositions. Accordingly, in one embodiment, the present invention provides
ation compositions and combination administration methods n a CD74-specific
antibody is combined or co-administered with an tic virus. Examples of such viruses
include oncolytic iruses and herpes viruses, which may or may not be modified
viruses (see for instance Shah et al., J Neurooncol. 65(3), 203-26 (2003), Stiles et al.,
Surgery. 134(2), 357-64 (2003), Sunarmura et al., Pancreas. 28(3), 326-9 (2004),
Teshigahara et al., J Surg Oncol. 85(1), 42-7 (2004), Varghese et al., Cancer Gene Ther.
9(12), 967-78 (2002), Wildner et al., Cancer Res. 59(2), 410-3 (1999), Yamanaka, Int J
Oncol. 24(4), 919-23 (2004) and Zwiebel et al., Semin Oncol. 28(4), 336-43 (2001).
Combination compositions and combination administration methods of the present
invention may also e "whole cell" and "adoptive" immunotherapy methods. For
ce, such methods may comprise infusion or usion of immune system cells (for
instance infiltrating lymphocytes (TILs), such as CD4+ and/or CD8+ T cells (for
ce T cells expanded with tumor-specific antigens and/or genetic enhancements),
antibody-expressing B cells or other antibody-producing or -presenting cells, tic cells
(e.g., dendritic cells cultured with a DC-expanding agent such as GM-CSF and/or Flt3-L,
and/or tumor-associated antigen-loaded dendritic cells), anti-tumor NK cells, so-called
hybrid cells, or combinations thereof. Cell s may also be useful in such methods and
compositions. Cellular "vaccines" in clinical trials that may be useful in such aspects include
Canvaxin™, APC-8015 (Dendreon), HSPPC-96 (Antigenics), and Melacine® cell lysates.
Antigens shed from cancer cells, and mixtures thereof (see for instance Bystryn et al.,
Clinical Cancer Research Vol. 7, 1882-1887, July 2001), optionally admixed with adjuvants
such as alum, may also be components in such methods and combination compositions.
I n one embodiment, a CD74-specific antibody or ADC is delivered t o a patient in
combination with the ation of an internal vaccination method. Internal vaccination
refers t o induced tumor or cancer cell death, such as drug-induced or ion-induced,
cryo-ablation-induced or radiofrequency ablation-induced cell death of tumor cells, in a
patient, that typically leads to elicitation of an immune response directed towards (i) the
tumor cells as a whole or (ii) parts of the tumor cells including (a) secreted proteins,
glycoproteins or other products, (b) membrane-associated proteins or glycoproteins or other
components ated with or inserted in membranes, and/or (c) intracellular proteins or
other intracellular components. An internal vaccination-induced immune response may be
humoral (i.e. antibody - complement-mediated) or ediated (e.g., the development
and/or increase of endogenous cytotoxic T lymphocytes that ize the internally killed
tumor cells or parts thereof). I n addition to herapy, non-limiting examples of drugs
and agents that may be used t o induce said tumor cell death and internal vaccination are
conventional chemotherapeutic agents, ycle inhibitors, anti-angiogenesis drugs,
monoclonal antibodies, apoptosis-inducing agents, and signal transduction inhibitors.
Examples of other anti-cancer agents, which may be relevant as eutic agents
for use in combination with a pecific antibody or ADC for treating the disorders as
described above are differentiation inducing , retinoic acid analogues (such as all
trans retinoic acid, 13-cis retinoic acid and similar agents), vitamin D analogues (such as
seocalcitol and similar agents), inhibitors of ErbB3, ErbB4, IGF-IR, insulin receptor,
PDGFRalpha, PDGFRbeta, Flk2, Flt4, FGFR1, FGFR2, FGFR3, FGFR4, TRKA, TRKC, c-met,
Ron, Sea, Tie, Tie2, Eph, Ret, Ros, Alk, LTK, PTK7 and similar agents.
Examples of other anti-cancer agents, which may be relevant as therapeutic agents
for use in combination with a CD74-specific antibody or ADC for treating the disorders as
described above are cathepsin B, modulators of cathepsin D ogenase activity,
hione-S-transferase (such as glutacylcysteine synthetase and lactate dehydrogenase),
and similar .
Examples of other anti-cancer agents, which may be relevant as therapeutic agents
for use in combination with a CD74-specific antibody for treating the disorders as described
above are ustine and epirubicin.
Examples of other anti-cancer agents, which may be relevant as therapeutic agents
for use in combination with a CD74-specific antibody for treating the disorders as bed
above are a HSP90 inhibitors like 17-(Allylamino)demethoxygeldanamycin, antibodies
directed against a tumor antigen such as PSA, CA125, KSA, etc., integrins like integrin b ΐ ,
tors of VCAM and similar .
Examples of other anti-cancer agents, which may be relevant as therapeutic agents
for use in combination with a CD74-specific antibody or ADC for treating the disorders as
described above are calcineurin-inhibitors (such as valspodar, PSC 833 and other MDR-1 or
p-glycoprotein inhibitors), TOR-inhibitors (such as siroiimus, everoiimus and rapamcyin) and
inhibitors of "lymphocyte homing" mechanisms (such as FTY720), and agents with effects
on cell signaling such as on molecule inhibitors (for instance anti-LFA, etc.).
I n one embodiment, a CD74-specific antibody or ADC may be stered in connection
with the delivery of one or more agents that promote access of the CD74-specific antibody
or combination composition to the interior of a tumor. Such methods may for example be
performed in association with the delivery of a relaxin, which is capable of relaxing a tumor
(see for ce US 6,719,977). I n one embodiment, a CD74-specific dy or ADC of
the present invention may be bonded to a cell penetrating peptide (CPP). Cell penetrating
peptides and related peptides (such as engineered cell penetrating antibodies) are described
in for instance Zhao et al., J l s. 254 (1-2), 137-45 (2001), Hong et al.,
Cancer Res. 60(23), 6551-6 (2000). Lindgren et al., Biochem J. 377fPt 1), 69-76 (2004),
r et al., J Cancer Res Clin Oncol. 129(12), 669-75 (2003), Pooga et al., FASEB J.
12(1), 67-77 (1998) and Tseng et al., Mol Pharmacol. 62(4), 864-72 (2002).
I n yet r embodiment, the pecific antibody or ADC is administered in
conjunction with a CD74 up-regulating agent, such as, e.g., IFNy or inactivated H. .
I n one embodiment, the present ion es a method for treating a disorder
involving cells expressing CD74 in a t, which method comprises administration of a
therapeutically effective amount of a CD74-specific antibody or ADC and at least one ant i
inflammatory, immunosuppressive and/or immunomodulatory agent t o a subject in need
thereof.
I n one embodiment such an anti-inflammatory agent may be selected from aspirin
and other salicylates, Cox-2 inhibitors (such as rofecoxib and celecoxib), NSAIDs (such as
ibuprofen, fenoprofen, naproxen, sulindac, diclofenac, piroxicam, ketoprofen, diflunisal,
nabumetone, etodolac, oxaprozin, and indomethacin), L-6R antibodies, anti-IL-8
antibodies (e.g. antibodies described in WO2004058797, such as 10F8), anti-IL-15
dies (e.g. antibodies described in WO03017935 and WO2004076620), L-15
receptor Abs, anti-CD4 antibodies (e.g. zanolimumab), Dlla antibodies (e.g.,
efalizumab), anti-alpha-4/beta-l integrin (VLA4) antibodies (e.g. natalizumab), CTLA4-Ig
for the treatment of inflammatory diseases, prednisolone, prednisone, disease modifying
antirheumatic drugs (DMARDs) such as methotrexate, hydroxychloroquine, sulfasalazine,
pyrimidine synthesis inhibitors (such as leflunomide), IL-1 receptor blocking agents (such as
anakinra), TNF-a blocking agents (such as etanercept, infliximab, and adalimumab) and
r agents.
I n one embodiment, such an immunosuppressive and/or immunomodulatory agent
may be selected from cyclosporine, azathioprine, mycophenolic acid, mycophenolate
mofetil, corticosteroids such as prednisone, methotrexate, gold salts, sulfasalazine,
antimalarials, brequinar, leflunomide, mizoribine, xyspergualine, 6-mercaptopurine,
cyclophosphamide, rapamycin, tacrolimus 6), thymopentin, in-a and similar
agents.
I n one embodiment, such an immunosuppressive and/or immunomodulatory agent
may be selected from suppressive Abs, such as antibodies binding to p75 of the
IL-2 receptor, antibodies against CD25 (e.g. those described in WO2004045512, such as
ABl, AB7, ABll, and AB12), antibodies against thymocyte globulin, or antibodies binding t o
for instance MHC, CD2, CD3 (such as, e.g., OKT3), CD4, CD7, CD28, B7, CD40, CD45,
IFNy, TNF-a, IL-4, IL-5, IL-6R, IL-7, IL-8, IL-10, CDlla, or CD58, or antibodies binding to
their respective receptor(s) or ligand(s).
I n one embodiment, such an immunosuppressive and/or immunomodulatory agent
may be selected from soluble IL-15R, IL-10, B7 molecules (B7-1, B7-2, variants thereof,
and fragments thereof), ICOS, and OX40, an inhibitor of a negative T cell tor (such as
an antibody against CTLA4) and similar agents.
I n one embodiment, the present invention provides a method for ng a disorder
involving cells sing CD74 in a subject, which method comprises administration of a
eutically ive amount of a CD74-specific antibody or ADC and an anti-C3b(i)
antibody to a t in need thereof.
I n one embodiment, a therapeutic agent for use in combination with CD74-specific
antibodies or ADCs for treating the disorders as described above may be selected from
histone ylase inhibitors (for instance phenylbutyrate) and/or DNA repair agents (for
instance DNA repair enzymes and related compositions such as dimericine).
Methods of the present invention for treating a disorder as described above
comprising administration of a therapeutically effective amount of a CD74-specific antibody
or ADC may also se anti-cancer directed photodynamic therapy (for ce ant i
cancer laser therapy - which optionally may be practiced with the use of photosensitizing
agent, see, for instance Zhang et al., J Control Release. 93(2), 141-50 (2003)), anti-cancer
sound-wave and shock-wave therapies (see for instance Kambe et al., Hum Cell. 10(1),
87-94 ), and/or anti-cancer nutraceutical therapy (see for instance Roudebush et al.,
Vet Clin North Am Small Anim Pract. 34(1), 249-69, viii (2004) and Rafi, Nutrition. 20(1),
78-82 (2004). Likewise, a CD74-specific antibody may be used for the preparation of a
pharmaceutical composition for treating a disorder as described above to be administered
with anti-cancer directed photodynamic y (for instance anti-cancer laser therapy -
which optionally may be practiced with the use of photosensitizing agent), anti-cancer
sound-wave and shock-wave therapies, and/or ancer nutraceutical y.
I n one embodiment, the present invention provides a method for treating a disorder
involving cells expressing CD74 in a subject, which method comprises administration of a
therapeutically effective amount of a CD74-specific dy or ADC of the present
invention, and radiotherapy to a subject in need thereof.
I n one ment, the present invention provides a method for ng or
preventing cancer, which method comprises administration of a therapeutically effective
amount of a CD74-specific antibody or ADC of the present invention, and radiotherapy to a
subject in need thereof.
I n one ment, the t invention provides the use of a CD74-specific
dy or ADC of the present invention, for the preparation of a pharmaceutical
composition for treating cancer to be administered in combination with radiotherapy.
Radiotherapy may comprise radiation or associated administration of
radiopharmaceuticals to a patient. The source of radiation may be either external or internal
to the patient being treated (radiation treatment may, for example, be in the form of
external beam radiation therapy (EBRT) or brachytherapy (BT)). Radioactive elements that
may be used in practicing such methods include, e.g., radium, cesium-137, iridium-192,
americium-241, 98, cobalt-57, copper-67, technetium-99, iodide-123, iodide-131,
and indium-Ill.
I n a further embodiment, the present ion provides a method for treating or
preventing cancer, which method comprises administration t o a t in need thereof of a
therapeutically ive amount of a CD74-specific dy or ADC of the present
invention, in combination with surgery.
As bed above, a pharmaceutical composition of the present invention may be
administered in combination therapy, i.e., combined with one or more agents relevant for
the e or condition t o be treated either as separate ceutical itions or
with a compound of the present invention co-formulated with one or more additional
therapeutic agents as described above. Such combination therapies may require lower
dosages of the compound of the present invention and/or the co-administered agents, thus
avoiding possible toxicities or complications associated with the various monotherapies.
I n one embodiment, the further therapeutic agent for a particular therapeutic use is
ed from the following:
- A CD20-specific antibody, particulary for treatment of a hematological malignancy
such as, e.g., B-CLL or follicular lymphoma;
- A CD138-specific antibody, particularly for treatment of a hematological malignancy
such as, e.g., myeloma;
- A CD38-specific antibody, ularly for treatment of a hematological malignancy
such as, e.g., myeloma or CLL;
- Melphalan (or melphalan hydrochloride) for treatment of a hematological malignancy
such as, e.g., myeloma;
- An anti-VEGF-A antibody such as, e.g., bevacizumab, particularly for treatment of a
cancer such as, e.g., breast cancer;
- Lenalidomide or bortezomib, particularly for treatment of a hematological malignancy
such as, e.g., myeloma;
- Fluorouracil or gemticabine, particularly for treatment of a cancer such as, e.g.,
pancreatic cancer;
- Irinotecan, particularly for treatment of cancer such as, e.g., ctal cancer, and
- Cisplatin or other platinum-derivative, particularly for treatment of a cancer such as,
e.g., SCCHN.
Diagnostic applications
The pecific antibodies of the ion may also be used for diagnostic purposes,
using a composition comprising a CD74-specific antibody as described herein. Accordingly,
the invention provides stic methods and compositions using the CD74-specific
antibodies described herein. Such methods and compositions can be used for purely
diagnostic es, such as detecting or identifying a disease involving CD74-expressing
cells, as well as for monitoring of the progress of therapeutic treatments, monitoring
disease progression, assessing status after treatment, ring for recurrence of disease,
ting risk of developing a disease, and the like.
I n one aspect, the CD74-specific antibodies of the present invention are used ex
vivo, such as in diagnosing a disease in which cells expressing CD74 are indicative of
disease or involved in the pathogenesis, by detecting levels of CD74 or levels of cells which
express CD74 on their cell surface in a sample taken from a patient. This may be achieved,
for example, by contacting the sample t o be , optionally along with a l sample,
with the CD74-specific antibody under conditions that allow for binding of the antibody to
CD74. Complex formation can then be detected (e.g., using an ELISA). When using a
control sample along with the test sample, the level of CD74-specific antibody or
CD74-specific antibody-CD74 complex is analyzed in both samples and a tically
significant higher level of CD74-specific antibody or CD74-specific antibody-CD74 complex
in the test sample indicates a higher level of CD74 in the test sample compared with the
control sample.
Examples of conventional immunoassays in which CD74-specific antibodies of the
present invention can be used include, without tion, ELISA, RIA, FACS assays,
plasmon resonance assays, chromatographic assays, tissue histochemistry, n
blot, and/or immunoprecipitation.
I n one ment, the invention relates t o a method for detecting the presence of
CD74 antigen, or a cell expressing CD74, in a sample comprising:
- contacting the sample with a CD74-specific antibody of the invention under conditions that
allow for binding of the CD74-specific antibody to CD74 in the sample; and
- analyzing whether a complex has been formed. Typically, the sample is a ical
sample.
I n one embodiment, the sample is a tissue sample known or suspected of containing
CD74 antigen and/or cells expressing CD74. For example, in situ detection of CD74
expression may be accomplished by ng a histological specimen from a patient, and
providing the antibody of the present invention to such a specimen. The antibody may be
ed by applying or by overlaying the antibody t o the specimen, which is then detected
using le means. It is then possible to determine not only the presence of CD74 or
CD74-expressing cells, but also the bution of CD74 or CD74-expressing cells in the
examined tissue (e.g., in the context of ing the spread of cancer cells). Using the
present invention, those of ordinary skill will readily perceive that any of a wide variety of
histological methods (such as staining procedures) may be modified in order to achieve
such in situ detection.
I n the above assays, the CD74-specific antibody can be labeled with a detectable
substance to allow CD74-bound dy to be detected. Alternatively, bound (primary)
CD74-specific antibody may be detected by a secondary antibody which is labeled with a
detectable substance and which binds to the y antibody.
The level of CD74 in a sample can also be estimated by a competition immunoassay
utilizing CD74 standards labeled with a detectable nce and an unlabeled
CD74-specific antibody. In this type of assay, the biological sample, the labeled CD74
standard(s) and the CD74-specific antibody are combined, and the amount of labeled CD74
standard bound to the unlabeled CD74-specific antibody is determined. The amount of CD74
in the biological sample is inversely proportional to the amount of labeled CD74 standard
bound to the CD74-specific antibody.
Suitable labels for the pecific dy, secondary antibody and/or CD74
standard used in in vitro diagnostic ques include, without limitation, various enzymes,
prosthetic groups, fluorescent materials, luminescent materials, and ctive materials.
Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,
ctosidase, and acetylcholinesterase; es of suitable prosthetic group complexes
e streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials
include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine,
rotriazinylamine scein, dansyl chloride and phycoerythrin; an example of a
luminescent material includes luminol; and examples of suitable radioactive material include
12 I , 1 1I , S, and H.
I n one aspect, the CD74-specific antibodies of the invention are used in the in vivo
imaging of CD74-expressing tissues such as tumors. For in vivo methods, antibody
fragments such as, e.g., (Fab')2, Fab and Fab' fragments, are particularly advantageous
because of their rapid distribution kinetics.
I n vivo imaging can be performed by any suitable technique. For example, a
CD74-specific antibody (such as, e.g., a fragment) labeled with "Tc, 1 1I , i I n or other
gamma-ray emitting isotope may be used to image CD74-specific antibody lation or
distribution in CD74-expressing tissues such as tumors with a gamma scintillation camera
(e.g., an t Apex 409ECT device), typically using low-energy, high resolution collimator
or a low-energy all-purpose collimator. Alternatively, labeling with Zr, Br, 1 F or other
positron-emitting radionuclide may be used to image CD74-specific antibody or antibody
fragment distribution in tumors using positron on tomography (PET). The images
obtained by the use of such techniques may be used to assess biodistribution of CD74 in a
patient, mammal, or tissue, for e in the context of using CD74 as a biomarker for the
presence of cancer cells. Variations on this technique may include the use of magnetic
resonance imaging (MRI) to improve imaging over gamma camera techniques. Conventional
immunoscintigraphy methods and ples are described in, e.g., Srivastava (ed.),
Radiolabeled Monoclonal dies For Imaging And Therapy (Plenum Press 1988), Chase,
al Applications of Radioisotopes," in Remington's Pharmaceutical Sciences, 18th
Edition, Gennaro et al., (eds.), PP- 624-652 (Mack Publishing Co., 1990), and Brown,
"Clinical Use of Monoclonal Antibodies," in Biotechnology And Pharmacy 227-49, Pezzuto et
al., (eds.) (Chapman & Hall 1993). Moreover, such images may also, or atively, serve
as the basis for surgical techniques to remove tumors. Furthermore, such in vivo imaging
techniques may allow for the identification and zation of a tumor in a ion where a
t is fied as having a tumor (due to the presence of other biomarkers,
metastases, etc.), but the tumor cannot be identified by traditional analytical techniques. All
of these methods are es of the present invention.
The in vivo imaging and other diagnostic methods provided by the t invention
are particularly useful in the detection of micrometastases in a human patient (e.g., a
patient not previously diagnosed with cancer or a patient in a period of recovery/remission
from a cancer).
I n one embodiment, the present invention provides an in vivo imaging method
wherein a CD74-specific antibody of the t invention is ated to a detectionpromoting
radio-opaque agent, the conjugated antibody is administered to a host, such as
by injection into the bloodstream, and the ce and location of the labeled antibody in
the host is assayed. Through this technique and any other diagnostic method provided
herein, the present invention provides a method for screening for the presence of diseaserelated
cells in a human patient or a biological sample taken from a human patient and/or
for assessing the distribution of CD74-specific antibody prior to CD74-specific ADC therapy.
For diagnostic imaging, radioisotopes may be bound t o a CD74-specific antibody
either directly or indirectly by using an ediary functional group. Useful intermediary
functional groups include chelators, such as ethylenediaminetetraacetic acid and
diethylenetriaminepentaacetic acid (see for instance US 5,057,313).
I n addition to radioisotopes and radio-opaque agents, diagnostic methods may be
performed using CD74-specific antibodies that are conjugated to dyes (such as with the
biotin-streptavidin complex), contrast agents, fluorescent compounds or molecules and
enhancing agents (e.g. paramagnetic ions) for magnetic resonance imaging (MRI) (see,
e.g., US Pat. No. 6,331,175, which bes MRI techniques and the preparation of
antibodies conjugated t o a MRI enhancing agent). Such diagnostic/detection agents may be
ed from agents for use in MRI, and scent nds. I n order to load a
CD74-specific antibody with radioactive metals or paramagnetic ions, it may be necessary
to react it with a reagent having a long tail to which a multiplicity of chelating groups are
attached for binding the ions. Such a tail may be a polymer such as a polylysine,
ccharide, or another derivatized or derivatizable chain having pendant groups to
which may be bound chelating groups such as, e.g., porphyrins, polyamines, crown ethers,
bisthiosemicarbazones, polyoximes, and like groups known to be useful for this purpose.
Chelates may be coupled to CD74-specific antibodies using standard chemistries.
Thus, the present invention provides a diagnostic CD74-specific antibody, wherein
the CD74-specific antibody is conjugated to a contrast agent (such as for magnetic
resonance imaging, computed tomography, or ound contrast-enhancing agent) or a
radionuclide that may be, for example, a gamma-, beta-, alpha-, Auger electron-, or
positron-emitting e.
I n a further aspect, the invention relates to a kit for detecting the presence of CD74
antigen or a cell expressing CD74, in a sample, comprising:
- A pecific dy or ADC of the ion; and
- Instructions for use of the kit.
I n one embodiment, the present invention provides a kit for diagnosis of cancer
comprising a container comprising a CD74-specific Ab, and one or more reagents for
ing g of the CD74-specific antibody to CD74. Reagents may include, for
example, fluorescent tags, enzymatic tags, or other detectable tags. The reagents may also
include secondary or tertiary antibodies or reagents for enzymatic reactions, wherein the
enzymatic reactions produce a product that may be visualized. In one embodiment, the
present invention provides a diagnostic kit comprising one or more CD74-specific Abs, of
the present invention in labeled or unlabeled form in suitable container(s), reagents for the
incubations for an ct assay, and substrates or tizing agents for detection in such
an assay, depending on the nature of the label. Control reagent(s) and instructions for use
also may be included.
Diagnostic kits may also be supplied for use with a CD74-specific Ab, such as a
conjugated/labeled CD74-specific Ab, for the detection of the presence of CD74 in a tissue
sample or host. In such stic kits, as well as in kits for eutic uses described
elsewhere herein, a CD74-specific antibody lly may be provided in a lyophilized form
in a container, either alone or in conjunction with onal antibodies specific for a target
cell or peptide. Typically, a pharmaceutically acceptable r (e.g., an inert diluent)
and/or components thereof, such as a Tris, phosphate, or carbonate buffer, stabilizers,
preservatives, biocides, inert proteins, e.g., serum albumin, or the like, also are included
(typically in a separate container for mixing) and additional reagents (also typically in
separate container(s)). In certain kits, a secondary dy capable of binding to the
CD74-specific Ab, which typically is present in a separate container, is also included. The
second antibody is typically ated to a label and formulated in a manner similar to the
pecific antibody of the present invention. Using the s described above and
elsewhere herein, CD74-specific antibodies may be used to define subsets of cancer/tumor
cells and characterize such cells and related tumor tissues.
Anti-idiotypic antibodies
I n a further aspect, the invention relates to an anti-idiotypic antibody which binds to
a pecific antibody of the invention as described herein.
An anti-idiotypic (Id) antibody is an antibody which recognizes unique determinants
generally ated with the antigen-binding site of an antibody. An anti-Id antibody may
be prepared by immunizing an animal of the same species and genetic type as the source of
a CD74-specific monoclonal antibody with the monoclonal antibody to which an anti-Id is
being prepared. The immunized animal typically can recognize and respond to the idiotypic
inants of the immunizing antibody by producing an antibody to these idiotypic
determinants (the anti-Id antibody). Such dies are described in for instance US
4,699,880. Such antibodies are further features of the present invention.
An anti-Id antibody may also be used as an "immunogen" to induce an immune
response in yet another animal, producing a so-called anti-anti-Id antibody. An anti-anti-Id
dy may be epitopically identical to the original mAb, which induced the anti-Id
antibody. Thus, by using dies to the idiotypic determinants of a mAb, it is possible to
identify other clones expressing antibodies of identical specificity. Anti-Id antibodies may be
varied (thereby producing anti-Id dy variants) and/or derivatized by any suitable
technique, such as those described elsewhere herein with respect to CD74-specific
antibodies of the present invention. For example, a monoclonal anti-Id antibody may be
coupled to a carrier such as keyhole limpet hemocyanin (KLH) and used to immunize
BALB/c mice. Sera from these mice typically will contain anti-anti-Id antibodies that have
the binding properties similar, if not identical, to an original/parent CD74-specific antibody.
The present invention is further illustrated by the following examples which should not be
construed as further limiting.
EXAMPLES
Example 1
Construction of CD74yl and -v2, 74yl and -v2 and CD74del2-36yl and -v2
expression s
The ng sequences for human CD74 variant 1 (CD74vl) (identical to Genbank
sequence NP_00 0) and human CD74 variant 2 (CD74v2) ical to k
ce AAV383110330) were made synthetically and fully codon optimized (GeneArt,
Regensburg, Germany). The constructs were cloned in the mammalian expression vector
pEE13.4 (Lonza Biologies, Slough, UK). These constructs were named pEE13.4CD74vl and
pEE13.4CD74v2. To enhance the expression level of CD74 on the cell surface, the
cytoplasmic ER ion signal (aa2-36) was removed as described (Khalil H et al., J Cell
Sci 2005; 118: 4679-4687). To this end, new constructs were made by amplifying the
CD74-encoding regions from pEE13.4CD74vl and pEE13.4CD74v2, and removing the aa2-
36 encoding regions in the process. These PCR fragments were ed in pEE13.4 and
fully sequenced to confirm the correctness of the new constructs. These expression s
were named 4CD74vldel2-36 and pEE13.4CD74v2del2-36.
The encoding regions for the extracellular domains of CD74vl (aa 73-296) and -v2
(aa 73-232) were amplified by PCR from pEE13.4CD74vl and pEE13.4CD74v2, in the
process introducing the encoding region for a ric N-terminal His tag. The PCR
fragments were cloned in mammalian expression vector pEE12.4 (Lonza Biologies)
containing the encoding region of an ent signal peptide (HMM38 [Barash S et al.,
Biochem Biophys Res Commun 2002; 294: 835-842). The expression vectors were fully
sequenced and named pEE12.4SPHisCD74vl and pEE12.4SPHisCD74v2. The resulting
proteins were named HisCD74vl and HisCD74v2.
The protein ces of CD74 variants are shown in Figure 1.
Example 2
Transient expression in HEK-293F cells and in CHO-S cells
Freestyle™ 293-F (a HEK-293 subclone adapted t o suspension growth and chemically
defined Freestyle medium; HEK-293F) cells were obtained from Invitrogen and transfected
with pEE13.4CD74vl, pEE13.4CD74v2, pEE13.4CD74del2-36vl, pEE13.4CD74del2-36v2,
pEE12.4SPHisCD74vl or pEE12.4SPHisCD74v2, using 293fectin (Invitrogen) according t o
the manufacturer's instructions.
Cell culture supernatants, in the case of pEE12.4SPHisCD74vl or pEE12.4CD74v2,
were harvested and soluble HisCD74vl or 4v2 was purified by metal affinity
chromatography, as described below.
I n the case of 4CD74vl, 4CD74v2, pEE13.4CD74vldel2-36 or
4CD74v2del2-36, cells were harvested 1-2 days post transfection and used in
subsequent assays. These cells were named TH2013-CD74vl, TH2013-CD74v2,
TH2013-CD74vldel2-36 and TH2013-CD74v2del2-36.
A suspension-adapted CHO-K1SV cell line (CHO-S, Invitrogen) was transfected with
pEE13.4CD74vl, pEE13.4CD74v2, pEE13.4CD74vldel2-36 or pEE13.4CD74v2del2-36,
according to the manufacturer's ol using the CHO-Max t (Invitrogen).
Transfected CHO-S cells were harvested 1-2 days post transfection and used in subsequent
assays. These cells were named TC2013-CD74vl, TC2013-CD74v2, -CD74vldel2-36
and TC2013-CD74v2del2-36.
I n the case of antibody expression, the appropriate heavy chain and light chain
vectors, as described in Example 9, were co-expressed in HEK-293F cells as described
supra.
Example 3
Stable expression in NSO cells
The pEE13.4CD74vldel2-36 plasmid was transfected in NSO cells (Lonza Biologies). Cells
were selected for stable integration of the expression vector by culture in glutamine-free cell
culture medium in the presence of 25 m M sulphoximine (MSX) as described
(Bebbington CR et al., hnology (N Y) 1992; 10: 5). Cells expressing CD74 were
pooled and used as a semi-stable population or individual stable clones were selected and
used. These cells were named el-vl-012.
Example 4
Purification of His-taaaed CD74
HisCD74vl and HisCD74v2 were expressed in HEK-293F cells. The His-tag in the ns
s purification with immobilized metal affinity chromatography. I n this process, a
chelator fixed onto the chromatographic resin is charged with Co2+ cations. CD74ECDHis-
containing supernatant is incubated with the resin in batch mode (i.e. on). His-tagged
protein binds strongly t o the resin beads, while other proteins present in the culture
supernatant do not bind strongly. After incubation, the beads are retrieved from the
atant and packed into a column. The column is washed in order t o remove weakly
bound proteins. The strongly bound CD74ECDHis proteins are then eluted with a buffer
containing imidazole, which competes with the binding of His to Co2+ . The eluent is removed
from the protein by buffer exchange on a ing column.
Example 5
zation procedure of transgenic mice
Antibodies HuMab-CD74-005, -006, -008 and -011 were derived from the immunizations of
HCol7 HuMAb mice (human monoclonal antibody; Medarex Inc., San Jose, CA, USA) which
have four genetic modifications. These mice were made transgenic for the human Ig heavy
and human Ig kappa light chain and double knock out for the mouse heavy and mouse
kappa light chain loci. These disruptions prevent the expression of any antibodies that are
tely murine. Different strains were used; HCol2, HCol2-BALB/c, HCol7 and HCo20.
These differ in the number of human VH (variable region of heavy chain) and VL (variable
region of light chain) genes. HCol2-BALB/c mice were derived by crossbreeding with KCo5-
BALB/c (kappa light chain transgenic) mice.
Six different immunogens were used for the immunizations: TH2013-CD74vldel2-
36, TH2013-CD74v2del2-36, N2013del-vl-012, SU-DHL-4 cells (Human B cell lymphoma
cell line) and HisCD74vl or HisCD74v2 coupled t o the carrier protein KLH (Keyhole Limpet
Hemocyanin). Mice were zed every fortnight, alternating with 5 x 106 cells or with 15
m of n. Eight immunizations were performed in total, four intraperitoneal (IP) and
four subcutaneous (SC).
Antibodies -005, -006 and -008 were obtained from immunization of an HCol7
mouse with 5xl0 6 TH2013-CD74vldel2-36 cells IP, alternated with 15 m HisCD74v2 SC.
The first immunization was performed IP, with cells in complete Freund's nt (CFA;
Difco Laboratories, Detroit, MI, USA), the following immunizations in incomplete Freund's
adjuvant (I FA) (protein, SC) or in PBS (cells, IP).
Antibody -011 was obtained from the immunization of an HCol7 mouse with 5xl0 6
TH2013-CD74vldel2-36 cells IP, ated with 15 mg HisCD74vl SC. The first
immunization was performed with protein in CFA (IP), the following immunizations in IFA
in, SC) or PBS (cells, IP).
When serum titers were found to be ient (dilution of serum of 1/50 or lower
found positive in antigen-specific screening assay as described in Example 6 on at least two
sequential, biweekly, screening events), mice were additionally boosted twice intravenously
(IV) with 10 mg HisCD74 n in 100 m I_ PBS, four and three days before fusion.
Example 6
Homogeneous antiaen-specific screening assay
Mouse sera and hybridoma supernatants were analyzed in a high throughput screening
(HTS) Fluorometric Micro Volume Assay Technology (FMAT assay; Applied Biosystems,
Foster City, CA, USA) for the presence of anti-CD74 antibodies. I n this assay, TC2013-
CD74vldel2-36 and TC2013-CD74v2del2-36 cells were used to detect human anti-CD74
antibodies. Wild type CHO-S cells were used to measure non-specific g. Samples were
added to the cells to allow binding to CD74. Subsequently, binding of HuMab was detected
using a fluorescent conjugate (Goat anti-human IgG-Cy5; Jackson Immunoresearch). Mouse
anti-human CD74 antibody (Becton Dickinson; IgG2a, k; clone M-B741), labeled with
Alexa-647, as described below, was used as a positive control and mouse-chrompure
(Jackson Immunoresearch) d with Alexa-647 was used as a ve control.
Antibodies were labeled with Alexa Fluor® 647 Dye (Molecular Probes), hereinafter
"Alexa-647", using the following procedure:
An antibody solution of 1 mg/mL IgG was ed in 0.1 M sodiumcarbonate buffer
pH 9.0 (NaHC0 , Riedel de Haen, cat. no. 31437;). Alexa-647 was prepared y, by
adding 100 m I DMSO (Sigma, cat. no. D2438) and 900 m I 0.1 M sodiumcarbonate buffer pH
9.0 to one vial (Alexa Fluor® 647 carboxylic acid, succinimidyl ester (lmg/vial), Molecular
Probes, Leiden, The Netherlands, cat. no. 6). A five-times molar excess of
Alexa-647, calculated as indicated below, was added to the IgG solution and incubated,
while rotating, in the dark at RT for 1 hour. After labeling, unbound Alexa-647 was
d, using a PD-10 column (Amersham Biosciences, cat. no. 1701), with Tris
buffer pH 8.0 (50 m M Tris [Trizma base, Sigma, cat. no. T-6066]; 100 m M NaCI [Riedel de
Haen, cat. no. 31437]; 0.01% sodium azide [NaN , Riedel de Haen, cat. no. ). The
amount of 647 t o be added to the IgG on was calculated using the formula:
Volume Alexa-647 to be added (in m I_) = (IgG cone (mg/ml_)/MW IgG (Da) * ratio * volume
* MW Alexa-647 * 1,000.
MW IgG = 150,000 Da; ratio is the molar excess of Alexa-647 to be used; volume is
the volume of the sample t o be d (in ml_); MW Alexa-647 = 1250 Da.
Protein concentration (IgG) and degree of labeling (D.O.L.) were determined by
ing OD 280 nm and 650 nm on an Ultrospec 2100 Pro (Amersham Biosciences). IgG
tration (mg/mL) was ated using the formula :
IgG concentration = [A - (0.03 * A
280 5o)]/IgG extinction coefficient.
D.O.L. was calculated using the formula:
D.O.L. = A /239,000/[A - (0.03 * A )/(IgG extinction coefficient * MW IgG)].
0 2 8o 0
239,000 is the extinction coefficient of Alexa-647 at in cm^M 1; 0.03 is the correction
factor (A o free dye/A free dye) (both provided by the manufacturer).
2 max
Bovine serum albumin (BSA; Sigma, cat. no. A 2934) was added from a 10% (w/v) solution
to a final concentration of 0.1% (w/v) and labeled antibodies were stored at 5°C.
I n a few fusion screens, in addition to the anti-human IgG-Cy5.5, t o detect human
antibodies, an anti-mouse IgG Cy5.5-labeled conjugate was used, to detect specific chimeric
antibodies. Samples were scanned using an Applied tems 8200 ar Detection
System (8200 CDS) and 'counts x fluorescence' was used as read-out.
Example 7
HuMab hvbridoma-qeneration
HuMAb mice with sufficient (defined as above) n-specific titer development were
sacrificed and the spleen and lymph nodes flanking the abdominal aorta and caval vein were
collected. Fusion of splenocytes and lymph node cells to a mouse myeloma cell line was
done by electrofusion using a CEEF 50 ofusion System (Cyto Pulse Sciences, Glen
Burnie, MD, USA), essentially according t o the manufacturer's instructions. Fused cells were
seeded fusion medium containing 10% Fetal Clone I Bovine serum (Perbio), 1 m M sodium
pyruvate (Cambrex), 0.5 U/mL penicillin, 0.5 U/mL streptomycin (Cambrex), 50 m M
2-mercaptoethanol (Invitrogen), 600 ng/mL interleukin 6 (IL-6) (Strathmann), 1 x HAT
(Sigma) and 0.5 mg/mL kanamycin (Invitrogen) in HyQ mADCF-Mab (Perbio). After ten
days, supernatant was harvested and cells were refreshed with harvest , containing
% Fetal Clone I Bovine serum, 0.5 U/mL penicillin, 0.5 U/mL streptomycin, 600 ng/mL
IL-6 and 1 x proHT (Cambrex) in HyQ mADCF-Mab. Supernatants of the hybridoma cultures
were screened by primary FMAT screening assays on TC2013-CD74vldel2-36 cells and
TC2013-CD74v2del2-36 cells to detect hybridomas producing human (or chimeric)
anti-CD74 antibodies as described supra. The 60 best primary wells were seeded in
semisolid medium made from 40% CloneMedia (Genetix, Hampshire, UK) and 60% HyQ 2x
complete medium (Hyclone, Waltham, USA). From each primary well, two wells of a Genetix
black 6-well plate were seeded. From each well, 33 sub clones were picked, using the
ClonePix system (Genetix). The sub clones were picked in harvest medium. After seven
days, the atants of the sub clones were screened again for CD74-specific human IgG
binding and human IgG concentration was measured using Octet (Fortebio, Menlo Park,
USA). From each primary well, the best sub clone was expanded in expansion medium
containing only 600 ng/mL IL-6, 0.5 U/mL penicillin, 0.5 U/mL streptomycin and 1 x proHT.
The sub clones were expanded from one 96-well plate well t o one 24-well plate well to four
24-well plate wells to six 6-well plate wells to lask (small scale production).
Supernatants of the hyperflasks were screened for CD74-specific human IgG g.
Clones derived by this process were designated PC2013.
Mass-Spectrometrv of purified antibodies
Small aliquots of 0.8 mL antibody-containing supernatant from 6-well or Hyperflask stage
were ed using PhyTip columns containing Protein G resin (PhyNexus Inc., San Jose,
USA ) on a ne ALH 3000 workstation (Caliper Lifesciences, Hopkinton, USA). The
PhyTip columns were used according t o manufacturer's instructions, but s were
replaced. PBS (B.Braun, Medical B.V., Oss, Netherlands) was used as Binding Buffer and
0.1M e-HCI pH 2.7 (Fluka Riedel-de Haen, Buchs, Germany) was used as Elution
Buffer. After purification, samples were neutralized with 2M Tris-HCI pH 9.0 (Sigma-Aldrich,
Zwijndrecht, Netherlands). atively, in some cases larger volumes of culture
supernatant were purified using Protein A affinity column tography.
After purification, samples were placed in a 384-well plate (Waters, 100 uL
square-well plate, art# 631). Samples were de-glycosylated with N-glycosidase F
(Roche cat no 11365177001) at 37°C, O/N. DTT (15 mg/mL) was added ( 1 pL/well) and
incubated at 37°C for 1 h . Samples (5 or 6 m I_) were desalted on an y UPLC™
(Waters, Milford, USA) with a BEH300 C18, 1.7 mh-i, 2.1x 50 mm column at 60°C. MQ water
and LC-MS grade acetonitrile (Biosolve, cat no 01204101, Valkenswaard, The lands),
both with 0 . 1% formic acid (Fluka, cat no 56302, Buchs, Germany), were used as Eluens A
and B. Time-of-flight electrospray ionization mass spectra were recorded on-line on a
micrOTOF™ mass spectrometer (Bruker, Bremen, Germany) operating in the positive ion
mode. Prior to analysis, a 900-3000 m/z scale was ated with ES tuning mix (Agilent
Technologies, Santa Clara, USA). Mass spectra were deconvoluted with DataAnalysis™
software v3.4 (Bruker) using the Maximal Entropy algorithm searching for molecular
weights between 5 and 80 kDa.
After deconvolution the ing heavy and light chain masses for all samples were
compared in order to find duplicate dies. I n the comparison of the heavy chains the
possible presence of C-terminal lysine variants was taken into t. This ed in a list
of unique antibodies, where unique is defined as a unique combination of heavy and light
chains. I n case duplicate antibodies were found, results from other tests were used t o
decide which material was used to continue experiments with.
Mass spectrometry analysis of the molecular weights of heavy and light chains of 4 1
anti-CD74 hybridomas yielded 18 unique dies (unique heavy chain/light chain
combination).
Example 9
Sequence analysis of the CD74-specific HuMab variable domains and cloning in
expression vectors
Total RNA of the anti-CD74 HuMab antibodies was prepared from 5xl0 6 hybridoma cells and
'-RACE-Complementary DNA (cDNA) was prepared from 100 ng total RNA, using the
SMART RACE cDNA Amplification kit (Clontech), according to the manufacturer's
ctions. VH (variable region of heavy chain) and VL (variable region of light chain)
coding regions were amplified by PCR. Amplified PCR products of antibodies 006, 008 and
011 were cloned into the pCR-Blunt II-TOPO vector (Invitrogen) using the Zero Blunt PCR
cloning kit (Invitrogen).
Amplified VH and VL PCR products of antibody 005 were cloned in pcDNA3.3 vectors
rogen) encoding Glf and. Kappa nt domains. For each HuMab, 16 VL clones and
8 VH clones were sequenced. Clones with ted heavy and light chain mass in
agreement with the mass of the hybridoma-derived material of the same antibody (as
determined by mass spectrometry) were selected for r study and expression.
The resulting ces are shown in the Sequence Listing and Figure 2 herein.
Table 1 and Table 2 (below) give an overview of antibody sequence information and
most homologous germline sequences.
Table 1: Heavy chain homologies
J-GENE D-GENE CDR-IMGT
Ab V-GENE and allele ON identity, % (nt) and allele and allele lengths
005 IGHV33*01 100.0 (288/288 nt) IGHJ4*02 IGHD3-10*01 8 .8 .17
006 IGHV33*01 98.6 (284/288 nt) IGHJ4*02 IGHD3-16*02 8 .8 .17
008 IGHV33*01 100.0 (288/288 nt) IGHJ4*02 IGHD3-16*02 8 .8 .17
011 IGHV3-33*01 99.7 (287/288 nt) IGHJ6*02 IGHD3-10*01 8 .8 .16
Table 2: Light chain homologies
J-GENE CDR-IMGT
Ab V-GENE and allele V-REGION identity % (nt) and allele s
005 IGKV1 D-16*01 99.6 (278/279 nt) IGKJ4*01 6 .3.9
006 IGKV1 D-16*01 100.0 (279/279 nt) IGKJ4*01 6 .3.9
008 IGKV1 D-16*01 100.0 (279/279 nt) IGKJ4*01 6 .3.9
Oil IGKV1 D-16*01 100.0 79 nt) IGKJ4*01 6 .3.9
Table 3 : References to the sequence listing:
e 10
Purification of antibodies
Culture supernatant was filtered over 0.2 m h dead-end filters, loaded on 5 mL Protein A
s (rProtein A FF, Amersham Bioscience) and eluted with 0.1 M citric acid-NaOH, pH
3 . The eluate was immediately neutralized with 2 M Tris-HCI, pH 9 and ed t o 12.6 m M
NaH P0 , 140 m M NaCI, pH 7.4 (B.Braun), O/N. After dialysis, samples were sterile-filtered
2 4
over 0.2 m h dead-end filters. Purity was determined by GE and concentration was
measured by nephelometry and absorbance at 280 nm. ed antibodies were aliquoted
and stored at -80°C. Once thawed, purified antibody aliquots were kept at 4°C. Mass
spectrometry was performed to identify the molecular mass of the antibody heavy and light
chains sed by the hybridomas as described in Example 9 .
Example 11
Binding of CD74-specific HuMab antibodies to recombinant extracellular domain of
two CD74 isoforms, determined bv ELISA, and to cellular CD74 on Raii cells,
determined bv FACS
Binding of anti-CD74 HuMab antibodies to two ms of CD74 was measured by ELISA
(coated recombinant extracellular domain of CD74) and to cellular CD74 on Raji cells (ATCC,
as, VA) by FACS analysis.
ELISA plates (Greiner BioOne) were coated O/N at 4°C with 2 mg/mL, 100 m per
well, recombinant CD74vl or CD74v2 in PBS (B. Braun Melsungen AG). Sequences and
production of the isoforms were described supra. ELISA wells were washed three times with
PBS containing 0.05% 20 (PBST), emptied, and blocked with 1% (w/v) BSA fraction
V (Roche) in PBS at RT for 1 h while shaking (300 rpm), and emptied. Subsequently, 100 m
anti-CD74 HuMab antibodies were added in serial ons in 0.2% (w/v) BSA fraction V in
PBST (assay buffer) and incubated while shaking at RT for 90 min. ELISA plates were
washed three times with PBST, emptied, and bound HuMab antibodies were detected using
HRP-conjugated goat-anti human IgG (100 m ; 1:5,000; Peroxidase Affinipure Goat antihuman
IgG, F(ab') Fragment Specific [min X Bov,Hrs,Ms Sr Prot]; Jackson
Immunoresearch) in assay buffer and incubated while shaking at RT for 90 min. Plates were
washed three times with PBST, emptied, and ted with 100 m ABTS solution (50 ml
ABTS buffer [Roche] and one ABTS tablet [50 mg; Roche]). After incubation in the dark at
RT for 30 min, the reaction was stopped by addition of 100 m per well oxalic acid (2%
[w/v]). Plates were measured at OD 405 nm in an ELISA reader (Biotek Instruments, EL808
Absorbance Microplate Reader).
For FACS is, 105 cells in 100 m FACS buffer (PBS supplemented with 0.1%
BSA and 0.02% sodium azide) were seeded per well in 96-well round-bottom plates. Cells
were spun down (1200 rpm, 4°C, 5 min) and supernatant was discarded. Serially diluted
anti-CD74 HuMab antibodies were added (100 m I_) and incubated on ice for 1 h . Cells were
washed with FACS buffer, supernatants were ded, and 100 m I_ of R-Phycoerythrin
labeled goat uman IgG (R-Phycoerythrin AffiniPure F(ab')2 Frag Gt Anti-Human IgG,
Fey Frag Spec [min X Bov,Hrs,Ms Sr Prot]; Jackson Immunoresearch), diluted 1 : 100 in
FACS buffer, was added. After 1 h on ice (in the dark), cells were washed once in FACS
buffer, atant was ded, and specific binding of the HuMab antibodies was
detected by flow cytometry on a FACS Canto I I (BD Biosciences).
e control Ab IgGl-bl2 was used as a ve control. Binding curves were
analyzed using non-linear regression (sigmoidal dose-response with variable slope) using
GraphPad Prism 5 software Pad Software, San Diego, CA, USA).
Figure 3 shows that HuMab-CD74-006 and -011 bound with high affinity (EC values
between 210 and 344 ng/mL) to both isoforms of the CD74 extracellular domain.
HuMab-CD74-008 bound with intermediate affinity (EC between 759 and 1391 ng/mL) to
both isoforms.
Figure 4 shows that HuMab-CD74-006 and -011 also bound with high affinity (EC
between 150 and 200 ng/mL) t o cellular CD74 expressed by Raji cells. CD74-008
and -005 bound t o cellular CD74 with intermediate affinity (EC values could not be
determined because maximum binding was not reached).
Table 4 shows EC values of CD74-specific HuMab antibodies for binding to the
extracellular domain of CD74vl and CD74v2 by ELISA and to cellular CD74 by FACS on Raji
cells.
Table 4 : Overview of EC values for binding of CD74 specific HuMab antibodies to the
extracellular domain of CD74vl and CD74v2, ined by ELISA, and t o cellular CD74 on
Raji cells, determined by FACS. All HuMab antibodies were produced by transiently
co-transfecting HEK293F cells with relevant heavy and light chain expression vectors (as
described supra).
HuMab-CD74- EC ) EC (FACS)
50 50
CD74vl CD74v2
005 nt nt nd
006 321 210 196
008 1391 759 nd
011 344 245 151
EC values are in ng/mL.
nd - could not be calculated,
nt - not tested.
Example 12
Cross-reactivitv of anti-CD74 HuMab antibodies to cvnomolqus monkey s
The capacity of CD74-specific HuMab antibodies t o bind to cynomolgus CD74 was tested by
immunohistochemistry. Immunohistochemistry with anti-CD74 HuMab antibodies was
performed on frozen human tonsil and cynomolgus lymph node tissue, with anticipated
CD74 expression on (follicular) B lymphocytes and macrophages. Frozen tissue sections
were cut (4-6 m h thickness) and d in acetone. HuMab dies were complexed with
fluorescein-isothiocyanate (FITC) by incubation with goat anti-human IgG(Fc)-FITC (Fab)
(Protos) ( 1 : 1 ratio with Humab). Prior to HuMab staining ( 1 mg/mL), tissues were blocked
for endogenous biotin, peroxidase (PO) and immunoglobulins. HuMab-Fab-FITC complex
was detected by subsequent incubations with rabbit anti-FITC (Invitrogen) (diluted 1 : 1000)
and PO-conjugated goat anti-rabbit IgG (Powervision, [rb IgG]-PO; undiluted). PO activity
was visualized with amino-ethyl-carbazole (AEC) as substrate, resulting in a red color, and
nuclei were visualized with hematoxylin (blue). -stainings were examined with light
microscopy (Axioskop-2 plus), converted to digital pictures by an Axiocam-camera and
stored as l pictures.
Figure 5 shows that HuMab-CD74-006 and -011 showed cross-reactivity with
cynomolgus CD74, as shown by staining of macrophages and follicular B cells (staining for
isotype control is ve). The extent of cross- reactivity with cynomolgus CD74 was less
for HuMab-CD74-006 than for -011, as shown by less intensive staining of cynomolgus
tissue as compared with human tissue.
Example 13
Induction of ADCC and CDC
Induction of ADCC by CD74-specific HuMab antibodies was tested in a 1Cr release assay.
Briefly, Raji cells were labeled with 100 m 1Cr and used as target cells. Peripheral blood
mononuclear cells, isolated from buffy coats, were used as effector cells. Target cells were
pre-incubated with anti-CD74 HuMab dies (RT, 30 min) and effector cells were added,
resulting in an effector t o target ratio of 100: 1, and incubated at 37°C, 5% C0 , O/N. 1Cr
e in the supernatant was measured in a gamma counter. No significant induction of
ADCC by anti-CD74 HuMab antibodies was detected.
Induction of CDC by anti-CD74 HuMab antibodies was tested using propidium iodide
. y, Raji cells were pre-incubated with anti-CD74 HuMab antibodies (RT, 15
min) and normal human serum was added, to a final tration of 20%, and ted
at 37°C, 5% C0 for 45 min. Plates were put on ice t o stop the reaction. Propidium iodide
was added and cells were ed by FACS analysis. No significant induction of CDC by
anti-CD74 HuMab antibodies was detected.
Example 14
Antibody-mediated internalization and cell killing b anti-CD74 HuMab antibodies
in an anti-kappa-ETA' assay
To evaluate the suitability of the anti-CD74 HuMab antibodies for an dy-drug
conjugate approach, a c in vitro ased killing assay using kappa-directed
pseudomonas-exotoxin A (anti-kappa-ETA') was developed. I n this assay, a construct
consisting of a high affinity anti-human kappa light chain domain antibody and a truncated
form of the pseudomonas-exotoxin A plus a KDEL retention motif was used. Upon
internalization, the anti-kappa-domain-antibody-ETA' construct undergoes lysis and
disulfide-bond reduction, separating the catalytic and the binding domain. The tic
domain is believed t o be transported from the Golgi system t o the endoplasmic reticulum
via the KDEL retention motif, and subsequently translocated t o the cytosol where it inhibits
protein synthesis and induces apoptosis (Kreitman RJ. BioDrugs 2009; 23(1): 1-13).
Antibody-mediated internalization and cell killing by the toxin was tested for different
anti-CD74 HuMab antibodies with Raji cells. The number of CD74 molecules expressed on
the Raji cell surface was estimated t o be 104 molecules per cell, using QIFIKIT® method
(Dako, Glostrup, Denmark). 104 cells per well in cell e medium were seeded in 96-well
tissue culture plates (Greiner e). Plates were incubated at 37°C for 1 h, t o let cells
settle down. To identify anti-CD74 HuMab antibodies that enable internalization of and
killing by the toxin, a fixed concentration ( 1 mg/mL final concentration in the wells) of antikappa-ETA'
, that did not induce non-specific cell death in the absence of dy, was preincubated
for 30 min with a ed amount of anti-CD74 HuMab antibodies before addition
t o the cells. After three days, the amount of viable cells was quantified with AlamarBlue
(BioSource International, San Francisco, US), added in 10 m I_ per well according t o the
manufacturer's instructions. After incubation at 37°C for 4 h, fluorescence was monitored
using the EnVision 2101 Multilabel reader (PerkinElmer, Turku, Finland) with standard
AlamarBlue settings. A n e control antibody (IgGl-bl2), pre-incubated with antikappa-ETA'
, was used as a negative l. sporine (Sigma-Aldrich) was used as a
control for determining background signal and added t o cells at a final concentration of 1
mg/mL.
Percentage viability was calculated as follows:
(FL-treated _ FL-backg round) / (FL _
n t r o l FL-backg round) X 100%.
ro i = scence from untreated wells
FLbackground = fluorescence from staurosporine-treated wells.
Figure 6 and Table 5 show that all anti-kappa-ETA'-pre-incubated anti-CD74 HuMab
antibodies were able t o kill Raji cells in a dose-dependent manner. Anti-kappa-ETA'
pre-incubated HuMab-CD74-006, -011, -005 and -008 induced efficient killing (EC 0
between 25 and 250 m / h and minimal percentage viability left between 0 and 15). Antikappa-ETA'
pre-incubated control mAb IgGl-bl2 did not induce cell killing.
Table 5 - Overview of EC values and percentages of cell viability left after treatment of
Raji cells with anti-kappa-ETA'-pre-incubated anti-CD74 HuMab antibodies. Data shown are
EC values (in mg/mL) and minimal percentages viability of Raji cells treated with anti-
kappa-ETA' pre-incubated anti-CD74 HuMab antibodies, measured in one representative
experiment.
Antibody % viability EC
-CD74-)
005 3.24 120
006 1.50 57
008 14.65 247
011 0.47 25
IgGl-bl2 85.89 n.d. a)
a) Could not be ated .
Example 15
Preparation of CD74-specific ADCs
HuMab-CD74-005, HuMab-CD74-006, CD74-011 and the negative control IgGl-bl2
were produced transiently in HEK-293F cells. The antibodies were purified by Protein A
chromatography according t o standard procedures, finally yielding approximately 263 mg
purified HuMab-CD74-005, 165 mg HuMab-CD74-006 and 720 mg HuMab-CD74-011. The
amount of ated antibody obtained is shown in Table 6 . The drug-linker vcMMAE or
mcMMAF was alkylated to the cysteines of the reduced antibodies according t o procedures
described in literature (Sun et al. (2005) Bioconjugate Chem. 16: 1282-1290; McDonagh et
al., (2006) Protein Eng. Design Sel. 19: 299-307; Alley et al., (2008) Bioconjugate Chem.
19: 759-765). The reaction was ed by the on of an excess of N-acetylcysteine.
Any residual unconjugated drug was removed by diafiltration and the final CD74-specific
antibody drug conjugates were formulated in PBS.
The pecific dy drug conjugates were subsequently analyzed for
concentration (by absorbance at 280 nm), the drug-to-antibody ratio DAR') by reverse
phase chromatography (RP-HPLC) and hobic interaction tography (HIC), the
amount of unconjugated drug (by reverse phase chromatography), the percentage
aggregation (by size-exclusion chromatography, SEC-HPLC) and the endotoxin levels (by
Limulus Amebocyte Lysate (LAL) endotoxin test). The results are shown in Table 7 .
Table 6 - Amount of ADC obta ined
Table 7 - Ana lysis of antibody-d rug conj ugates
* DAR could not be assig ned beca use of tion of pea ks
Example 16
Binding of anti-CD74 ADCs to recombinant extracellular domain of ,
determined bv ELISA
Bind ing of CD74-specific ADCs to CD74 was measu red by ELISA (coated recombina nt
extracel lula r doma in of CD74vl ) and compa red with bind ing of unconj ugated CD74-specific
HuMa b anti bod ies.
ELISA plates (Greiner BioOne) were coated with 2 mg/mL, 100 m per wel l,
recombi nant CD74ECDH is in PBS (B. Bra un Melsungen AG) at 4°C, O/N . ELISA plates were
emptied and blocked with 200 m n II PBS conta ini ng 0 .05% Tween-20 (PBST) while
sha king (300 rpm), at RT for 1 hou r, washed three times with 300 m PBST and emptied .
Subsequently, 100 m I_ anti-CD74 ADCs or unconjugated CD74-specific HuMab antibodies
were added in serial dilutions in PBST and incubated while shaking at RT for 2 hours. ELISA
plates were washed with PBST and emptied. Bound anti-CD74 ADCs and unconjugated
HuMab antibodies were ed by addition of HRP-conjugated mouse-anti human IgGl
(100 m I_; 0.015 mg/mL; n; # M1328) in PBST and incubation while shaking, at RT for
2 hours. Plates were washed with PBST, emptied and incubated with 100 m I_ ABTS solution
(50 ml ABTS buffer [Roche] and one ABTS tablet [50 mg; Roche]). After tion in the
dark while shaking, at RT for 30 min, the reaction was stopped by incubation with 100 m I_
per well oxalic acid (2% [w/v]; Riedel de Haen) in the dark while shaking, for 10 min. Plates
were measured at OD 405 nm in an ELISA reader (Biotek Instruments, EL808 Absorbance
Microplate Reader).
l2, an antibody binding t o a non-related antigen, was used as a negative
control (both unconjugated as well as in ADC format). Binding curves were analyzed by
non-linear regression (sigmoidal dose-response with variable slope) using GraphPad Prism 5
software (GraphPad Software, San Diego, CA, USA).
All anti-CD74 HuMab antibodies and ADCs bound within a similar range t o the
CD74vl extracellular domain in an ELISA (EC values between 0.02 and 0.04 mg/mL), as
demonstrated by the binding curves in Figure 7 . Table 8 shows EC values of CD74-specific
HuMab antibodies and ADCs for binding to the extracellular domain of CD74.
Table 8 - Overview of EC values for binding of CD74-specific HuMab antibodies and ADCs
to the extracellular domain of CD74vl, determined by ELISA. EC values are in mg/mL.
Data shown are mean EC values ated from four independent ments.
Example 17
g of CD74-specific ADCs to surface-expressed CD74, ined bv FACS
analysis on Daudi cells
Binding of D74 ADCs to surface-expressed CD74 was measured by FACS analysis on
Daudi cells and compared with binding of unconjugated anti-CD74 HuMab antibodies.
1 x 105 Daudi cells in 100 m PBS containing 0.1% bovine serum albumin (BSA)
(Roche, cat. no. 10735086001) and 0.02% sodium azide (Sigma-Aldrich, cat. no. 13412)
(FACS buffer) were seeded per well in 96-well round-bottom plates (Greiner bio-one, cat.
no. 650101). Cells were spun down (1200 rpm, 4°C, 3 min) and supernatant was discarded.
Serially diluted anti-CD74 HuMab antibodies or ADCs were added (100 m I_) and incubated on
ice for 30 min. Cells were washed twice with 150 m I_ FACS buffer and 100 m I_ rabbit
uman IgG-FITC (cat. nr. F0185, Dako), diluted 1:100 in FACS buffer, was added. After
min on ice (in the dark), cells were washed twice in 150 m I_ FACS buffer and ic
binding of the HuMab antibodies and ADCs was detected by flow cytometry on a FACS Canto
I I (BD Biosciences).
Isotype control antibody IgGl-bl2, an antibody binding to a non-related antigen, was used
as a negative control (both unconjugated and as an ADC). Binding curves were analyzed
using non-linear regression (sigmoidal dose-response with variable slope) using GraphPad
Prism 5 re (GraphPad Software, San Diego, CA, USA).
Figure 8 shows binding curves and Tables 9 and 10 show EC values and maximal
mean fluorescence intensities for binding to surface-expressed CD74 of anti-CD74 HuMab
antibodies and ADCs. All but one conjugated anti-CD74 HuMab antibodies bound t o
surface-expressed CD74 on Daudi cells with an affinity similar to the corresponding
unconjugated HuMab antibodies. The vcMMAE-conjugate of HuMab-CD74-005 bound with
higher ty (lower EC value) than the unconjugated HuMab. HuMab-CD74-005 and its
mcMMAF-conjugate bound with lower ty than HuMab-CD74-006 and -011 and their
conjugates. Maximal binding was lower for vcMMAE-conjugated HuMab-CD74-006 and -011
than for the corresponding unconjugated HuMab antibodies.
Table 9 - Overview of EC values for binding of CD74-specific HuMab antibodies and ADCs
to surface-expressed CD74, determined by FACS analysis on Daudi cells. EC values are in
mg/mL. Data shown are mean EC values calculated from three independent experiments.
Table 10 - Overview of mean fluoresencence intensities at 10 mg/mL of CD74-specific
HuMab antibodies and ADCs, determined by FACS analysis on Daudi cells. Data shown are
mean l MFI values as measured at 10 mg/mL of HuMab-CD74 mAbs and ADCs. Mean
maximal MFI values were calculated from three independent ments.
l binding (FACS)
CD74-
Unconjugated vcMMAE mcMMAF
005 2784 2863 2526
006 4599 3277 4050
Example 18
Antibodv-mediated internalization and cell killing bv anti-CD74 ADCs in an in vitro
killing assay
To determine the capacity of anti-CD74 ADCs to induce cytotoxicity, an in vitro cell-based
killing assay was med.
Cell killing of four cell lines was tested for the ent anti-CD74 ADCs. All cell lines
were obtained from an Tissue Culture Collection (ATCC, Manassas, VA, USA): Raji
(cat. no. CCL-86), Daudi (cat. no. 3), M4A4 (cat. no. 14; derived from the
human cell line MDA MB 435) and NCI-H747 cells (cat. no. CCL-252, derived from colorectal
arcinoma metastasis). Cells were seeded in optimal concentration (Raji: 1 x 104
well; Daudi: 1 x 103 cells/well, M4A4: 2 x 103 cells/well, NCI-H747 3 x 103 cells/well)
in 100 m cell culture medium (for Daudi and Raji; RPMI 1640 [Lonza, cat. no. BE12-115F]
supplemented with 10% Cosmic Calf Serum [Perbio Science Nederland B.V., cat. no.
SH30087.04], 2 m M L-glutamin [Lonza, cat. no. BE17-605F] and ImM Sodium Pyruvate
[Lonza, cat. no. BE13-115E]; for 47: RPMI 1640 supplemented with 10% Cosmic
Calf Serum, 1 m M Sodium Pyruvate, 0 .15% Sodium Bicarbonate [Lonza, cat. no. BE17-
613E] and 0.5% Glucose [Sigma, cat. no. G8769]; and for M4A4: DMEM [Lonza, cat. no.
BE12-709F] mented with 10% Cosmic Calf Serum) in l tissue culture plates
(Greiner Bio-one) and allowed to adhere. Serial dilutions of anti-CD74 ADCs were added and
incubated at 37°C for three (Raji, Daudi) or five (M4A4, NCI-H747) days. The amount of
viable cells was quantified with AlamarBlue (cat. nr. DAL1100, BioSource International, San
Francisco, US), according t o the manufacturer's instructions. Fluorescence was monitored
using the EnVision 2101 Multilabel reader (PerkinElmer, Turku, Finland) with standard
AlamarBlue settings. IgGl-bl2 (an antibody binding to a non-related antigen) ADCs were
used as ve controls. Staurosporine (Sigma, # S6942) was used to induce l cell
g. The amount of CD74 molecules on cell lines was determined by QIFIKIT® (Dako,
Glostrup, Denmark), according t o the manufacturer's instructions, using mouse IgGl
anti-CD74 (clone By2; Santa Cruz, cat. no. SC-20062) and isotype control (CLB, cat. no.
M1415) antibody. Both antibodies were used at a concentration of 10 mg/mL. It was
determined that Raji and Daudi cells express ~ 20,000; and M4A4 cells ~ 11,000 CD74
molecules on the cell surface.
Figure 9 and Table 11 show that all anti-CD74 ADCs were able t o kill Raji, Daudi and
M4A4 cells in a dose-dependent manner. IC values for all conjugates were about 5-12
times higher on M4A4 cells (i.e. lower efficacy), expressing about six-fold lower levels of
CD74. NCI-H747 cells were only killed at the highest dose of ADCs tested (10 mg/mL). For
HuMab-CD74-006 and -011 mcMMAF conjugates were slightly more efficient in inducing
killing of Daudi and Raji cells than vcMMEA conjugates (-006: on Daudi cells three-fold
lower and on Raji cells five-fold lower IC ; -Oil: on Daudi cells two-fold lower and on Raji
cells four-fold lower IC ) .
Table 11 - Overview of IC values and tages of cell killing d by anti-CD74
ADCs. Data shown are mean IC values (in mg/mL) and mean maximal percentages kill (at
a concentration of 10 mg/mL) of the indicated cell lines d with anti-CD74 ADCs. Data
were calculated from three independent experiments. Percentage of cell killing (% kill) was
calculated as follows:
( F I ntreated _ x
F I a nti-CD74 ADC-treated) / ( M I nt r ated _ Flstauroporine-treated) 100%.
a) Could not be calculated since plateau level of curve was not reached.
Example 19
Therapeutic treatment of Daudi tumor xenografts in SCID mice with CD74-specific
ADCs
The in vivo efficacy of HuMab-CD74-011 ADCs was determined in ished intravenous
(i.v.) Daudi (Burkitt's lymphoma) xenograft tumors in SCID mice.
Daudi cells were transfected by electroporation with gWIZ luciferase (Aldevron,
Fargo, ND, USA) and pPur vector (BD Biosciences, Alphen a/d Rijn, The Netherlands) in a
4 :1 ratio. After 48 h, puromycin was added for selection of a stably transfected clone
(Daudi-luc). Daudi-luc #1E3 cells were cultured in RPMI supplemented with 10% cosmic calf
serum (cat. no. SH30087.04, Hyclone), 1% penicillin/streptomycin (cat. no. DE17-603,
Cambrex, y), 1% sodium te and 1 mg/mL cin (cat. no. P-8833, Sigma,
Zwijndrecht, The Netherlands). 2.5 x 106 Daudi-luc tumor cells in 100 m I_ PBS were injected
i.v. in the tail vein of female SCID mice. Mice were imaged directly after tumor inoculation,
followed by imaging at weekly intervals starting on day 14. For imaging, mice were
etized using isoflurane, followed by intraperitoneal (i.p.) administration of 2.5 mg
D-luciferin (acid form, cat.no. BTll-1000; Biothema, Haninge, Sweden) in 200 m I_ 10
mg/mL TRIS (cat.no. T60666-lkg, Sigma). Bioluminescence imaging (BLI), from the back
side l view), started 10 min after administration of D-luciferin, 5 min exposure time,
on a Biospace Imager. Black and white images were made for anatomical reference. Mice
were treated twice weekly with 60 mg (~3 mg/kg) HuMab-CD74-011 and control antibody
(IgGl-bl2), both as ADC and as unconjugated IgGl, in 100 m I_ PBS from day 2 1 after tumor
inoculation, four times in total. Before treatment, mice were divided in groups of seven mice
each, each group having equal average BLI signals and equal variances.
Figure 10 shows that both HuMab-CD74vcMMAE and -mcMMAF were effective
in reducing the size of i.v. Daudi-luc tumors. As shown in Figure 10, there was an apparent
tendency for a higher tumor growth inhibition in the case of unconjugated HuMab-CD74-011
as compared to the control antibody group, although the differences were not significant.
Example 20
Therapeutic treatment of Raii tumor xenografts in SCID mice with anti-CD74 ADCs
The in vivo cy of D74 ADCs was also determined in an i.v. Raji xenograft tumor
model in SCID mice.
Raji cells were transfected by electroporation with gWIZ luciferase (Aldevron, Fargo,
ND, USA) and pPur vector (BD Biosciences, Alphen a/d Rijn, The Netherlands) in a 4 :1 ratio.
After 48 h, puromycin was added for selection of a stably transfected clone (Raji-luc).
Raji-luc #2D1 cells were cultured in RPMI supplemented with 10% cosmic calf serum (cat.
no. SH30087.04, e), 1% penicillin/streptomycin (cat. no. 03, x,
Germany), 1% sodium pyruvate and 1 mg/mL puromycin (cat. no. P-8833, Sigma,
Zwijndrecht, The Netherlands). 2.5 x 106 uc tumor cells in 100 m I_ PBS were ed
i.v. in the tail vein of female SCID mice. Mice were imaged ly after tumor inoculation,
followed by imaging twice weekly from day 7 onwards. For imaging, mice were anesthetized
using isoflurane, followed by i.p. administration of 2.5 mg D-luciferin (acid form, cat.no.
BTll-1000; Biothema, Haninge, Sweden) in 200 m I 10 mg/mL TRIS (cat.no. T60666-lkg,
Sigma). Bioluminescence imaging (BLI), from the back side (dorsal view), started 10 min
after administration of D-luciferin, 5 min exposure time, on a Biospace Imager. Black and
white images were made for anatomical reference. Mice were treated twice weekly with 60
mg (~3 mg/kg) HuMab-CD74-011 or control antibody (IgGl-bl2), both as ADC and as
unconjugated IgG, in 100 m I_ PBS, from day 11 after tumor inoculation, four times in total.
Before treatment, mice were divided in groups of seven mice each, each group having equal
average BLI signals and equal variances.
Figure 11 shows that both HuMab-CD74vcMMAE and -mcMMAF eliminated
lly all Raji-luc tumors. As shown in Figure 11, there was an apparent tendency for a
higher tumor growth tion in the case of unconjugated HuMab-CD74-011 as compared
to the control antibody group, although the ences were not significant.
Example 21
Therapeutic treatment of Raii tumor xenografts in SCID mice with anti-CD74 ADCs
The in vivo efficacy of anti-CD74 ADCs was also determined in ished subcutaneous
(s.c.) Raji (Burkitt's lymphoma) xenograft tumors in SCID mice.
x 106 Raji-luc #2D1 tumor cells (obtained as described Example 20) in 200 m I_ PBS
were injected s.c. in the right flank of female SCID mice, followed by two injections with
anti-CD74 ADCs or controls (IgGl-bl2; both as ADC and as unconjugated IgGl), one when
tumor sizes were on average ~ 400 mm3, on day 17, and the other four days later, on day
2 1 (per injection 60 se, ~ 3 mg/kg, in 100 m I_, intraperitoneal^). Before the first
ent, mice with tumor growth were divided into groups with equal tumor volume
bution. Tumor volume was determined at least two times per week. Tumor volumes
(mm 3) were calculated from caliper (PLEXX) measurements as: 0.52 x h) x (width) 2.
Figure 12 shows that all anti-CD74 ADCs effectively reduced the size of established
s.c. Raji-luc tumors. Tumors in mice treated with l2, both as ADC and unconjugated,
continued t o grow.
Example 22
Therapeutic treatment of M4A4 tumor xenografts in SCID mice with anti-CD74
ADCs
The in vivo efficacy of anti-CD74 ADCs was also determined in established subcutaneous
(s.c.) M4A4 xenograft tumors in SCID mice. M4A4 melanoma cells (cat. no.
CRL-2914;American Tissue e Collection, ATCC; derived from the human cell line
MDA-MB-435) were cultured in DMEM (cat. no. BE12-709F, Cambrex, Germany) containing
% cosmic calf serum (cat. no. SH30087.04, Hyclone, The Netherlands) and 1%
penicillin/streptomycin (cat. no. DE17-603, Cambrex, Germany). 107 M4A4 tumor cells in
200 m I_ PBS were injected s.c. in the right flank of female SCID mice, followed by four
injections with anti-CD74 ADCs or controls (IgGl-bl2; both as ADC and as unconjugated
IgGl), starting when tumor sizes were ~ 200 mm3: day 11, day 14, day 18 and day 2 1 (per
injection 60 se, ~ 3 mg/kg, in 100 m I_, intraperitoneal^). Before the first treatment,
mice were d in groups with equal average tumor volume and equal variance in tumor
volume. Tumor volume was determined at least two times per week. Tumor volumes (mm 3)
were calculated from caliper ) measurements as: 0.52 x (length) x (width) 2.
Figure 13 shows that, whereas all anti-CD74 ADCs inhibited tumor growth of
established s.c. M4A4 tumors, the vcMMAE conjugates strongly reduced the tumor size.
Compared with unconjugated IgGl-bl2, the ADCs of IgGl-bl2 slightly ted tumor
growth.
Example 23
Determination of the te of D74 HuMab dies on Daudi cells
This Example describes determination of the off-rates of anti-CD74 HuMab antibodies in
g to Daudi cells.
Antibodies were labeled with Alexa Fluor® 488 Dye (Molecular Probes), hereinafter
"Alexa-488", using the following procedure:
An antibody solution of 1 mg/mL IgG was prepared in 0.1 M sodiumcarbonate buffer
pH 9.0 (NaHC0 , Riedel de Haen, cat. no. 31437;). Alexa-488 was prepared freshly, by
adding 100 m I_ DMSO (Sigma, cat. no. D2438) t o one vial (Alexa Fluor® 488 carboxylic acid,
imidyl ester ial), Molecular Probes, Leiden, The Netherlands, cat. no. A-
20000). A 25-times molar excess of Alexa-488, calculated as indicated below, was added to
the IgG solution and incubated, while rotating, in the dark at RT for 1 hour. After labeling,
unbound 488 was removed, using a PD-10 column (Amersham Biosciences, cat. no.
1701), with Tris buffer pH 8.0 (50 m M Tris a base, Sigma, cat. no. T-6066];
100 m M NaCI [Riedel de Haen, cat. no. 31437]; 0.01% sodium azide [NaN , Riedel de Haen,
cat. no. 13412]). The amount of Alexa-488 to be added t o the IgG solution was calculated
using the formula:
Volume Alexa-488 to be added (in m I_) = (IgG cone (mg/ml_)/MW IgG (Da) * ratio * volume
* MW Alexa-488 * 100.
MW IgG = 150,000 Da; ratio is the molar excess of Alexa-488 to be used; volume is
the volume of the sample t o be labeled (in ml_); MW Alexa-488 = 643 Da.
Protein concentration (IgG) and degree of ng (D.O.L.) were determined by
measuring OD 280 nm and 495 nm on an Ultrospec 2100 Pro (Amersham Biosciences). IgG
concentration (mg/mL) was calculated using the a :
IgG concentration = [A
2 o - (0.11 * A )]/IgG extinction coefficient.
D.O.L. was calculated using the formula:
D.O.L. = A /71,000/[A28o - (0.11 * A )/(IgG extinction coefficient * MW IgG)].
49 49
71,000 is the extinction coefficient of Alexa-488 at in cm^M 1; 0.11 is the tion
factor (A o free dye/A free dye) (both provided by the cturer).
2 max
Bovine serum albumin (BSA; Sigma, cat. no. A 2934) was added from a 10% (w/v)
solution to a final concentration of 0 . 1% (w/v) and labeled antibodies were stored at 5°C.
Daudi cells were incubated with Alexalabeled anti-CD74 HuMab antibodies.
Daudi cells were washed twice with ice cold PBS. 105 cells per well in ice-cold FACS buffer
were seeded in 96-well round-bottom tissue culture plates (Greiner Bio-one). 0.5 mg/mL
(HuMab-CD74-006 and -011; final concentration) or 1 mg/mL (HuMab-CD74-008; final
concentration) Alexalabeled anti-CD74 HuMab was added in ice-cold FACS buffer. After
incubation on ice for 30 min, 50 mg/mL (HuMab-CD74-006 and -011; final concentration) or
100 mg/mL (HuMab-CD74-008; final concentration) unlabeled anti-CD74 HuMab was added
and incubated on ice for different time intervals ranging from 15 to 180 min. Total
incubation time with unlabeled antibody is ted below the graphs. To determine
l g, Daudi cells were incubated with Alexalabeled HuMab antibodies on
ice for 30 min. As a ve control, cells were incubated with isotype control antibody
IgGl-bl2 (0.5 mg/mL final concentration), followed by unlabeled IgGl-bl2 (50 mg/mL final
concentration). After antibody incubation, cells were washed once in FACS buffer and bound
Alexa—abeled anti-CD74 HuMab antibodies were detected by flow cytometry on a FACS
Canto I I (BD Biosciences).
Figure 14 shows that off-rates of HuMab-CD74-006 and -008 measured at 0°C were
quite rapid (half of the bound Alexalabeled antibodies were replaced with unlabeled
antibodies within ~ 3 and ~ 4 min at 0°C, K values were 0.24 and 0.20 min 1; [K = k ff ]),
whereas off-rate of -011 measured at 0°C was a little bit slower (half of the bound Alexa
488 labeled antibodies were replaced with unlabeled antibodies within ~10 min at 0°C, K
value was 0.07 min 1) .
Example 24
alization and accumulation of anti-CD74 HuMab antibodies
To determine whether anti-CD74 HuMab antibodies are suitable for an antibody-drug
ate approach, internalization and lation of antibodies was studied by FACS
analysis after incubation of different anti-CD74 HuMab antibodies with Daudi cells. 105 cells
per well in cell e medium were seeded in 96-well round-bottom tissue culture plates
(Greiner Bio-one). 10 mg/mL (final concentration) Alexalabeled anti-CD74 HuMab
antibodies were added at different time points and incubated at 4°C (to measure binding to
cell surface expressed CD74) or at 37°C (to measure g and internalization). Total
incubation time with antibody is indicated below the graphs. Internalization and
accumulation at 37°C was also tested using Raji and M4A4 cells with a final concentration of
3 mg/mL Alexalabeled anti-CD74 HuMab antibodies. After incubation with dy,
cells were put on ice and plates were washed twice with FACS buffer. Cell-associated labeled
antibodies were detected by flow cytometry on a FACS Canto I I (BD Biosciences).
Figure 15A shows that only low levels of binding of Alexalabeled anti-CD74
HuMab antibodies to the cell surface of Daudi were detected after tion at 4°C at any
time point. Therefore, the observed fluorescence intensities measured after incubation at
37°C represent internalized antibody. Figure 15B shows that all anti-CD74 HuMab
antibodies tested were internalized, but with different cies. Internalization was most
rapid for HuMab-CD74-011, slower for HuMab-CD74-006 and most slow for
HuMab-CD74-008. The same was observed for internalization and accumulation in Raji cells
(15C) and M4A4 cells (15D).
Example 25
Prophylactic ent of Daudi tumor xenografts in SCID mice with anti CD74
HuMab antibodies
The in vivo efficacy of anti-CD74 HuMab antibodies was determined in an intravenous (i.v.)
Daudi tt's lymphoma) xenograft tumor model in SCID mice. Daudi cells were
transfected by electroporation with gWIZ luciferase (Aldevron, Fargo, ND, USA) and pPur
vector (BD Biosciences, Alphen a/d Rijn, The Netherlands) in a 4 :1 ratio. After 48 h,
puromycin was added for selection of a stably transfected clone (Daudi-luc). Daudi luc #1E3
cells were cultured in RPMI supplemented with 10% cosmic calf serum (cat. no.
SH30087.04, e), 1% llin/streptomycin (cat. no. DE17 603, Cambrex,
Germany), 1% sodium pyruvate and 1 mg/mL puromycin (cat. no. P 8833, Sigma,
Zwijndrecht, The Netherlands). 2.5 x 106 Daudi luc tumor cells in 100 m I_ PBS were injected
i.v. in the tail vein of female SCID mice (7 mice per group). Mice were treated at the day of
tumor inoculation with 100 mg (~5 mg/kg) HuMab-CD74-005, -006 or -011 or control
antibody (IgGl bl2), in 200 m I_ PBS, intraperitoneally (i.p.). Mice were imaged directly after
tumor inoculation, ed by imaging at weekly intervals starting on day 14. For g,
mice were anesthetized using isoflurane, followed by i.p. administration of 2.5 mg D
luciferin (acid form, cat.no. BT11 1000; Biothema, e, Sweden) in 200 m I_ 10 mg/mL
TRIS o. T60666-lkg, Sigma). inescence imaging (BLI), from the back side
(dorsal view), started 10 min after administration of D luciferin, 5 min exposure time, on a
Biospace Imager. Black and white images were made for anatomical reference.
Figure 16 shows that all tested anti-CD74 HuMab dies almost completely
prevented the outgrowth of i.v. Daudi luc tumors.
EQUIVALENTS
Those skilled in the art will recognize, or be able t o ascertain using no more than routine
experimentation, many equivalents of the specific embodiments of the invention described
herein. Such equivalents are intended t o be encompassed by the following claims. Any and
all combination of embodiments disclosed in dependent claims is also contemplated to be
within the scope of the invention.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161438383P | 2011-02-01 | 2011-02-01 | |
DKPA201100064 | 2011-02-01 | ||
DKPA201100064 | 2011-02-01 | ||
US61/438,383 | 2011-02-01 | ||
NZ61367612 | 2012-02-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ717560A NZ717560A (en) | 2017-09-29 |
NZ717560B2 true NZ717560B2 (en) | 2018-01-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220323582A1 (en) | Human antibodies and antibody-drug conjugates against cd74 | |
US20210395384A1 (en) | Human antibody drug conjugates against tissue factor | |
US9663578B2 (en) | Monoclonal antibodies against CD32b | |
US20180044431A1 (en) | Human antibodies against tissue factor and methods of use thereof | |
NZ717560B2 (en) | Human antibodies and antibody-drug conjugates against cd74 | |
NZ717560A (en) | Human antibodies and antibody-drug conjugates against cd74 | |
AU2013203136A1 (en) | Human antibody drug conjugates against tissue factor | |
BR112013019564B1 (en) | ANTIBODIES, EXPRESSION VECTOR, RECOMBINANT PROKYOTIC HOST CELL, PHARMACEUTICAL COMPOSITION, AND, USE OF AN ANTIBODY |